Compositions and methods for selective depletion of target molecules
Patent Information
- Application Number
- JP2023532341
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-30
- Filing Date
- 2021-11-29
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Many human diseases are associated with the accumulation or overexpression of soluble and cell surface proteins that are considered 'undruggable' targets due to difficulty in targeting them with small molecule therapeutics, such as in neurodegenerative diseases like Alzheimer's where amyloid proteins accumulate without effective cure.
Development of peptide conjugates comprising a cell receptor-binding peptide and a target-binding peptide, engineered to have differential affinities for the cell receptor at different pH levels, allowing selective depletion of target molecules through endocytosis and lysosomal degradation.
The peptide conjugates effectively deplete target proteins, reducing their levels in diseases by recycling and reusing the receptor, thus providing a therapeutic approach to conditions like cancer and neurodegenerative diseases.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 119,195, entitled "Compositions and Methods for Selective Depletion of Target Molecules," filed November 30, 2020, which is incorporated herein by reference in its entirety for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The said ASCII copy, created on November 24, 2021, is named 108406-702531_SL.txt and is 665,995 bytes in size. [Background technology]
[0003] The accumulation or overexpression of soluble and cell surface proteins has been demonstrated in a variety of human diseases, ranging from neurodegenerative disorders to cancer. Furthermore, many diseases are associated with mutations in soluble or cell surface proteins that result in constitutive activity, resistance to treatment, or dominant-negative activity. However, many of these proteins have been deemed "undruggable," "hard-to-drug," or "undruggable" targets due to the difficulty of targeting them with small molecule therapeutics. For example, in neurodegenerative Alzheimer's disease, amyloid proteins accumulate to form plaques in the brain, a hallmark feature of the disease. Despite their important role in neurodegeneration, there are no therapeutics that target these proteins. There is a need for compositions and methods for targeting and selectively depleting disease-associated soluble and cell surface proteins. Summary of the Invention
[0004] In various aspects, the present disclosure provides peptide conjugates comprising a cell receptor-binding peptide and a target-binding peptide complexed with the cell receptor-binding peptide, wherein (i) the target-binding peptide is engineered to have a lower affinity for the target in an endosome than in the extracellular environment, (ii) the cell receptor-binding peptide is engineered to have a lower affinity for the cell receptor in an endosome than in the extracellular environment, or both (i) and (ii).
[0005] In some embodiments, the affinity of the target-binding peptide for the target, the affinity of the cell receptor-binding peptide for the cell receptor, or both, is pH-dependent. In some embodiments, the affinity of the target-binding peptide for the target, the affinity of the cell receptor-binding peptide for the cell receptor, or both, is ionic strength-dependent.
[0006] In various aspects, the present disclosure provides a peptide conjugate comprising a cell receptor-binding peptide and a target-binding peptide complexed with the cell receptor-binding peptide, wherein (i) the affinity of the target-binding peptide for the target is pH-dependent, (ii) the affinity of the cell receptor-binding peptide for the cell receptor is pH-dependent, or both (i) and (ii).
[0007] In some embodiments, the cell receptor-binding peptide is a transferrin receptor-binding peptide or a PD-L1-binding peptide. In some embodiments, the cell receptor-binding peptide is a transferrin receptor-binding peptide. In some embodiments, the cell receptor-binding peptide is a PD-L1-binding peptide. In some embodiments, the receptor is a transferrin receptor or PD-L1. In some embodiments, the receptor is a transferrin receptor. In some embodiments, the cell receptor is PD-L1.
[0008] In some embodiments, the cell receptor-binding peptide binds to a cell receptor at a pH of 4.5 to 7.4, 5.5 to 7.4, or 6.5 to 7.4. In some embodiments, the cell receptor-binding peptide can bind to a cell receptor at pH 7.4 with a dissociation constant (KD) of 100 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less. In some embodiments, the cell receptor-binding peptide can bind to a cell receptor at pH 5.5 with a dissociation constant (KD) of 100 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less. In some embodiments, the affinity of the cell receptor for the cell receptor is pH independent, ie, the affinity of the cell receptor-binding peptide for the cell receptor at pH 7.4 and pH 5.5 differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold.
[0009] In some embodiments, the affinity of the cell receptor-binding peptide for the cell receptor is pH-dependent. In some embodiments, the affinity of the cell receptor-binding peptide for the cell receptor decreases as the pH decreases. In some embodiments, the affinity of the cell receptor-binding peptide for the cell receptor is higher at pH 7.4 than at pH 5.5.
[0010] In some embodiments, the affinity of the target-binding peptide for the target is pH-dependent. In some embodiments, the affinity of the target-binding peptide for the target decreases as the pH decreases. In some embodiments, the affinity of the target-binding peptide for the target is higher at a higher pH than at a lower pH. In some embodiments, the higher pH is pH 7.4, pH 7.2, pH 7.0, or pH 6.8. In some embodiments, the lower pH is pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5. In some embodiments, the affinity of the target-binding peptide for the target is higher at pH 7.4 than at pH 6.0. In some embodiments, the affinity of the target-binding peptide for the target is higher at pH 7.4 than at pH 5.5. In some embodiments, the target-binding peptide is capable of binding to a target molecule with a dissociation constant (KD) of 100 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, 1 nM or less, or 0.1 nM or less at pH 7.4. In some embodiments, the target-binding peptide is capable of binding to a target molecule with a dissociation constant (KD) of 1 nM or more, 2 nM or more, 5 nM or more, 10 nM or more, 20 nM or more, 50 nM or more, 100 nM or more, 200 nM or more, or 500 nM or more at pH 5.5. In some embodiments, the affinity of the target-binding peptide for the target at pH 7.4 is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the target-binding peptide for the target at pH 5.5. In some embodiments, the target-binding peptide comprises one or more histidine amino acid residues. In some embodiments, the affinity of the target-binding peptide for the target decreases as ionic strength increases. In some embodiments, the target-binding peptide comprises one or more polar or charged amino acid residues that can form polar or charge-charge interactions with the target molecule.
[0011] In some aspects, the cell receptor-binding peptide is conjugated to the target-binding peptide. In some aspects, the cell receptor-binding peptide and the target-binding peptide form a single polypeptide chain. In some aspects, the peptide complex comprises a dimer dimerized via a dimerization domain. In some aspects, the dimerization domain comprises an Fc domain. In some aspects, the dimer is a homodimer dimerized via a homodimerization domain. In some embodiments, the homodimerization domain comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 245 to 259. In some aspects, the dimer is a heterodimer dimerized via a first heterodimerization domain and a second heterodimerization domain. In some embodiments, the first heterodimerization domain comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO:260, SEQ ID NO:262, SEQ ID NO:264, SEQ ID NO:266, SEQ ID NO:268, SEQ ID NO:270, SEQ ID NO:272, SEQ ID NO:274, SEQ ID NO:276, SEQ ID NO:278, SEQ ID NO:280, SEQ ID NO:282, SEQ ID NO:284, or SEQ ID NO:286. In some embodiments, the second heterodimerization domain comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO:261, SEQ ID NO:263, SEQ ID NO:265, SEQ ID NO:267, SEQ ID NO:269, SEQ ID NO:271, SEQ ID NO:273, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:279, SEQ ID NO:281, SEQ ID NO:283, SEQ ID NO:285, or SEQ ID NO:287.
[0012] In some embodiments, the target-binding peptide is linked to the dimerization domain via a peptide linker. In some embodiments, the cell receptor-binding peptide is linked to the dimerization domain via a peptide linker. In some embodiments, the cell receptor-binding peptide is linked to the target-binding peptide via a peptide linker. In some embodiments, the peptide linker has a length of 1 to 50 amino acid residues, 2 to 40 amino acid residues, 3 to 20 amino acid residues, or 3 to 10 amino acid residues. In some embodiments, the linker comprises glycine and serine amino acids. In some embodiments, the peptide linker has a duration length of 6 Å or less, 8 Å or less, 10 Å or less, 12 Å or less, 15 Å or less, 20 Å or less, 20 Å or less, 25 Å or less, 30 Å or less, 40 Å or less, or 50 Å or less. In some embodiments, the peptide linker is derived from an immunoglobulin peptide. In some embodiments, the peptide linker is derived from a double-knot toxin peptide. In some embodiments, the peptide linker comprises the sequence of any one of SEQ ID NOs:129 to 141, 195 to 218, 223 to 227, or 391.
[0013] In some embodiments, the cell receptor-binding peptide, the target-binding peptide, or both comprise a miniprotein, nanobody, antibody, antibody fragment, scFv, DARPin, or affibody. In some embodiments, the antibody comprises an IgG, or the antibody fragment comprises a Fab, F(ab)2, scFv, or (scFv)2. In some embodiments, the miniprotein comprises a cystine-dense peptide, affitin, adnectin, avimer, Kunitz domain, nanophytin, fynomer, bicyclic peptide, beta-hairpin, or stapled peptide. In some embodiments, the cell receptor-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds.
[0014] In some embodiments, the target-binding peptide comprises at least one disulfide bond, at least two disulfide bonds, at least three disulfide bonds, or at least four disulfide bonds. In some embodiments, the cell receptor-binding peptide comprises at least six cysteine residues. In some embodiments, the at least six cysteine residues are located at amino acid positions 4, 8, 18, 32, 42, and 46 of the cell receptor-binding peptide. In some embodiments, the at least six cysteine residues form at least three disulfide bonds.
[0015] In some embodiments, the cell receptor-binding peptide comprises the sequence of any one of SEQ ID NOs: 148 to 177. In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 96, 65 to 95, 97 to 128, 220 to 222, or 1 to 64, or at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a fragment of any one of SEQ ID NOs: 96, 65 to 95, 97 to 128, 220 to 222, or 1 to 64. In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 96, or to a fragment of SEQ ID NO: 96. In some aspects, the cell receptor-binding peptide comprises the sequence of SEQ ID NO: 96. In some aspects, the cell receptor-binding peptide comprises the sequence of any one of SEQ ID NOs: 392 through 399.In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO:187, SEQ ID NOs:233-239, SEQ ID NOs:400-456, or SEQ ID NO:241, or a fragment of any one of SEQ ID NOs:187, SEQ ID NOs:233-239, SEQ ID NOs:400-456, or SEQ ID NO:241. In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:187, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:400, or SEQ ID NO:401, or a fragment of SEQ ID NO:187, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:400, or SEQ ID NO:401. In some embodiments, the cell receptor-binding peptide comprises the sequence of SEQ ID NO:187, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:400, or SEQ ID NO:401.In further embodiments, the fragment comprises at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, or at least 50 amino acid residues.
[0016] In some embodiments, the cell receptor-binding peptide comprises one or more histidine residues in the cell receptor binding interface. In some embodiments, the target-binding peptide comprises one or more histidine residues in the target-binding interface. In some embodiments, the target-binding peptide is a PD-L1-binding peptide, an EGFR-binding peptide, or a TNFα-binding peptide. In some embodiments, the PD-L1-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 233, 234, 187, 235-239, 400-456, or 240. In some embodiments, the EGFR-binding peptide binds to EGFR variant III or tyrosine kinase inhibitor-resistant EGFR. In some embodiments, the EGFR-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 219, or SEQ ID NO: 242. In some aspects, the EGFR-binding peptide comprises the sequence of SEQ ID NO: 242. In some aspects, the EGFR-binding peptide comprises the sequence of SEQ ID NO: 243.
[0017] In some embodiments, the target is a cell surface molecule, a growth factor receptor, a secreted peptide, a secreted protein, a circulating molecule, a cell signaling molecule, an extracellular matrix macromolecule, a neurotransmitter, a cytokine, a growth factor, a tumor-associated antigen, a tumor-specific antigen or hormone, a checkpoint inhibitor, an immune checkpoint inhibitor, an inhibitory immunoreceptor, a ligand for an inhibitory immunoreceptor, a macrophage surface protein, a lipopolysaccharide, an antibody, an inhibitory immunoreceptor, a tumor-associated antigen, a tumor-specific antigen, or an autoantibody. In some embodiments, the target is collagen, elastin, a microfibrillar protein, a proteoglycan, CD200R, CD300a, CD300f, CEACAM1, FcgRiib, ILT-2, ILT-3, ILT-4, ILT-5, LAIR-1, PECAM-1, PILR-α, SIRL-1, SIRP-α, CLEC4A, Ly49Q, MIC, CD3, CD47, CD28, CD137, CD89, CD14, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD25, CD7 4, CD40L, MUC1, MUC16, MUC2, MUC5AC, MUC4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TNF-α, EG FR, EGFRvIII, TKI-resistant EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, IGFR1, CTLA4, STRO1, complement factor C4, complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, The target is myloid beta, huntingtin, alpha-synuclein, glucocerebrosidase, alpha-glucosidase, IL-1, IL-1R, IL-1α, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, a member of the B7 family, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, PD-1, or PD-L1. In some embodiments, the target is PD-L1, EGFR, or TNFα.
[0018] In some embodiments, the peptide conjugate has at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs:288-313 or SEQ ID NOs:315-346, or to any one of SEQ ID NOs:347, SEQ ID NO:348, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:371, SEQ ID NO:373, SEQ ID NO:376, SEQ ID NO:378, SEQ ID NO:382, SEQ ID NO:384, SEQ ID NO:387, or SEQ ID NO:389. In some embodiments, the peptide complex comprises the sequence of SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:307, SEQ ID NO:313, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:342, or SEQ ID NO:343; SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:310, SEQ ID NO:315, or SEQ ID NO:316 dimerized with SEQ ID NO:302, SEQ ID NO:305, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:344, or SEQ ID NO:345; SEQ ID NO:296 dimerized with SEQ ID NO:302, SEQ ID NO:339, or SEQ ID NO:344; SEQ ID NO:298; SEQ ID NO:299 dimerized with SEQ ID NO:301; SEQ ID NO:331 or SEQ ID NO:336 dimerized with SEQ ID NO:330 or SEQ ID NO:335; or SEQ ID NO:292, SEQ ID NO:315, or SEQ ID NO:316 dimerized with SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:334, or SEQ ID NO:335.In some embodiments, the peptide complex comprises the sequence of SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:308, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:322, or SEQ ID NO:323; SEQ ID NO:292, SEQ ID NO:294, SEQ ID NO:315, SEQ ID NO:316 dimerized with SEQ ID NO:304, SEQ ID NO:306, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:324, or SEQ ID NO:325; SEQ ID NO:295 or SEQ ID NO:297 dimerized with SEQ ID NO:304, SEQ ID NO:319, SEQ ID NO:321, or SEQ ID NO:324; SEQ ID NO:298 or SEQ ID NO:300 dimerized with SEQ ID NO:303; or SEQ ID NO:326 dimerized with SEQ ID NO:306, SEQ ID NO:311, SEQ ID NO:320, or SEQ ID NO:325.
[0019] In some embodiments, the off-rate of the cell receptor-binding peptide from the cell receptor is slower than the recycling rate of the cell receptor. In some embodiments, the off-rate of the cell receptor-binding peptide from the cell receptor is within 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 7 minutes, 10 minutes, 15 minutes, or 20 minutes. In some embodiments, the peptide complex can be endocytosed via receptor-mediated endocytosis. In some embodiments, the receptor-mediated endocytosis is transferrin receptor-mediated endocytosis. In some embodiments, the cell receptor-binding peptide remains bound to the cell receptor within the endocytic vesicle. In some embodiments, the peptide complex is recycled when the cell receptor-binding peptide binds to the cell receptor and the cell receptor is recycled. In some embodiments, the target is released or dissociated from the target-binding peptide when the peptide complex is endocytosed via receptor-mediated endocytosis.
[0020] In some embodiments, the target is an extracellular protein, a circulating protein, or a soluble protein. In some embodiments, the target is a cell surface protein. In some embodiments, the target is a transmembrane protein. In some embodiments, the peptide complex further comprises a second target-binding peptide. In some embodiments, the second target-binding peptide binds to a second target. In some embodiments, the target and the second target form a dimer upon binding to the target-binding peptide and the second target-binding peptide. In some embodiments, dimerization of the target and the second target increases the rate of endocytosis of the target and the second target. In some embodiments, the second target is the same as the target.
[0021] In some embodiments, the peptide conjugate further comprises a half-life modifying agent conjugated to the cell receptor-binding peptide, the target-binding peptide, or both. In some embodiments, the half-life modifying agent comprises a polymer, polyethylene glycol (PEG), hydroxyethyl starch, polyvinyl alcohol, a water-soluble polymer, a zwitterionic water-soluble polymer, a water-soluble poly(amino acid), a water-soluble polymer of proline, alanine, and serine, a water-soluble polymer comprising glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin. In some embodiments, the molecule that binds to albumin is a serum albumin-binding peptide. In some embodiments, the serum albumin-binding peptide comprises the sequence of any one of SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 193. In some embodiments, the cell receptor-binding peptide, the target-binding peptide, or both are recombinantly expressed.
[0022] In some embodiments, the target-binding peptide is configured to dissociate from the target at pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5. In some embodiments, the cell receptor-binding peptide is configured to dissociate from the cell receptor at pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5.
[0023] In various aspects, the present disclosure provides methods for selectively depleting a target molecule, the method comprising contacting a peptide complex comprising a cell receptor-binding peptide and a target-binding peptide complexed with a cell that expresses a cell receptor; binding the target-binding peptide to the target molecule under extracellular conditions; binding the cell receptor-binding peptide to the cell receptor under extracellular conditions; endocytosing the peptide complex, the target molecule, and the cell receptor; dissociating the target-binding peptide from the target molecule, the cell receptor-binding peptide from the cell receptor, or both, under endosomal conditions; and degrading the target molecule, thereby depleting the target molecule.
[0024] In various aspects, the present disclosure provides methods for selectively depleting a target molecule, the method comprising contacting a peptide conjugate described herein with a cell expressing a cellular receptor; allowing the target-binding peptide to bind to the target molecule under extracellular conditions; allowing the cellular receptor-binding peptide to bind to the cellular receptor under extracellular conditions; endocytosing the peptide conjugate, the target molecule, and the cellular receptor into an endocytic or lysosomal compartment; releasing the target-binding peptide from the target molecule, the cellular receptor-binding peptide from the cellular receptor, or both, under endosomal conditions; and degrading the target molecule, thereby depleting the target molecule.
[0025] In some embodiments, the method further comprises recycling the peptide conjugate and the cellular receptor. In some embodiments, the cellular receptor is a transferrin receptor or PD-L1, and the cellular receptor-binding peptide is a transferrin receptor-binding peptide or a PD-L1-binding peptide. In some embodiments, the cellular receptor-binding peptide is a transferrin receptor-binding peptide, and the cellular receptor is a transferrin receptor. In some embodiments, the cellular receptor-binding peptide is a PD-L1-binding peptide, and the cellular receptor is PD-L1. In some embodiments, endocytosing comprises receptor-mediated endocytosis. In some embodiments, the cellular receptor-binding peptide remains bound to the cellular receptor in an endocytic or lysosomal compartment. In some embodiments, the target molecule is degraded in the endocytic or lysosomal compartment. In some embodiments, the receptor-mediated endocytosis is transferrin receptor-mediated endocytosis.
[0026] In some embodiments, the target molecule is an extracellular protein, a circulating protein, or a soluble protein. In some embodiments, the target molecule is a cell surface protein. In some embodiments, the target molecule is a transmembrane protein. In some embodiments, the method includes allowing the peptide complex to penetrate a cell layer, including the blood-brain barrier (BBB). In some embodiments, the target molecule is degraded in the central nervous system. In some embodiments, the cell expresses a cellular receptor.
[0027] In some embodiments, the method comprises binding the cell receptor-binding peptide to the cell receptor under extracellular conditions with a dissociation constant (KD) of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM, or 0.1 nM or less. In some embodiments, the method comprises binding the cell receptor-binding peptide to the cell receptor under endosomal conditions with a dissociation constant (KD) of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM, or 0.1 nM or less.
[0028] In some embodiments, the target-binding peptide remains bound to the target molecule in the endocytic compartment. In some embodiments, the method comprises binding the target-binding peptide to the target molecule under extracellular conditions with a dissociation constant (KD) of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM, or 0.1 nM or less. In some embodiments, the method comprises binding the target-binding peptide to the target molecule under endosomal conditions with a dissociation constant (KD) of 1 nM or more, 2 nM or more, 5 nM or more, 10 nM or more, 20 nM or more, 50 nM or more, 100 nM or more, 200 nM or more, or 500 nM or more. In some embodiments, the method comprises binding a cell receptor-binding peptide to a cell receptor with an affinity that differs by no more than 2-fold, no more than 5-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold under extracellular conditions compared to under endosomal conditions. In some embodiments, the method comprises forming one or more polar or charge-charge interactions between the target-binding peptide and the target molecule.
[0029] In some aspects, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs:96, 65-95, 97-128, 220-222, or 1-64. In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:96. In some aspects, the cell receptor-binding peptide comprises the sequence of SEQ ID NO:96. In some aspects, the cell receptor-binding peptide comprises the sequence of any one of SEQ ID NOs:392-399. In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO:187, SEQ ID NOs:233-239, SEQ ID NOs:400-456, or SEQ ID NO:241, or a fragment of any one of SEQ ID NOs:187, SEQ ID NOs:233-239, SEQ ID NOs:400-456, or SEQ ID NO:241.In some embodiments, the cell receptor-binding peptide comprises a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 238, or SEQ ID NO: 239, or to a fragment of SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 238, or SEQ ID NO: 239. In some aspects, the cell receptor-binding peptide comprises the sequence of SEQ ID NO: 187, SEQ ID NO: 235, SEQ ID NO: 238, or SEQ ID NO: 239.
[0030] In some embodiments, the method further comprises binding the second target molecule to a second target-binding peptide. In some embodiments, the target molecule and the second target molecule form a dimer upon binding to the target-binding peptide and the second target-binding peptide. In some embodiments, the method comprises increasing the rate of endocytosis of the target molecule and the second target molecule upon dimerization of the target molecule and the second target molecule. In some embodiments, the second target molecule is degraded upon endocytosis of the target molecule and the second target molecule. In some embodiments, the second target molecule is the same as the target molecule.
[0031] In various aspects, the present disclosure provides methods of treating a disease or condition in a subject, the method comprising administering to the subject a peptide complex comprising a cell receptor-binding peptide and a target-binding peptide complexed with the cell receptor-binding peptide; allowing the target-binding peptide to bind under extracellular conditions to a target molecule associated with the disease or condition on cells of the subject expressing the target molecule and the cell receptor; allowing the cell receptor-binding peptide to bind under extracellular conditions to a cell receptor on the cells of the subject; endocytosing the peptide complex, the target molecule, and the cell receptor; dissociating the target-binding peptide from the target molecule, the cell receptor-binding peptide from the cell receptor, or both, under endosomal conditions; and degrading the target molecule, thereby treating the disease or condition.
[0032] In various aspects, the present disclosure provides methods of treating a disease or condition in a subject, the method comprising administering a peptide conjugate described herein to the subject; allowing the target-binding peptide to bind under extracellular conditions to a target molecule associated with the disease or condition on cells of the subject expressing the target molecule and a cellular receptor; allowing the cellular receptor-binding peptide to bind under extracellular conditions to a cellular receptor on the cells of the subject; endocytosing the peptide conjugate, the target molecule, and the cellular receptor; dissociating the target-binding peptide from the target molecule, the cellular receptor-binding peptide from the cellular receptor, or both, under endosomal conditions; and degrading the target molecule, thereby treating the disease or condition.
[0033] In some embodiments, the target molecule is a cell surface molecule, a growth factor receptor, a secreted peptide, a secreted protein, a circulating molecule, a cell signaling molecule, an extracellular matrix macromolecule, a neurotransmitter, a cytokine, a growth factor, a tumor-associated antigen, a tumor-specific antigen or hormone, a checkpoint inhibitor, an immune checkpoint inhibitor, an inhibitory immunoreceptor, a ligand for an inhibitory immunoreceptor, a macrophage surface protein, a lipopolysaccharide, an antibody, an inhibitory immunoreceptor, a tumor-associated antigen, a tumor-specific antigen, or an autoantibody. In some embodiments, the target molecule is collagen, elastin, a microfibrillar protein, a proteoglycan, CD200R, CD300a, CD300f, CEACAM1, FcgRiib, ILT-2, ILT-3, ILT-4, ILT-5, LAIR-1, PECAM-1, PILR-α, SIRL-1, SIRP-α, CLEC4A, Ly49Q, MIC, CD3, CD4 7, CD28, CD137, CD89, CD14, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD25, C D74, CD40L, MUC1, MUC16, MUC2, MUC5AC, MUC4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TNF-α, E GFR, EGFRvIII, TKI-resistant EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, IGFR1, CTLA4, STRO1, complement factor C4, complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, Myloid beta, huntingtin, alpha-synuclein, glucocerebrosidase, alpha-glucosidase, IL-1, IL-1R, IL-1α, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, a member of the B7 family, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, PD-1, or PD-L1. In some embodiments, the target molecule is a receptor tyrosine kinase.In some embodiments, the receptor tyrosine kinase is an EGF receptor, ErbB, insulin receptor, PDGF receptor, VEGF receptor, FGF receptor, CCK receptor, NGF receptor, HGF receptor, Eph receptor, AXL receptor, TIE receptor, RYK receptor, DDR receptor, RET receptor, ROS receptor, LTK receptor, ROR receptor, MuSK receptor, or LMR receptor. In some embodiments, the target molecule is a pathogen or a pathogen surface molecule.
[0034] In some embodiments, the disease or condition is cancer, neurodegenerative disease, lysosomal storage disease, inflammatory disease, autoimmune disease, neuroinflammatory disease, immune disease, or pain.In some embodiments, the cancer is breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, myeloma, cancer of blood cell origin, lung cancer, sarcoma, gastric cancer, gastrointestinal cancer, glioblastoma, head and neck cancer, non-small cell lung cancer, squamous non-small cell lung cancer, pancreatic cancer, ovarian cancer, blood cancer, skin cancer, liver cancer, kidney cancer, or colorectal cancer.In some embodiments, the cancer is TKI resistance, cetuximab resistance, necitumumab resistance, or panitumumab resistance. In some embodiments, the cancer is advanced cancer, metastatic cancer, metastatic cancer of the central nervous system, metastatic breast cancer, metastatic skin cancer, refractory cancer, KRAS wild-type cancer, KRAS mutant cancer, or exon 20 mutant non-small cell lung cancer. In some embodiments, the target molecule is HER2, EGFR, FGFR-1, PD-L1, VEGF, PD-1, CD38, GD2, SLAMF7, CTLA-4, CCR4, CD20, PDGFRα, VEGFR2, CD33, CD30, CD22, CD79B, Nectin-4, or TROP2. In some embodiments, the target molecule is EGFR or PD-L1. In some embodiments, the method further comprises administering an additional treatment to the subject. In some embodiments, the additional treatment comprises radiation, chemotherapy, platinum therapy, or antimetabolite therapy. In some embodiments, the additional therapy comprises fluorouracil, FOLFIRI, irinotecan, FOLFOX, gemcitabine, or cisplatin.
[0035] In some embodiments, the neurodegenerative disease is Alzheimer's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Parkinson's disease, or spinal muscular atrophy. In some embodiments, the target molecule is tau, amyloid beta, huntingtin, or alpha-synuclein. In some embodiments, the lysosomal storage disease is Gaucher disease or Pompe disease. In some embodiments, the target molecule is glucocerebrosidase or alpha-glucosidase. In some embodiments, the inflammatory disease is rheumatoid arthritis, psoriasis, multiple sclerosis, glomerulonephritis, lupus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, cutaneous vasculitis, neuroinflammatory disease, inflammation-associated neurodegeneration, Alzheimer's disease, stroke, traumatic brain injury, Sjogren's disease, or cystic fibrosis. In some embodiments, the target molecule is apolipoprotein E4, TNF-α, IL-1, IL-6, IL-7, IL-12, or IL-23. In some embodiments, the target molecule is TNF-α. In some embodiments, the cell is a cancer cell, an immune cell, a central nervous system cell, a neuron, a T cell, a B cell, a macrophage, a monocyte, a neutrophil, a dendritic cell, a mast cell, a basophil, or an eosinophil.
[0036] In some aspects, the method further comprises forming a ternary complex between the selective depletion complex, the target molecule, and the cellular receptor. In some aspects, the formation of the ternary complex increases recycling or turnover of the cellular receptor, the target molecule, or both. In some aspects, the formation of the ternary complex increases binding of the target molecule to the cellular receptor.
[0037] Incorporation by Reference All publications, patents, and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0038] The novel features described herein are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative implementations, in which the principles of the invention are utilized, and the accompanying drawings of which: [Brief explanation of the drawings]
[0039] [Figure 1]Figure 1 shows a Coomassie-stained gel of human soluble transferrin receptor (hTfR) extracellular domain protein and flow cytometry plots demonstrating the sequential enrichment of cells binding to the hTfR extracellular domain from a pooled high-diversity peptide library. (A) A Coomassie-stained gel of transferrin receptor (hTfR) protein demonstrating successful purification of TfR. (B) Flow cytometry plots of cells displaying candidate TfR-binding peptides after a single flow sorting run. Cells were sorted based on their ability to bind to fluorescent streptavidin-labeled TfR. Data points in the upper right region represent cells expressing candidate peptides, quantified by GFP fluorescence, that bind to TfR, quantified by fluorescent TfR-streptavidin fluorescence. (C) A negative control flow cytometry plot of cells displaying candidate TfR-binding peptides after a single flow sorting run. Cells were stained based on their ability to bind to a fluorescent streptavidin-labeled control protein. Data points in the upper right region represent cells expressing candidate peptides quantified by GFP fluorescence that bind to a negative control protein, as quantified by fluorescence of a fluorescent control protein-streptavidin. (D) Flow cytometry plots of cells displaying candidate TfR-binding peptides after a second flow sort after the first flow sort shown in (B). Cells were sorted based on their ability to bind to TfR labeled with fluorescent streptavidin. Data points in the upper right region represent cells expressing candidate peptides quantified by GFP fluorescence that bind to TfR, as quantified by fluorescence of fluorescent TfR-streptavidin. (E) Flow cytometry plots of cells displaying candidate TfR-binding peptides after a second flow sort after the first flow sort shown in (B) and (C). Cells were stained based on their ability to bind to a control protein labeled with fluorescent streptavidin. Data points in the upper right region represent cells expressing candidate peptides quantified by GFP fluorescence that bind to a negative control protein, as quantified by fluorescence of a fluorescent control protein-streptavidin.F shows a flow cytometry plot of cells displaying candidate TfR-binding peptides after the third flow sort after the second flow sort shown in D. Cells were sorted based on their ability to bind to TfR labeled with fluorescent streptavidin. Data points in the upper right region represent cells expressing candidate peptides quantified by GFP fluorescence that bind to TfR, as quantified by fluorescent TfR-streptavidin fluorescence. Boxes indicate cells expressing peptides that bind to TfR. G shows a negative control flow cytometry plot of cells displaying candidate TfR-binding peptides after the third flow sort after the second flow sort shown in D and E. Cells were stained based on their ability to bind to a control protein labeled with fluorescent streptavidin. Data points in the upper right region represent cells expressing candidate peptides quantified by GFP fluorescence that bind to the negative control protein, as quantified by fluorescent control protein-streptavidin fluorescence. Boxes indicate cells expressing peptides that bind to the negative control protein. [Figure 2]Flow cytometry of cells displaying single clone TfR-binding peptides and screened for binding to either TfR or a negative control protein confirms binding of the TfR-binding peptides to the TfR identified in Figures 1A-1G. To verify that binding is independent of streptavidin labeling, flow cytometry was performed using TfR or control proteins labeled with either streptavidin or anti-His antibody. Figure A shows a negative control flow cytometry plot of cells expressing the TfR-binding peptide of SEQ ID NO: 1 (x-axis, GFP) screened for binding to a labeled negative control protein (y-axis, stained with fluorescent anti-His antibody). Figure B shows a flow cytometry plot of cells expressing the TfR-binding peptide of SEQ ID NO: 1 (x-axis, GFP) screened for binding to TfR (y-axis, stained with fluorescent anti-His antibody). Boxes indicate cells expressing the TfR-binding peptide and binding to TfR. (C) shows a negative control flow cytometry plot of cells expressing the TfR-binding peptide of SEQ ID NO: 1 (x-axis, GFP) screened for binding to a labeled negative control protein (y-axis, stained with fluorescent anti-streptavidin). (D) shows a flow cytometry plot of cells expressing the TfR-binding peptide of SEQ ID NO: 1 (x-axis, GFP) screened for binding to TfR (y-axis, stained with fluorescent anti-streptavidin). Boxes indicate cells expressing the TfR-binding peptide and binding to TfR. [Figure 3]Figure 3 shows TfR binding to peptide variants generated by permuting variants enriched by site-saturation mutagenesis (SSM). Each graph represents a completed round of SSM, and each shaded bar in the corresponding graph indicates the number of mutations in the specific variant peptide indicated below the bar compared to the respective reference peptide sequence on which the SSM round was initiated (SEQ ID NO: 1 in Figure 3A or SEQ ID NO: 2 in Figure 3B). The data show the relative binding affinity of the identified peptides to TfR and represent the final step of the SSM employed, indicating the next generation of molecules. Figure 3A shows the level of hTfR binding to variants containing the sequences SEQ ID NOs: 3 to 23, respectively, obtained from site-saturation mutagenesis (SSM) for affinity maturation of a peptide having the sequence SEQ ID NO: 1. Figure 3B shows the level of hTfR binding to peptide variants containing the sequences SEQ ID NOs: 24 to 28 and SEQ ID NOs: 30 to 32, respectively, obtained from site-saturation mutagenesis (SSM) for affinity maturation of a starting peptide having the sequence SEQ ID NO: 2. [Figure 4] Figure 1 shows surface plasmon resonance (SPR) curves illustrating the binding of TfR-binding peptide variants with different affinities to TfR. Dissociation kinetics was quantified for each peptide variant. Surface plasmon resonance (SPR) traces over time are shown using 300 nM each of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 32. SEQ ID NO: 32 exhibits the strongest binding to TfR, as assessed by SPR. Data were normalized to the maximum response of each trace. [Figure 5] 1 shows surface plasmon resonance (SPR) traces showing hTfR binding at varying concentrations of a peptide having the sequence of SEQ ID NO: 2. Based on this data, the dissociation constant (KD) of the peptide of SEQ ID NO: 2 was determined to be 8.7 nM. [Figure 6] 1 shows surface plasmon resonance (SPR) traces showing hTfR binding at varying concentrations of a peptide having the sequence of SEQ ID NO: 4. Based on this data, the dissociation constant (KD) of the peptide of SEQ ID NO: 4 was determined to be 14.8 nM. [Figure 7] Figure 1 shows surface plasmon resonance (SPR) binding and single-cycle kinetic data for SEQ ID NO: 32 binding to captured biotinylated hTfR. Five concentrations of peptide having the sequence of SEQ ID NO: 32 (0.037 nM, 0.11 nM, 0.33 nM, 1 nM, and 3 nM) were injected over two densities of captured biotinylated (Bt)-hTfR and analyzed globally. Analysis parameters were kept constant for high- and low-density runs, and data from both channels were included in the same analysis. Based on this data, the dissociation constant (KD) of the peptide of SEQ ID NO: 32 was determined to be 216 pM, the on-rate (k) was determined to be 8.55 x 106 M-1 s-1, and the off-rate (kd) was determined to be 1.85 x 10-3 s-1. [Figure 8] Figure 1 shows binding and single-cycle kinetic data for SEQ ID NO:30 binding to captured biotinylated hTfR by SPR. Five concentrations of peptide having the sequence of SEQ ID NO:30 (0.037 nM, 0.11 nM, 0.33 nM, 1 nM, and 3 nM) were injected over two densities of captured Bt-hTfR and analyzed globally. Analysis parameters were kept constant for high- and low-density runs, and data from both channels were included in the same analysis. Based on this data, the dissociation constant (KD) of the peptide of SEQ ID NO:30 was determined to be 486 pM, the on-rate (k) was determined to be 8.57 x 10 M s, and the off-rate (kd) was determined to be 4.16 x 10 s. [Figure 9]Figure 1 shows the purification and testing of soluble transferrin receptor (TfR) extracellular domain to assess whether it binds to transferrin. Figure 2 shows surface plasmon resonance (SPR) traces of holotransferrin or apotransferrin (Tf) binding to purified TfR ectodomain. The data indicate that holoTf, but not apoTf, binds to the TfR ectodomain, as indicated by an increase in response (RU) over time for holoTf but not apoTf. This data validates that the soluble TfR used in screening for TfR-binding CDP peptides contains the endogenous protein structure of TfR on the surface of cells and provides evidence that the binders are useful for receptor-mediated endocytosis. Figure 3 shows a schematic diagram of the vector display scaffold and target binding used to screen and optimize peptide binding properties. A surface display vector (SDGF) encoding a GFP-tagged construct of a binder (e.g., SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 32) is expressed on the cell surface. A target protein (e.g., TfR) labeled with a fluorescent dye ("co-stain") binds to a surface-expressed binding agent. Because cells expressing a peptide with high affinity for the target protein recruit more of the co-stained target than cells expressing a peptide with low affinity for the target protein, the fluorescence intensity of the co-stain is used as a measure of peptide affinity for the target. Figure C shows flow cytometry verifying the specificity of TfR binding to Machupo virus glycoprotein, a known TfR binding target, as measured by the amount of bound Alexa Fluor 647-TfR (co-stained in Figure 9B). Cells transfected with Machupo virus glycoprotein (SDGF-MaCV) are tested with a combination of biotinylated TfR and Alexa Fluor 647-labeled streptavidin (Strep-647), SDGF-MaCV cells with Alexa Fluor 647-labeled elastase, or SDGF-elafin cells with TfR and Strep-647. The cell conjugates of elastase and elafin do not bind to cells.These results demonstrated that the soluble TfR used in the peptide screen constituted an endogenous protein structure and demonstrated both the specificity of TfR binding to its endogenous ligand and the utility of SDGF as a tool to identify novel TfR binding partners. [Figure 10] Figure 1 shows data using flow cytometry to identify binding of a TfR-binding cystine-dense peptide (CDP, SEQ ID NO: 32) fused to GFP to streptavidin-AlexaFluor647 (strep-647)-labeled TfR under pH conditions representing the physiological extracellular environment (pH 7.4) or the endosomal environment (pH 5.5). Figure 2A shows the results of flow cytometry in a binding assay to measure binding of the TfR-binding cystine-dense peptide (CDP) (SEQ ID NO: 32) to TfR at pH 7.4, representing the physiological extracellular environment. Cells expressing SEQ ID NO: 32 were stained with 10 nM TfR and 10 nM Strep-647 at pH 7.4. The box indicates the "slice" gate used in the quantification shown in Figure 2C. Figure 2B shows the results of flow cytometry in a binding assay to measure binding of the TfR-binding CDP (SEQ ID NO: 32) to TfR at pH 5.5. Cells expressing SEQ ID NO: 32 were stained with 10 nM TfR and 10 nM Strep-647 at pH 5.5, representing the endosomal environment. The box indicates the "slice" gate used in the quantification shown in C. C shows a comparison of the labeling efficiency of the TfR-binding peptide at pH 7.4 measured in A with that measured at pH 5.5 measured in B. The results show that binding of the TfR-binding cystine-dense peptide (CDP, SEQ ID NO: 32) is robust and comparable under both physiological extracellular and endosomal conditions. [Figure 11A]1 illustrates a schematic workflow for developing compositions for selective depletion of target molecules. Target-binding peptides are identified by staining an expression library containing candidate target-binding peptides with a labeled target molecule. Target-binding peptides from the library are distinguished by the accumulation of signal from the bound target molecule. Optionally, the identified target-binding peptides are selected and further matured for binding, e.g., using point mutation screening. The identified target-binding peptides are engineered for pH-dependent binding, e.g., by performing a histidine point mutation scan as shown in D. The resulting pH-dependent target-binding peptide is linked (e.g., as a fusion peptide) to a recycling agent (e.g., a TfR-binding peptide) to form a selective depletion complex. [Figure 11B] 1 shows a schematic representation of in vitro validation of the ability of selective depletion complexes to deplete targets, such as from the cell surface or medium. [Figure 11C] Schematic representation of phenotypic screening of selective depletion complexes. The selective depletion complexes can be validated by testing target depletion in cells expressing the selective depletion complex. The complexes can be further tested in healthy cells and transformed cell lines to determine disease-specific functions of the selective depletion complex. The specificity of the complex can be measured by testing for changes in target-specific cellular function, such as cancer-specific growth inhibition due to depletion of apoptosis inhibitors. [Figure 11D] Figure 1 shows an example of a histidine substitution scan to introduce pH-dependent binding affinity into a target-binding peptide. A histidine substitution scan of PD-L1-binding CDP (SEQ ID NO: 187) is shown. The peptide sequence is provided above and to the side, with each black box representing the first and second potential His substitution sites. Falling along the diagonal line from top left to bottom right represents a single His substitution. A peptide library containing the identified histidine-containing peptides can be generated and screened, for example, using the workflow shown in A. [Figure 12A]
[0023] A schematic diagram of a method for selectively depleting soluble target molecules using a composition comprising a target-binding peptide with pH-dependent binding and a TfR-binding peptide, such as a TfR-binding peptide with pH-independent binding, is shown. The composition binds to the TfR and the soluble target molecule and is endocytosed via transferrin receptor-mediated endocytosis. Acidification of the endocytic compartment releases the target molecule, which is partially or completely degraded in the lysosomal compartment. The TfR and composition are then recycled to the cell surface. [Figure 12B]
[0023] A schematic diagram of a method for selectively depleting surface target molecules using a composition comprising a target-binding peptide with pH-dependent binding and a TfR-binding peptide, such as a TfR-binding peptide with pH-independent binding. The composition binds to the TfR and the surface target molecule and is endocytosed via transferrin receptor-mediated endocytosis. Acidification of the endocytic compartment releases the target molecule, and some or all of the target molecule is degraded in the lysosomal compartment. The TfR and composition are recycled to the cell surface. [Figure 13]Figure 1 shows the production and purity of a peptide fused to a serum albumin-binding peptide (SA21). Figure 2 shows the production and purity of a TfR-binding peptide fused to a serum albumin peptide (SA21) corresponding to SEQ ID NO: 181. The peptide of SEQ ID NO: 181 was produced as a siderocalin (SCN, SEQ ID NO: 147) fusion and then cleaved from SCN by TEV. Purity was verified by SDS-PAGE (left) and RP-HPLC (right) under DTT-reducing ("R") or non-reducing ("NR") conditions. SDS-PAGE was also performed on the uncleaved ("U") siderocalin-CDP fusion peptide. This data demonstrates that SEQ ID NO: 181 fused to SCN was successfully produced and then cleaved by TEV cleavage to yield the free CDP fusion of SEQ ID NO: 181. Figure 3 shows the production and purity of a peptide fused to SA21 corresponding to SEQ ID NO: 182. The peptide of SEQ ID NO: 182 was produced as an SCN fusion and then cleaved from the SCN by TEV. Purity was verified by SDS-PAGE (left) and RP-HPLC (right) under DTT-reducing ("R") or non-reducing ("NR") conditions. SDS-PAGE was also performed on the uncleaved ("U") siderocalin-CDP fusion peptide. This data demonstrates that SCN-fused SEQ ID NO: 182 was successfully produced and then cleaved by TEV cleavage to yield the free CDP fusion of SEQ ID NO: 181. [Figure 14A] 1 shows a schematic representation of a CDP-CDP dimer comprising a target-binding CDP linked to a TfR-binding CDP via a double-knot toxin (DkTx) peptide linker (SEQ ID NO: 139, KKYKPYVPVTTN). [Figure 14B] 1 shows a schematic representation of a CDP-CDP dimer comprising a target-binding CDP linked to a TfR-binding CDP via a poly-GlySer linker (SEQ ID NO: 138, GGGSGGGSGGGS). [Figure 14C] Schematic representation of a CDP-CDP dimer comprising a target-binding CDP linked to a TfR-binding CDP via a human IgG linker with a Cys to Ser mutation at position 5 (SEQ ID NO: 140, EPKSSDKTHT). [Figure 15]Schematic representation of a TfR-binding peptide non-covalently linked to a target-binding peptide via an Fc bispecific dimer. [Figure 16A] Schematic representation of a fusion of a TfR-binding peptide and a target-binding peptide, separated by a peptide linker (e.g., any one of SEQ ID NOs: 129-141 or SEQ ID NOs: 195-218), comprising an albumin-binding protein (e.g., SEQ ID NO: 192) between the target-binding peptide and the TfR-binding peptide. [Figure 16B] Schematic representation of a fusion of a TfR-binding peptide and a target-binding peptide, comprising an albumin-binding protein (e.g., SEQ ID NO: 192) fused to the target-binding peptide by a peptide linker (e.g., any one of SEQ ID NOs: 129-141 or SEQ ID NOs: 195-218). [Figure 16C] Schematic representation of a fusion of a TfR-binding peptide and a target-binding peptide, comprising an albumin-binding protein (e.g., SEQ ID NO: 192) fused to a TfR-binding peptide by a peptide linker (e.g., any one of SEQ ID NOs: 129-141 or SEQ ID NOs: 195-218). [Figure 17A] This figure shows an SDS-PAGE gel of expressed, TEV-cleaved CDP-CDP dimers containing a TfR-binding peptide (SEQ ID NO: 2) fused to an ion channel-inhibitory CDP (Z1E-AnTx, Z1P-AnTx, EWSS-ShK, HsTx, Pro-Vm24, or Vm24) via either a DkTx linker (SEQ ID NO: 139) or a GS3 linker (SEQ ID NO: 141 or SEQ ID NOs: 195 to 218). Expression products after TEV cleavage included SCN-CDP dimers, SCN, and CDP dimers. The dimer bands present in each gel are indicated by rectangles. This demonstrates that the CDP dimers were successfully expressed and cleaved from SCN. From left to right, each gel contained the molecular weight of the latter ("L"), a peptide sample under non-reducing conditions ("NR"), and a peptide sample under reducing conditions ("R"). [Figure 17B]SDS-PAGE (left), RP-HPLC (center), and channel inhibition assay (right) are shown for a TfR-binding peptide (SEQ ID NO: 32, top), a Vm24 ion channel inhibitory peptide (center), and a CDP-CDP dimer (bottom) containing a TfR-binding peptide fused to a Vm25 ion channel inhibitory peptide. "Folding" indicates that the sample was analyzed under non-reducing conditions, and "Unfolding" indicates that the sample was analyzed under reducing conditions. This data demonstrates that a target-binding CDP (here, an ion channel inhibiting CDP) can dimerize with a TfR-binding peptide (such as SEQ ID NO: 32), be expressed, folded, and purified, and that the target-binding CDP can maintain its target-binding function while in a dimer with the TfR-binding CDP (the function shown here is ion channel inhibitory). [Figure 18]Figure 1 shows flow staining data demonstrating that the TfR-binding peptide is cross-reactive with mouse TfR (mTfR) in a cell surface binding assay. 293F cells expressing either human or mouse TfR on their surface were stained with a soluble TfR-binding peptide directly labeled with AlexaFluor 647 dye. This demonstrates that the TfR-binding peptide binds to both human (hTfR, SEQ ID NO: 190) and mouse TfR. Figure 2 shows the species specificity of the TfR used in these experiments, in this case, human TfR. Data are presented as two topographic density maps, showing flow cytometry data for transferrin stained with an anti-hTfR (CD71) antibody. The upper density map, arranged diagonally from bottom left to top right, shows 293ST + SDGF-hTfR. The lower density map, arranged horizontally, shows 293ST + SDGF-mTfR. The y-axis shows hTfR + streptavidin on a logarithmic scale of 0-107 in 10 increments. The x-axis shows GFP on a logarithmic scale of 0-106 in 10 increments. B shows the species specificity of the TfR used in these experiments, in this case, mouse TfR. Data are presented as two topographic density maps, showing flow cytometry data for transferrin stained with anti-mTfR (CD71) antibodies. The upper density map, arranged diagonally from bottom left to top right, shows 293ST + SDGF-mTfR. The lower density map, with three lobes, shows 293ST + SDGF-hTfR. The y-axis shows hTfR + streptavidin on a logarithmic scale of 10-4 to 107 in 10 increments. The x-axis shows GFP on a logarithmic scale of 0-106 in 10 increments. (C) Quantification of binding of a peptide having the sequence of SEQ ID NO: 1, a peptide having the sequence of SEQ ID NO: 2, a peptide having the sequence of SEQ ID NO: 30, and a peptide having the sequence of SEQ ID NO: 32 to human TfR. Data are shown as four topographic density maps representing flow cytometry data using 293ST cells + SDGF-hTFR. Three density maps are nearly superimposable and are positioned on top of the fourth density map. The bottom density map is positioned horizontally and represents SEQ ID NO: 1 (first generation). The top three density maps are positioned diagonally from bottom left to top right.The density map slightly above the other two corresponds to SEQ ID NO: 32 (generation 3). The density map slightly below the other two corresponds to SEQ ID NO: 2 (generation 2). The third density map corresponds to SEQ ID NO: 30 (generation 3). This data shows that peptides having the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, and SEQ ID NO: 32 bind to human TfR. The peptide having the sequence of SEQ ID NO: 1 binds weaker than the other three peptides tested. The y-axis shows hTfR + streptavidin on a logarithmic scale of 0 to 10 in increments of 10. The x-axis shows GFP on a logarithmic scale of 0 to 10 in increments of 10. D shows quantification of binding of peptides having the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, and SEQ ID NO: 32 to mouse TfR. Data are presented as four topographic density maps, showing flow cytometry data using 293ST cells + SDGF-mTFR. Three density maps are nearly superimposable and are positioned on top of the fourth. The bottom density map is positioned horizontally and shows SEQ ID NO: 1 (first generation). The top three density maps are positioned diagonally from bottom left to top right. The density map slightly above the other two corresponds to SEQ ID NO: 32 (third generation). The density map slightly below the other two corresponds to SEQ ID NO: 2 (second generation). The third density map corresponds to SEQ ID NO: 30 (third generation). This data shows that peptides having the sequences SEQ ID NO: 2, SEQ ID NO: 30, and SEQ ID NO: 32 bind to mouse TfR. The peptide having the sequence SEQ ID NO: 1 did not demonstrate binding to mTfR under the conditions tested. The y-axis shows hTfR + streptavidin on a logarithmic scale from 0 to 10 in increments of 10. The x-axis shows GFP on a logarithmic scale from 0 to 106 in increments of 10. [Figure 19]Figure 1 shows the CDP-NT peptide complex inducing an IP1 response downstream of the neurotensin receptor (NTSR) in both CRE-luciferase (CRE-Luc) mice and mammalian cells. A shows the relevant pathways affecting CRE-driven luciferase in CRE-Luc mice. PLC indicates phospholipase C. AC indicates adenylyl cyclase. CaMK indicates calmodulin-dependent protein kinase. CREB indicates cAMP response element-binding protein. PKA indicates protein kinase A. PDE indicates cAMP phosphodiesterase. FS indicates forskolin. Rol indicates rolipram. GPCR indicates G protein-coupled receptor. B shows in vitro neurotensin (NT) receptor binding, demonstrating IP1 accumulation only in response to NT or the NT peptide complex in HEK-293 cells expressing NTSR1. IP1 was measured by FRET ratio readout using an assay kit (CisBio 62IPAPEB). Well numbers were N=3 for all except vehicle, which was N=36. Bars indicate sample means. mTF=mouse transferrin. Baseline HEK293=mean assay value of HEK293 cells not expressing NTSR1 (N=36 wells) was included as a reference. [Figure 20A]The mechanisms of resistance to tyrosine kinase inhibitor (TKI) or anti-EGFR antibody therapy (e.g., cetuximab) in EGFR-driven cancer cells are illustrated schematically. EGFR-driven cancer cells with normal EGFR (Panel 1) are sensitive to both anti-EGFR antibodies and tyrosine kinase inhibitors, with reduced downstream KRAS and MEK signaling in response to either treatment (indicated by gray dashed arrows). EGFR mutations that prevent TKI binding (Panel 2) are resistant to TKIs and show little or no change in downstream signaling in response to TKI treatment (indicated by black solid arrows). TKI-resistant EGFR-driven cancer cells can remain sensitive to anti-EGFR antibodies. Heterodimerization and cross-activation by other related growth factor receptors (e.g., HER2, ERBB3, or MET) renders EGFR-driven cancer cells (Panel 3) that overexpress the dimerization partner insensitive to either or both anti-EGFR antibodies and TKIs. EGFR-driven cancer cells in which EGFR is constitutively active, such as EGFR variant III (EGFRvIII) (Panel 4), are insensitive to anti-EGFR antibodies that prevent EGFR activation by dimerization. Cells with constitutively active EGFR can still be sensitive to TKIs. [Figure 20B]This figure shows a schematic depicting the use of selective depletion complexes (SDCs) to overcome resistance mechanisms in EGFR-driven cancer cells. This demonstrates that SDCs can be effective against EGFR-driven cancers, including cancers or cancer cells with normal EGFR and cancers or cancer cells resistant to TKI or EGFR antibody therapy. EGFR-driven cancer cells with normal EGFR (Panel 1) are effectively depleted by SDC, resulting in reduced downstream KRAS and MEK signaling in response to SDC treatment (indicated by gray dashed arrows). Mutant EGFRs that prevent TKI binding (Panel 2) are effectively depleted by SDC, resulting in reduced downstream KRAS and MEK signaling in response to SDC treatment. EGFRs that heterodimerize and cross-activate with overexpressed growth factor receptors (e.g., HER2, ERBB3, MET, Panel 3) are effectively depleted by SDC, resulting in reduced downstream KRAS and MEK signaling in response to SDC treatment. Depletion of heterodimerized EGFR can also deplete heterodimerization partners (e.g., HER2, ERBB3, or MET, panel 3). Constitutively active EGFRs such as EGFRvIII (panel 4) are effectively depleted by SDC, resulting in decreased downstream KRAS and MEK signaling in response to SDC treatment. [Figure 21]Figure 11 shows flow sorting data demonstrating enrichment of peptides with pH-dependent binding to PD-L1. The data demonstrate that pH-dependent binding peptides can be generated by flow sorting. A histidine-doped library based on the PD-L1-binding peptide (SEQ ID NO: 187), prepared as described in Figure 11D, was screened for peptides that exhibited stronger PD-L1 binding at neutral pH (7.4) and weaker binding at acidic pH (5.5). The input library was initially screened for high PD-L1 binding at pH 7.4. The second and third rounds of screening ("Sort 1" and "Sort 2," respectively) were performed at pH 5.5 to mimic endosomal pH and enriched for peptides with poor PD-L1 binding at this pH. The final round of screening ("Sort 3") was performed at pH 7.4. After screening, differential binding was observed at pH 7.4 and pH 5.5 ("Sort 4"). The pentagonal areas in each graph indicate the populations selected during sorting. The darker topographic density map shows PD-L1 staining under pH 7.4 conditions, and the lighter topographic density map shows PD-L1 staining under pH 5.5 conditions. [Figure 22]Figure 21 shows binding data at pH 7.4 (left bar) and pH 5.5 (right bar) for the pH-dependent PD-L1-binding peptide variants identified. Variants of SEQ ID NO: 187 with E2H, M13H, and K16H substitutions were screened individually and in combination for pH-dependent binding to PD-L1. Peptide variants containing substitutions in E2H (SEQ ID NO: 234), M13H (SEQ ID NO: 235), K16H (SEQ ID NO: 236), E2H and M13H (SEQ ID NO: 237), E2H and K16H (SEQ ID NO: 233), M13H and K16H (SEQ ID NO: 238), or E2H, M13H, and K16H (SEQ ID NO: 239) showed varying degrees of pH-dependent binding to PD-L1. "UTF" indicates untransfected cells (negative control). The parent peptide (SEQ ID NO: 187) showed some pH-dependent binding to PD-L1. Some variants of SEQ ID NO: 187 showed more pH-dependence in PD-L1 binding than the parent, while some variants of SEQ ID NO: 187 showed less pH-dependence in PD-L1 binding than the parent. Peptide SEQ ID NO: 234 was shown to have a large difference in binding at pH 7.4 versus pH 5.5, demonstrating higher binding at pH 7.4 than at pH 5.5. Peptide SEQ ID NO: 233 (black arrow) was shown to have a particularly large difference in binding at pH 7.4 versus pH 5.5, also demonstrating higher binding at pH 7.4 than at pH 5.5. This data demonstrates the generation of peptides that bind to PD-L1 at higher levels at pH 7.4 and lower levels at pH 5.5. [Figure 23A] 23B and 23C show schematic diagrams of the domain organization of selective depletion complexes such as those utilized in the assays shown in Figures 23B and 23C. The selective depletion complexes comprise, from N- to C-terminus, a target-binding peptide, a first peptide linker (GGGGSx4, SEQ ID NO:224), an albumin-binding peptide (SEQ ID NO:227), a second peptide linker (GGGGSx4, SEQ ID NO:224), and a TfR-binding peptide. [Figure 23B]Figure 23A shows an SDS-PAGE gel of two purified selective depletion complexes arranged as shown in Figure 23A, as well as two negative control complexes in which the TfR-binding peptide was replaced with a peptide that does not bind to TfR. Peptide 1 (SEQ ID NO:367) contained the target-binding peptide that binds to EGFR (SEQ ID NO:244) and the peptide that does not significantly bind to TfR corresponding to SEQ ID NO:232. Peptide 2 (SEQ ID NO:328) contained the target-binding peptide that binds to EGFR (SEQ ID NO:244) and the high-affinity TfR-binding peptide corresponding to SEQ ID NO:96. Peptide 3 (SEQ ID NO:357) contained the target-binding peptide that binds to PD-L1 (SEQ ID NO:187) and the peptide that does not significantly bind to TfR corresponding to SEQ ID NO:232. Peptide 4 (SEQ ID NO:356) contained the target-binding peptide that binds to PD-L1 (SEQ ID NO:187) and the high-affinity TfR-binding peptide corresponding to SEQ ID NO:96. This data demonstrates the production and purity of these peptides. [Figure 23C] Figure 23B shows the formation of ternary complexes between the four peptide complexes shown in Figure 23B and cells expressing EGFR (left) or PD-L1 (right). Cells were stained with fluorescently labeled TfR to detect ternary complex formation between the target protein, peptide complex, and TfR expressed on the cell surface. Peptide 2 (SEQ ID NO: 328), which contains an EGFR-binding peptide and a high-affinity TfR-binding peptide, formed a ternary complex with EGFR-expressing cells but not with PD-L1-expressing cells. Peptide 4 (SEQ ID NO: 356), which contains a PD-L1-binding peptide and a high-affinity TfR-binding peptide, formed a ternary complex with PD-L1-expressing cells but not with EGFR-expressing cells. Peptides 1 and 3, which do not contain a high-affinity TfR-binding peptide, did not form a ternary complex. These data demonstrate that peptide complexes containing a target-binding peptide and a TfR-binding peptide can form ternary complexes with the target and TfR on the cell surface. [Figure 24A] Schematic showing the formation of a ternary complex between a selective depletion complex (comprising SDC, a target-binding peptide, a receptor-binding peptide, and a His tag (SEQ ID NO: 228)), a target protein expressed on the cell surface, and a transferrin receptor expressed on the cell surface. [Figure 24B] Binding data are shown for peptide conjugates with (+) or without (-) a target-binding peptide that binds to PD-L1 (SEQ ID NO: 187, "PDL1") and with or without a receptor-binding peptide that binds to TfR (SEQ ID NO: 96, "TfR") to cells expressing TfR with or without PD-L1 ("PDL1"). All peptide conjugates contained a His tag (SEQ ID NO: 228). The first bar corresponds to a PBS negative control without peptide conjugate. The second and third bars were measured using the peptide conjugate of SEQ ID NO: 357. The fourth and fifth bars were measured using the peptide conjugate of SEQ ID NO: 356, which can bind to both PD-L1 and TfR. Peptide conjugates containing both PD-L1-binding and TfR-binding peptides may be selective depletion complexes (SDCs). Binding was measured using a fluorescent anti-His antibody bound to the His tag on the peptide conjugate. High levels of binding were observed when SDCs that bind both PD-L1 and TfR were used on cells expressing both PD-L1 and TfR. The data indicate that when cells express both the target and the receptor, SDCs containing peptides that bind both the target and the receptor bind to the cells at high levels (fifth bar). The data also indicate that TfR-binding peptide complexes bind to TfR-expressing cells (fourth bar), whereas the addition of surface target-binding material increases SDC binding (fifth bar), likely due to cooperative binding. Cooperative binding can also be achieved by using SDCs containing two TfR-binding peptides. [Figure 25A]Examples of monovalent selective depletion complexes containing a single target-binding moiety (in this example, an EGFR-binding nanobody or PD-L1-binding CDP) and a single receptor-binding moiety (in this example, a TfR-binding CDP or scFv) are shown schematically. These can be configured as a single protein in which both moieties are separated by a linker, or as a dimeric complex in which one monomer contains the TfR-binding moiety and the other monomer contains the target-binding moiety. Active catalytic molecules are molecules in which the TfR-binding moiety binds in a pH-independent manner and the target-binding moiety binds in a pH-dependent manner. Active noncatalytic molecules are molecules in which the TfR-binding moiety binds in a pH-dependent manner and the target-binding moiety binds in a pH-independent manner. Either active catalytic or active noncatalytic molecules are expected to cause selective depletion of their targets. Noncatalytic molecules travel with their targets through the endosomal degradation pathway, while catalytic molecules follow TfR back to the cell surface and bind to another target. An exemplary control molecule is one to which both the TfR-binding moiety and the target-binding moiety bind in a pH-independent manner, but which is expected to cause selective depletion of the target as effectively or to the same extent as an active catalytic or non-active molecule, or which is not expected to cause selective depletion of the target at all or in a significant manner. Other controls can be used to assess the TfR dependence of an active catalytic molecule or an active non-catalytic molecule, and can include comparative measurements of depletion of molecules that do not bind to TfR. The control is one to cause selective depletion of the target as effectively or to the same extent as an active catalytic or non-catalytic molecule, or which is not expected to cause selective depletion of the target at all or in a significant manner. [Figure 25B] An example of a selective depletion complex with different valencies for TfR binding and / or target binding is shown schematically. The figure shows an Fc fusion in which the TfR-binding moiety (in this case, a pH-independent TfR-binding CDP) can be present once (monovalent) or twice (bivalent) within the molecule, and the target-binding moiety (in this case, a pH-dependent EGFR-binding nanobody) can be present once (monovalent) or twice (bivalent) within the molecule. Fc fusions in which the two monomers are not identical can be assembled by knobs-in-holes (KIH) dimerization. Multivalent selective depletion complexes can also be expressed as a single polypeptide chain (not shown). [Figure 26A] Figure 1 shows the co-crystal structure of a high-affinity PD-L1 binding CDP (SEQ ID NO: 187, cartoon) bound or docked to PD-L1 (surface, light shading indicates oxygen, dark shading indicates nitrogen). [Figure 26B] Figure 26 shows the relative binding enrichment, expressed as the absolute value of the mean SSM enrichment, for PD-L1-binding CDP variants containing amino acid substitutions at resolved (R) or unresolved (UR) residues, as seen in the co-crystal structure in Figure 26 A. Substitutions at resolved residues had a greater positive or negative effect on binding than substitutions at unresolved residues (**: P = 0.0055), indicating that resolved residues played a greater role in the interaction with PD-L1 than unresolved residues. [Figure 26C] Overlay of PD-1 (mesh) and SEQ ID NO:187 (cartoon) at the binding interface with PD-L1 is shown (surface; light shading indicates oxygen, dark shading indicates nitrogen). The PD-1 binding site overlaps with SEQ ID NO:187, indicating that SEQ ID NO:187 is predicted to compete with PD-1 for binding to PD-L1. [Figure 26D] Figure 26A shows close-up views of the PD-L1 co-crystal structure of SEQ ID NO: 187 from two different angles. Residues of SEQ ID NO: 187 that interact with PD-L1 are shown as sticks, including K5, V9, W12, M13, K16, V39, F40, L43, and D44. Residues of PD-L1 that interact with SEQ ID NO: 187 are also labeled, including Y56, Q66, R113, M115, A121, and Y123. [Figure 26E] Isolated side chains of selected residues of SEQ ID NO:187 (gray) are shown at the PD-L1 binding interface to the parent CDP (black, minimally clashing rotamers). The labeled residues of SEQ ID NO:187, including M13, V39, F40, and L43, correspond to substitutions relative to the parent CDP that improved binding to PD-L1. [Figure 26F]Figure 1 shows a close-up of the binding interface between SEQ ID NO:187 (cartoon) and PD-L1 (surface). The PD-L1 surface is color-coded according to human (Hs) and mouse (Mm) homology. White corresponds to identical residues, dark shading corresponds to similar residues, and light shading corresponds to different residues. These differences in the binding interface between human PD-L1 and mouse PD-L1 are consistent with the lack of mouse PD-L1 cross-reactivity seen with SEQ ID NO:187. [Figure 26G] The co-crystal structure of SEQ ID NO:187 with PD-L1 is shown, where SEQ ID NO:187 is shown as a wire diagram with the side chain of interest indicated by the thick stick (top). For comparison, the binding of PD-1 to PD-L1 is shown below. DETAILED DESCRIPTION OF THE INVENTION
[0040] Described herein are compositions and methods for selectively depleting target molecules using cellular endocytic pathways (e.g., transferrin receptor-mediated endocytosis). Extracellular, soluble, and cell surface proteins mediate signaling between cells and organs, including proliferation, cell death, inflammation, and metabolism. Such proteins undergo a periodic cycle of production, use, and degradation, typically within the endosomal-lysosomal pathway. In this pathway, endocytic vesicles containing materials taken up from the extracellular space and embedded membrane proteins are acidified and fuse with or enter lysosomes containing enzymes that degrade such proteins. Selective removal of specific cell surface or soluble proteins from circulating or disease-related tissues via selective delivery to lysosomes can be used to treat diseases caused by the overexpression or accumulation of soluble or cell surface proteins, or diseases associated with mutations in the soluble or surface proteins (e.g., mutations that result in constitutive activity, resistance to treatment, or dominant-negative activity). Alternatively, or in addition, the selective depletion complexes described herein can be used to deliver administered therapeutic agents to the endosomal or lysosomal compartment, for example, to treat lysosomal storage diseases such as Gaucher disease (glucocerebrosidase deficiency) or Pompe disease (α-glucosidase deficiency). A therapeutic molecule (e.g., a lysosomal enzyme for enzyme replacement therapy) can be administered together with a selective depletion complex containing a target-binding peptide that binds to the therapeutic molecule, thereby delivering the therapeutic molecule to endosomes or lysosomes. In some embodiments, the selective depletion construct can function as a selective delivery complex, facilitating delivery of active enzymes to endosomes or lysosomes. For example, lysosomal enzymes can be delivered using a selective depletion complex, retaining enzymatic activity within the endosome or lysosome. Administration of a lysosomal enzyme in combination with a selective depletion complex containing a target-binding peptide that binds to the lysosomal enzyme can increase the therapeutic response per dose of enzyme administered compared to administration of the lysosomal enzyme alone.For selective depletion of target proteins or delivery of lysosomal proteins, lysosomal delivery can be achieved by exploiting existing protein uptake and recycling mechanisms and engineering pH-dependent binding domains into the target-binding molecules.
[0041] A unique example of an endocytic pathway that can be used for selective depletion of target molecules is via the internalization and trafficking of transferrin via the transferrin receptor (TfR), which is typically used for the recycling of transferrin via the TfR for iron delivery to cells and tissues. Transferrin is known as a serum chaperone for iron ions directed to redox-sensitive intracellular enzymes. Iron-loaded transferrin (holo-transferrin) delivers iron into cells via specific binding to TfR, where it is transported to endosomes, where the pH is lowered by natural proton pumps. Under acidic conditions, transferrin loses its iron-binding affinity and releases iron into the cell, while maintaining its TfR-binding affinity. The TfR:transferrin complex is then recycled to the cell surface, exposing transferrin to neutral pH conditions. Transferrin that is not bound by iron (apo-transferrin) no longer has TfR affinity under neutral pH conditions at the cell surface and is released into the circulation to pick up more iron, essentially repeating the process of catalyzing iron delivery to cells.
[0042] The disclosed compositions and methods utilize the transferrin receptor endocytosis and recycling pathway to deliver target molecules (e.g., soluble or cell-surface proteins) to endocytic vesicles for lysosomal degradation. The disclosed compositions and methods can be used to selectively degrade specific target receptors or soluble proteins overexpressed in diseases via this pathway. As a result of lysosomal degradation of the target receptor or soluble protein, the described compositions and methods effectively reduce, diminish, eliminate, or deplete the target receptor from circulating cell-surface or soluble proteins, which has many applications in medicine as described herein. The disclosed selective depletion complexes utilize a TfR-binding peptide (e.g., a TfR-binding cysteine-dense peptide) conjugated to a target-binding peptide (e.g., a target-binding cystine-dense peptide, target-binding antibody, target-binding nanobody, target-binding antibody fragment, or other targeting agent) that can recruit target molecules to the TfR by binding to both the TfR (via the TfR-binding peptide) and the target (via the target binding). During endocytosis, the TfR can deliver the selective depletion complex and the target molecule into an endocytic vesicle. In some embodiments, the TfR-binding peptide of the selective depletion complex can have high affinity for TfR from extracellular pH (approximately pH 7.4) to endosomal pH (approximately pH 5.5), inclusive. The TfR-binding peptide can maintain its affinity for TfR upon internalization and acidification of the endosomal compartment. The target-binding peptide of the selective depletion complex can have higher affinity for the target molecule at extracellular pH and lower affinity for the target molecule at lower endosomal pH. Within the endocytic vesicle, the selective depletion complex remains bound to the TfR and can release the target molecule upon endosomal acidification. Once the target is released, the selective depletion complex remains bound to the TfR, and the TfR is recycled to the cell surface to be reloaded with another target molecule. The target molecule can remain lodged in the endosome, where it is delivered to the lysosome for degradation.In some embodiments, the TfR-binding peptide of the selective depletion complex can have a higher affinity for TfR at extracellular pH and a lower affinity for the target molecule at lower endosomal pH. Once inside endocytic vesicles, the selective depletion complex can be released from the TfR upon endosomal acidification.
[0043] The disclosed methods can include contacting a cell (e.g., a cell expressing TfR) with a selective depletion complex (e.g., a molecule comprising a TfR-binding peptide and a target-binding peptide). The selective depletion complex can recruit a target molecule to an endocytic vesicle via transferrin receptor-mediated (TfR-mediated) endocytosis. The target molecule can be released into the endocytic vesicle, where it is delivered to lysosomes for degradation. The selective depletion complex can remain bound to TfR and remain bound to TfR as it recycles to the cell surface. Such methods can be used to deplete target molecules, such as molecules associated with a disease or condition. For example, the disclosed methods can be used to selectively deplete soluble or cell-surface proteins that are overexpressed, contain disease-associated mutations (e.g., mutations that cause constitutive activity, therapy resistance, or dominant-negative activity), or accumulate in a disease or condition.
[0044] In some embodiments, the selective depletion complexes described herein can comprise peptide conjugates, peptide complexes, peptide constructs, fusion peptides, or fusion molecules (e.g., peptide constructs or peptide complexes) linked by chemical conjugation of any type of molecule, such as a small molecule, peptide, or protein, or by recombinant fusion of a peptide or protein, respectively. The terms "fusion peptide" and "peptide fusion" are used interchangeably herein. In some embodiments, the peptide construct or peptide complex can be produced biologically or synthetically. Thus, in some cases, the selective depletion complex can comprise a TfR-binding peptide domain linked to another molecule or group of molecules, such as a small molecule, peptide, or protein, or to other macromolecules, such as a nanoparticle.
[0045] In some embodiments, the selective depletion complexes described herein can be peptide complexes comprising one or more TfR-binding peptides described herein conjugated, linked, or fused to one or more target-binding peptides, one or more active agents (e.g., therapeutic agents, detectable agents, or combinations thereof), or combinations thereof. The selective depletion complexes described herein can include chemical conjugates and recombinant fusion molecules. In some cases, chemical conjugates can comprise TfR-binding peptides described herein chemically conjugated or linked to another peptide (e.g., a target-binding peptide), molecule, agent, or combinations thereof. Molecules can include small molecules, peptides, polypeptides, proteins, or other macromolecules (e.g., nanoparticles) and polymers (e.g., nucleic acids, polylysine, or polyethylene glycol). In some cases, the TfR-binding peptides of the present disclosure are conjugated to another peptide or molecule via a linker. The linker moiety can include a cleavable (e.g., pH-sensitive linker or enzyme-labile linker) or stable linker. In some embodiments, the peptide complex is a fusion molecule (e.g., a fusion peptide or a fusion protein) that can be recombinantly expressed, and the fusion molecule can include one or more TfR-binding peptides fused to one or more other molecules, peptides, polypeptides, proteins, or other macromolecules, that can be recombinantly expressed.
[0046] The selective depletion complexes of the present disclosure (e.g., complexes comprising a TfR-binding peptide and a target-binding peptide) can have a therapeutic effect at a lower dose or have a longer-lasting therapeutic effect compared to lysosome-delivered molecules that are degraded but not recycled to the cell surface. The selective depletion complexes of the present disclosure can recycle to the cell surface and "reload" targets rather than being degraded in the lysosome, meaning that a single selective depletion complex of the present disclosure can potentially promote the degradation of multiple targets through a potential catalytic effect. Lysosome-delivered molecules that are not recycled to the cell surface may themselves be degraded or accumulate in lysosomes without being recycled or "reloaded." The selective depletion complexes of the present disclosure (e.g., complexes comprising a TfR-binding peptide and a target-binding peptide) can have a wider therapeutic window (i.e., the dose above which a therapeutic drug response is observed but below which toxicity is observed) compared to lysosome-delivered molecules that are not recycled to the cell surface. The therapeutic window of a drug (e.g., a selective depletion complex of the present disclosure) is the dose range in which the drug is effective without unacceptable toxic effects. The selective depletion complexes of the present disclosure (e.g., complexes comprising a TfR-binding peptide and a target-binding peptide) can be used with less risk of toxicity. The selective depletion complexes of the present disclosure (e.g., complexes comprising a TfR-binding peptide and a target-binding peptide) can be used at lower molar doses than alternative therapies that do not recycle to the cell surface (e.g., lysosome-delivered molecules). Due to the selectivity and recyclable nature of the selective depletion complexes of the present disclosure within cells, they offer the advantage that, as therapeutic agents, they are not depleted as rapidly as non-recyclable delivery compositions that target the lysosome and are depleted as they are used. Furthermore, due to the selectivity and recycling aspects of the selective depletion complexes of the present disclosure, as therapeutic agents, they offer the advantage of being less toxic than non-selective therapeutic agents. This is particularly advantageous in cancer applications, where therapeutic agents can be non-selective and highly toxic, exhibiting adverse side effects on normal cells, organs, and tissues, or requiring less than effective therapeutic doses, thereby reducing their ability to alleviate, cure, or eliminate disease.
[0047] The selective depletion complexes of the present disclosure (e.g., complexes comprising a TfR-binding peptide and a target-binding peptide) may be less immunogenic than alternative therapies (e.g., lysosomal delivery molecules) that include sugars, glycans, sugar-like molecule-containing polymers, or other derivatives. The selective depletion complexes of the present disclosure may be less immunogenic than alternative therapies (e.g., lysosomal delivery molecules) that target the mannose-6-phosphate receptor or the asialoglycoprotein receptor. The selective depletion complexes of the present disclosure can be produced by a single recombinant expression system, which may improve production yield, purity, cost, or production time over molecules that require multiple synthetic steps to generate ligands for the mannose-6-phosphate receptor or the asialoglycoprotein receptor. The selective depletion complexes of the present disclosure may have greater therapeutic efficacy or lower therapeutic doses due to the ability to design linkers to maximize their ability to simultaneously bind to the TfR and the target, including targets that bind on the cell surface. The TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure may be less immunogenic than TfR-binding antibody-based therapeutics because they contain fewer epitopes that elicit adaptive immune responses. The TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure may exhibit easier and less disruptive incorporation of active agents into protein fusion complexes compared to TfR-binding antibody-based therapeutics. The TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure may have a smaller surface area than TfR-binding antibody-based therapeutics, thereby reducing the risk of off-target binding. The TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure may be formulated at higher molar concentrations than TfR-binding antibody-based therapeutics because of their smaller molecular weight, smaller hydrodynamic radius, or lower molar solution viscosity.
[0048] In some embodiments, the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure exhibit lower on-target toxicity than anti-TfR antibodies or other therapeutic agents when administered to a subject at the same molar dose or a similarly effective dose. In some embodiments, the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides exhibit lower off-target toxicity than antibodies or other therapeutic agents when administered to a subject at the same molar dose or a similarly effective dose. For example, the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure can be administered to a subject at a molar dose that is about 1-, 2-, 3-, 4-, 5-, 10-, 15-, 20-, 25-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, or 100-fold higher than an antibody, yet observe comparable or lower toxicity. In some embodiments, the TfR-binding peptides, TfR-binding peptide conjugates, or TfR-binding fusion peptides of the present disclosure exhibit greater efficacy than anti-TfR antibodies or other therapeutic agents when administered to a subject at the same weight dose as the anti-TfR antibodies or other therapeutic agents. When fused to a half-life extending moiety (e.g., Fc, SA21, PEG), the TfR-binding peptides of the present disclosure can be delivered at even lower doses while maintaining activity and efficacy, thus far superior to the administration of anti-TfR antibodies or other therapeutic agents.
[0049] In some embodiments, the present disclosure provides peptides (e.g., CDPs, knot peptides, or hitchins), chemical conjugates (e.g., comprising one or more TfR-binding peptides and one or more active agents), or recombinantly expressed fusion molecules (e.g., comprising one or more TfR-binding peptides and one or more active agents) that bind to TfR. The TfR-binding peptide may be a cysteine-dense peptide (CDP). The terms "peptide," "miniprotein," "protein," "CDP," "TfR-binding peptide," "TfR-binding CDP," "TfR-binding peptide," and "engineered TfR-binding peptide" are used interchangeably herein. Binding of the peptides described in this disclosure to TfR can facilitate transcytosis of selective depletion complexes, peptides, peptide complexes, or peptide constructs (e.g., fusion proteins, or peptides conjugated, linked, or fused to drugs) across a cellular barrier (e.g., the BBB). Binding of the peptides described herein to TfR can promote endocytosis of selective depletion complexes, peptides, or peptide complexes in any cells expressing TfR, as well as in some cancer cells, liver cells, spleen cells, and bone marrow cells. Also disclosed herein is the use of a mammalian surface display screening platform to screen a diverse library of CDPs to identify CDPs that specifically bind to human TfR. Such identified peptides can be modified to improve binding to TfR and used in selective depletion complexes as peptides or peptide complexes that bind to TfR and recycle to the cell surface (e.g., pH-independent TFR-binding CDPs as shown in Figures 12A and 12B). Also disclosed herein is the use of a mammalian surface display screening platform to screen a diverse library of CDPs to identify CDPs that specifically bind to a target desired for degradation.Such identified peptides can be optimized for binding to a selected target and used in selective depletion complexes as peptides or peptide complexes (e.g., pH-dependent target-binding CDPs as shown in Figures 12A and 12B) that bind to such selected targets and are released in endosomes for intracellular degradation. Further affinity maturation can then be performed to obtain an allelic series of TfR-binding CDPs or target-binding CDPs with varying affinities, as needed. In some embodiments, TfR-binding CDPs or target-binding CDPs are identified, and binding can be determined by crystallography or other methods. The peptides of the present disclosure can have cross-reactivity across species. For example, the peptides disclosed herein optionally bind to human and mouse TfR. The peptides disclosed herein accumulate in the CNS after intravenous administration and can penetrate the BBB via TfR binding. Disclosed herein are TfR-binding CDPs for use as therapeutic delivery agents in oncology, autoimmune diseases, acute and chronic neurodegeneration, and pain management. Delivery of active agents or pharmaceutical agents via TfR-binding CDPs may be advantageous over conventional anti-TfR antibodies due to easier manufacturing (peptides can be produced by biological or synthetic means), improved stability, improved therapeutic window, and smaller size (less potential for steric hindrance of cargo activity). Thus, the disclosed methods and compositions may provide a solution to the problem of effectively transporting cargo molecules (e.g., therapeutic and / or diagnostic small molecules, peptides, or proteins) into the CNS (e.g., the brain). For example, peptides of the present disclosure aid in drug delivery to tumors located in the brain.
[0050] In some embodiments of the present disclosure, CDPs, knot peptides, hitchins, or diverse libraries of knot peptide or hitchin-derived peptides can be used in conjunction with mammalian surface display screening platforms to identify peptides that specifically bind to human TfRs for which recycling or degradation is desired. (See, e.g., Crook et al. (2017) Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets. Nat Commun 8:2244.) In some embodiments, CDPs, knot peptides, hitchins, or diverse libraries of knot peptide or hitchin-derived peptides are mutated from endogenous peptide sequences to obtain novel peptide sequences. Once TfR- or target-binding peptides are identified, affinity maturation (e.g., site-saturation mutagenesis) can be performed to generate an allelic series of binders with varying (e.g., improved) affinities for TfR or targets. These techniques can be used in combination with various other analytical methods (e.g., crystallography or spectroscopy) to identify the nature of the peptide-receptor interaction (e.g., amino acid residues important for receptor binding, etc.) Optionally, the peptides of the present disclosure are matured to bind to the human TfR.
[0051] In some embodiments, engineered peptides (e.g., histidine-containing or histidine-rich target-binding peptides) of the present disclosure have high target-binding affinity at physiological extracellular pH (e.g., a pH of about pH 7.2 to about pH 7.5, a pH of about pH 6.5 to about pH 7.5, or a pH of about pH 6.5 to about pH 6.9), but may exhibit significantly reduced binding affinity at low pH levels, such as those of endosomes at about pH 6.5, about pH 6.0, or about pH 5.5. The extracellular pH may be, for example, pH 7.4. The extracellular pH may be lower, including in the tumor microenvironment, such as pH 7.2, 7.0, or 6.8. In some embodiments, for example, in the tumor environment, the extracellular pH may be about pH 6.5 to about pH 6.9. During endocytosis, the pH of the endosome decreases. The pH of the endosome may be lowered by the action of proton pumps or by coalescence with other vesicles with lower pH. The pH may drop to 7.0, then to 6.5, then to 6.0, then to below 5.5. Some endosomes are called early endosomes and may have a pH around 6.5. Some of these endosomes become recycling endosomes. Some endosomes are called late endosomes and may have a pH around 5.5. Some endosomes become or merge with lysosomes, which may have a pH of 4.5. Enzymes and other factors within the lysosomes may cause the degradation of the contents of the lysosomes. In some embodiments, the target-binding peptide is released into endosomes at about pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower. In some embodiments, the target-binding peptide can be released at any time during the endosomal maturation process due to a decrease in pH following endocytosis. In some cases, histidine scanning and comparative binding experiments can be performed to develop and screen such peptides.In some embodiments, amino acid residues in the peptides of the present disclosure are substituted with different amino acid residues to alter the pH-dependent binding affinity to a target or TfR. The amino acid substitutions can increase the binding affinity at low pH, increase the binding affinity at high pH, decrease the binding affinity at low pH, decrease the binding affinity at high pH, or a combination thereof. For example, a peptide or peptide complex used in a selective depletion complex that has high affinity for TfR and binds to TfR for recycling to the cell surface can be a pH-independent TfR-binding peptide (e.g., a pH-independent TfR-binding CDP) that is not released within endosomes. In some embodiments, the TfR-binding peptide can remain bound to TfR due to increased ionic strength in the endosomal compartment caused by endosomal acidification. In some embodiments, the TfR-binding peptide is stable at endosomal pH and does not release in endosomes under acidic conditions, such as pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower. Conversely, a peptide used in a selective depletion complex, such as a peptide or peptide complex that has high affinity for binding to a selected target and is released in endosomes for intracellular degradation, can be a pH-dependent target-binding CDP that is released in endosomes. In some embodiments, the target-binding peptide can release its target due to endosomal acidification, which increases the ionic strength of the endosomal compartment.In some embodiments, the target-binding peptides are less stable at endosomal pH and are released in whole or in part within endosomes under acidic conditions, such as, for example, pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower. In some cases, the TfR-binding peptides of the present disclosure can be optimized to improve function within vesicles (e.g., within endosomes) while retaining high TfR-binding ability. Exemplary TfR-binding peptides of the present disclosure are set forth in Table 1, including the amino acid sequences set forth in SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, or SEQ ID NO:1-SEQ ID NO:64.
[0052] Described herein, in some embodiments, are peptides and peptide conjugates, and methods for screening peptides and peptide conjugates for binding to proteins or molecules of interest, such as TfR, or for binding to target molecules for depletion, or both. Compared to wild-type or endogenous molecules, such as transferrin, the methods and compositions described herein can provide peptides with improved TfR binding ability, peptides that exhibit improved transport ability across the BBB, or any combination thereof. In some cases, the peptides described herein efficiently transport cargo molecules (e.g., target binding molecules) across an endothelial cell layer (e.g., the BBB) or an epithelial layer. In some embodiments, the TfR-binding peptides of the present disclosure bind to TfR and promote vesicular transcytosis. In some cases, the TfR-binding peptides of the present disclosure bind to cells that overexpress TfR (e.g., cancer cells) and promote uptake of the peptide by the cells. In some aspects, the TfR-binding peptides or peptide conjugates described herein promote vesicular transcytosis and uptake, or a combination thereof, by TfR-overexpressing cells, such as cancer cells. In some cases, the TfR-binding peptides of the present disclosure promote TfR-mediated endocytosis of the selective depletion complex and the target molecule.
[0053] The TfR-binding peptides of the present disclosure can bind to TfRs from different species, including human, monkey, mouse, and rat TfRs. In some cases, variations or mutations in any of the amino acid residues of the TfR-binding peptides can affect cross-reactivity. In some cases, variations or mutations in any of the amino acid residues of the TfR-binding peptides that interact with the binding site of the TfR can affect cross-reactivity.
[0054] Described herein are peptides, including, but not limited to, designed or engineered peptides, recombinant peptides, and cysteine-dense peptides (CDPs) / small disulfide-knot peptides (e.g., knot peptides, hitchins, and peptides derived therefrom), that are large enough to deliver cargo molecules while retaining the ability to bind to target proteins (e.g., TfR) with high affinity, yet small enough to access cellular tissues, such as the center of cellular aggregates (e.g., solid tumors). In some cases, the peptides described herein deliver cargo molecules across the BBB to the CNS (e.g., parenchyma) via vascular transcytosis. In some cases, the transcytosis is TfR-mediated.
[0055] Additionally, described herein are methods and compositions for determining the nature of peptide-receptor interactions (e.g., using X-ray crystallography) and for determining in vivo pharmacodynamic and pharmacokinetic properties, including accumulation in the CNS (e.g., brain) or other affected organs and tissues. Some of the peptides described herein have the ability to target and accumulate in tumor cells. In some cases, the tumor cells overexpress TfR. In some embodiments, the peptides of the present disclosure have high in vivo stability, e.g., high protease stability, high resistance to reducing agents such as glutathione (GSH), and can withstand high temperatures (e.g., up to 95°C).
[0056] The present disclosure, in some embodiments, provides a peptide or protein design approach based on 3D protein or receptor structures to identify peptides or proteins capable of binding to such receptors. In some cases, the receptor is a transferrin receptor.
[0057] As used herein, the abbreviations for natural L-enantiomer amino acids are standard and are as follows: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); valine (V, Val). Typically, Xaa can represent any amino acid. In some embodiments, X can be asparagine (N), glutamine (Q), histidine (H), lysine (K), or arginine (R).
[0058] Some embodiments of the present disclosure contemplate D-amino acid residues of any standard or non-standard amino acid or their analogs. When an amino acid sequence is represented by a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino-terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.
[0059] The terms "peptide," "polypeptide," "miniprotein," "protein," "hittin," "cysteine-dense peptide," "knot peptide," or "CDP" may be used interchangeably herein to refer to a polymer of amino acid residues. In various embodiments, a "peptide," "polypeptide," and "protein" may be a chain of amino acids whose alpha carbons are linked via peptide bonds. Thus, the terminal amino acid at one end of the chain (e.g., the amino-terminus or N-terminus) may have a free amino group, and the terminal amino acid at the other end of the chain (e.g., the carboxy-terminus or C-terminus) may have a free carboxyl group. As used herein, the term "amino terminus" (e.g., N-terminus for short) may refer to the free α-amino group on the amino terminal amino acid of a peptide, or the α-amino group (e.g., an imino group when involved in a peptide bond) of an amino acid at any other position within the peptide. Similarly, the term "carboxy terminus" may refer to the free carboxyl group on the carboxy terminal of a peptide, or the carboxyl group of an amino acid at any other position within the peptide. Peptides also include essentially any polyamino acid, including, but not limited to, peptidomimetics such as amino acids linked by ether or thioether to amide bonds.
[0060] As used herein, the term "peptide construct" may refer to a molecule comprising one or more peptides of the present disclosure that can be conjugated, linked, or fused to one or more peptide or cargo molecules. In some cases, the cargo molecule is an active agent. The term "active agent" may refer to any molecule, for example, any molecule capable of inducing a biological and / or physical effect (e.g., emission of radiation) that can enable localization, detection, or visualization of the respective peptide construct. In various embodiments, the term "active agent" refers to a therapeutic and / or diagnostic agent. The peptide construct of the present disclosure may comprise a TfR-binding peptide linked to one or more active agents via one or more linker moieties (e.g., cleavable or stable linkers) described herein.
[0061] As used herein, the term "peptide complex" can refer to one or more peptides of the present disclosure that are fused, linked, conjugated, or connected to form a complex. In some cases, the one or more peptides can include a TfR-binding peptide, a target-binding peptide, a half-life-modifying peptide, a peptide that modifies pharmacodynamic and / or pharmacokinetic properties, or a combination thereof. For example, a peptide complex comprising a TfR-binding peptide and a target-binding peptide can be referred to herein as a selective depletion complex.
[0062] As used herein, the terms "comprise" and "have" can be used interchangeably. For example, the terms "a peptide comprising the amino acid sequence of SEQ ID NO: 32" and "a peptide having the amino acid sequence of SEQ ID NO: 32" can be used interchangeably.
[0063] As used herein, unless otherwise specified, the term "TfR" or "transferrin receptor" is a type of protein used herein and can refer to transferrin receptors from any species (e.g., human or mouse TfR, or any human or non-human animal TfR). In some cases, the term "TfR" or "transferrin receptor" as used herein can refer to human TfR (hTfR) and can include TfR, or any of the known TfR homologs or orthologs, including TfR1, TfR2, soluble TfR, or any combination or fragment thereof (e.g., the extracellular domain).
[0064] As used herein, the terms "endosome," "endosomal," "endosomal compartment," or "endocytic pathway" can be used interchangeably and may refer to any one or more components of the intracellular endosomal network or trans-Golgi network (TGN). This allows vesicular transcytosis, or transport and movement of peptides and cargo between different membrane-bound compartments within the cell, including lysosomal degradation and recycling to the cell surface. Such pathways involve the maturation and transition of vesicles, commonly referred to as transport vesicles, from early endosomes to late endosomes and lysosomes, and it is understood that the acidity of endosomal compartments increases throughout the maturation process due to endosomal acidification. Lysosomes, which serve as the final vesicles in the mature endocytic pathway, typically contain hydrolytic enzymes that digest the contents of late endosomes. Other endosomes proceed through the endosomal recycling pathway, where their contents are recycled to the cell surface.
[0065] As used herein, "pH-independent" when used in reference to a molecule or moiety means that as the endosomal compartment becomes acidic, the binding affinity of the molecule or moiety to its target does not change to such an extent that it can dissociate from the target in the endosome.For example, the reference molecule or moiety has the same or similar affinity to its target at extracellular pH and endosomal pH.It is also understood that pH-independent molecules or moieties do not include pH-dependent molecules or moieties, because the binding affinity of pH-dependent molecules or moieties to their target changes as they enter and pass through the endosomal pathway, allowing them to dissociate from the target to some extent in the endosome, or the reference molecule or moiety has different affinity at extracellular pH and endosomal pH.
[0066] The term "engineered," when applied to a polynucleotide, indicates that the polynucleotide has been removed from its natural genetic environment, and therefore is free of other unrelated or undesired coding sequences, and is in a form suitable for use in a genetically engineered protein production system. Such engineered molecules are those that have been separated from their natural environment and include cDNA and genomic clones (i.e., prokaryotic or eukaryotic cells containing vectors that include segments of DNA derived from different organisms). Engineered DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally or non-natively occurring 5' and 3' untranslated regions, such as enhancers, promoters, and terminators.
[0067] An "engineered" polypeptide or protein is one that exists in a state other than its native environment, such as away from blood and animal tissue. In a preferred form, the engineered polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. The polypeptide is preferably provided in a highly purified form, e.g., greater than 90% pure, greater than 95% pure, more preferably greater than 98% pure, or greater than 99% pure. As used in this context, the term "engineered" does not exclude the existence of the same polypeptide in alternative physical forms, such as dimers, heterodimers, and multimers, or alternatively glycosylated, carboxylated, modified, or derivatized forms.
[0068] An "engineered" peptide or protein is a polypeptide that is distinctly different in structure, sequence, or composition from a naturally occurring polypeptide. Engineered peptides include non-natural peptides, artificial peptides, isolated peptides, synthetic peptides, designed peptides, modified peptides, or recombinantly expressed peptides. Engineered TfR-binding peptides, variants, or fragments thereof are provided herein. These engineered TfR-binding peptides can be further linked to a target-binding moiety or a half-life-extending moiety, or can be further linked to an active agent or a detectable agent, or any combination of the foregoing.
[0069] Polypeptides of the present disclosure include, for example, polypeptides that have been modified in some way to (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity, (5) alter binding affinity at specific pH values, and (6) impart or alter other physicochemical or functional properties. For example, single or multiple amino acid substitutions (e.g., conservative amino acid substitutions) are made in the naturally occurring sequence (e.g., in a portion of the polypeptide other than the domain(s) that form intermolecular contacts). A "conservative amino acid substitution" may refer to the substitution of an amino acid in a polypeptide with a functionally similar amino acid. The following six groups include amino acids that may be conservative substitutions for each other: i) alanine (A), serine (S), and threonine (T); ii) aspartic acid (D) and glutamic acid (E); iii) asparagine (N) and glutamine (Q); iv) arginine (R) and lysine (K); v) isoleucine (I), leucine (L), methionine (M), and valine (V); vi) phenylalanine (F), tyrosine (Y), and tryptophan (W). In some embodiments, conservative amino acid substitutions may include unnatural amino acids. For example, substitution of an amino acid for a non-naturally occurring derivative of the same amino acid may be a conservative substitution.
[0070] As used herein, the terms "polypeptide fragment" and "truncated polypeptide" can refer to a polypeptide having an amino-terminal and / or carboxy-terminal deletion compared to the corresponding full-length peptide or protein. In various embodiments, the fragment is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 amino acids in length. In various embodiments, fragments can also be, for example, up to 1000, up to 900, up to 800, up to 700, up to 600, up to 500, up to 450, up to 400, up to 350, up to 300, up to 250, up to 200, up to 150, up to 100, up to 50, up to 25, up to 10, or up to 5 amino acids in length. A fragment can further comprise one or more additional amino acids at either or both of its termini, for example, a sequence of amino acids derived from a different naturally occurring protein (e.g., an Fc or leucine zipper domain), or an artificial amino acid sequence (e.g., an artificial linker sequence).
[0071] As used herein, the terms "peptide" or "polypeptide," in connection with "variant," "mutant," or "enriched variant," or "permutation-enriched variant," can refer to a peptide or polypeptide that can include an amino acid sequence in which one or more amino acid residues have been inserted into, deleted from, and / or substituted from another polypeptide sequence. In various embodiments, the number of inserted, deleted, or substituted amino acid residues is at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 225, at least 250, at least 275, at least 300, at least 350, at least 400, at least 450, or at least 500 amino acids in length. Variants of the present disclosure include peptide conjugates or fusion molecules (e.g., peptide constructs or peptide complexes).
[0072] A "derivative" of a peptide or polypeptide can be a peptide or polypeptide that may have been chemically modified, e.g., conjugated to another chemical moiety, such as polyethylene glycol, albumin (e.g., human serum albumin), phosphorylation, and glycosylation.
[0073] The term "sequence identity" may be used interchangeably with "identity" herein and may refer to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% identity means the same as 80% sequence identity determined by a defined algorithm, meaning that a given sequence is at least 80% identical to another sequence of a different length. In various embodiments, the identity percentage is selected from, for example, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99%, or up to 100% sequence identity to a given sequence. In various embodiments, the percent identity is within the range of, for example, about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0074] The terms "sequence homology %" or "sequence homology percent" or "sequence identity percent" may be used interchangeably herein with the terms "homology %," "sequence identity %" or "identity %" and may refer to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same as 80% sequence homology determined by a defined algorithm; thus, homologs of a given sequence have greater than 80% sequence homology over the length of the given sequence. In various embodiments, the percent homology is selected from, for example, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, or up to 100% sequence homology to a given sequence. In various embodiments, the percent homology is within the range of, for example, about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0075] A protein or polypeptide may be "substantially pure," "substantially homogeneous," or "substantially purified" if at least about 60%-75% of a sample represents a single polypeptide species. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein may typically comprise about 50%, 60%, 70%, 80%, or 90% w / w of a protein sample, more commonly about 95%, e.g., greater than 98% or 99% pure. Protein purity or homogeneity can be demonstrated by a number of means well known in the art, such as subjecting a protein sample to polyacrylamide gel electrophoresis followed by staining the gel with stains well known in the art to visualize a single polypeptide band. For certain purposes, high resolution can be achieved by using high-performance liquid chromatography (e.g., HPLC) or other high-resolution analytical techniques (e.g., LC-mass spectrometry).
[0076] As used herein, the term "pharmaceutical composition" may generally refer to a composition suitable for pharmaceutical use in a subject, such as an animal (e.g., a human or a mouse). A pharmaceutical composition may include a pharmacologically effective amount of an active agent and a pharmaceutically acceptable carrier. The term "pharmacologically effective amount" may refer to an amount of an agent effective to produce an intended biological or pharmacological result.
[0077] As used herein, the term "pharmaceutically acceptable carrier" can refer to any of the standard pharmaceutical carriers, vehicles, buffers, and excipients, such as phosphate-buffered saline or buffered saline, 5% dextrose in water, and emulsions such as oil / water or water / oil emulsions, as well as various types of wetting agents and / or adjuvants. Suitable pharmaceutical carriers and formulations are described in Remington's Pharmaceutical Sciences, 21st Ed. 2005, Mack Publishing Co., Easton. A "pharmaceutically acceptable salt" can be a salt that can be formulated into a compound for pharmaceutical use, including, for example, metal salts (sodium, potassium, magnesium, calcium, etc.), and salts of ammonia or organic amines.
[0078] As used herein, the terms "treat," "treating," and "treatment" can refer to a method of alleviating or alleviating a biological disorder and / or at least one of its associated symptoms. As used herein, "alleviating" a disease, disorder, or condition means, for example, reducing the severity of the disease, disorder, or condition and / or the frequency of occurrence of its symptoms. Furthermore, references to "treatment" herein can include references to curative, palliative, and prophylactic or diagnostic treatment.
[0079] In general, the cells of the present disclosure can be eukaryotic or prokaryotic. The cells can be epithelial cells. The cells can be microbial, bacterial, yeast, fungal, or algal cells. The cells can be animal or plant cells. Animal cells can include cells derived from marine invertebrates, fish, insects, amphibians, reptiles, or mammals. Mammalian cells can be obtained from primates, apes, equines, bovines, porcines, canines, felines, or rodents. Mammals can be primates, apes, dogs, cats, rabbits, ferrets, etc. Rodents can be mice, rats, hamsters, gerbils, chinchillas, or guinea pigs. Avian cells can be derived from canaries, parakeets, or parrots. Reptile cells can be derived from turtles, lizards, or snakes. Fish cells can be derived from tropical fish. For example, fish cells can be derived from zebrafish (e.g., Danino rerio), helminth cells can be derived from nematodes (e.g., C. elegans), amphibian cells can be derived from frogs, and arthropod cells can be derived from tarantulas or hermit crabs.
[0080] Mammalian cells can also include cells obtained from a primate (e.g., a human or non-human primate). Mammalian cells can include blood cells, stem cells, epithelial cells, connective tissue cells, hormone-secreting cells, nerve cells, skeletal muscle cells, or immune system cells.
[0081] As used herein, the term "vector" generally refers to a DNA molecule capable of replication in a host cell and / or to which another DNA segment can be operatively linked so as to bring about replication of the attached segment. A plasmid is an exemplary vector.
[0082] As used herein, the term "subject" generally refers to a human or another animal. A subject can be of any age, for example, a subject can be an infant, toddler, child, pre-adolescent, adolescent, adult, or geriatric individual.
[0083] Ranges may be expressed herein from "approximately" one particular value and / or to "approximately" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations by use of the antecedent "about," it is understood that the particular value forms another embodiment. It is further understood that each endpoint of a range corresponds to, and is independent of, the other endpoint. As used herein, the term "about" refers to a range of plus or minus 15% from the specified numerical value, within the scope of particular use. For example, about 10 may include a range of 8.5 to 11.5.
[0084] peptide The selective depletion complexes of the present disclosure can include one or more peptides. For example, the selective depletion complexes of the present disclosure can include a TfR-binding peptide and a target-binding peptide. In some embodiments, two or more peptides can be connected via a linker. The peptides of the present disclosure (e.g., TfR-binding peptides, target-binding peptides, or peptides comprising a TfR-binding peptide linked to a target-binding peptide) can be used in methods for selectively depleting target molecules. The peptides of the present disclosure (e.g., TfR-binding peptides, target-binding peptides, or peptides comprising a TfR-binding peptide linked to a target-binding peptide) can be recycled to the cell surface after endocytosis.
[0085] In some examples, the peptides disclosed herein contain only one lysine residue or no lysine residues. In some examples, one or more or all lysine residues in the peptide are substituted with arginine residues. In some examples, one or more or all methionine residues in the peptide are substituted with leucine or isoleucine. One or more or all tryptophan residues in the peptide can be substituted with phenylalanine or tyrosine. In some examples, one or more or all asparagine residues in the peptide can be substituted with glutamine. In some embodiments, one or more or all aspartic acid residues can be substituted with glutamic acid residues. In some examples, one or more or all lysine residues in the peptide can be substituted with alanine or arginine. In some embodiments, the N-terminus of the peptide can be blocked or protected, such as with an acetyl group or a tert-butyloxycarbonyl group. Alternatively, or in combination, the C-terminus of the peptide can be blocked or protected, such as with an amide group or by forming an ester (e.g., a butyl or benzyl ester). In some embodiments, peptides are modified by methylation on free amines, for example, complete methylation is achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0086] In some embodiments, the dipeptide GS can be added as the first two N-terminal amino acids, as shown in SEQ ID NO:1 to SEQ ID NO:64, or such N-terminal dipeptide GS can be absent or replaced by any other one or two amino acids, as shown in SEQ ID NO:65 to SEQ ID NO:128. In some embodiments, the dipeptide GS is used as a linker or attached to a linker to form a peptide conjugate or fusion molecule, such as a peptide construct or peptide complex. In some embodiments, the linker is G x S y(SEQ ID NO: 130) peptide, where x and y are independently any integer, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and the G and S residues are arranged in any order. In some embodiments, the peptide linker comprises (GS)x (SEQ ID NO: 131), where x can be any integer, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGSSG (SEQ ID NO: 132), GGGGG (SEQ ID NO: 133), GSGSGSGS (SEQ ID NO: 134), GSGG (SEQ ID NO: 135), GGGGS (SEQ ID NO: 136), GGGS (SEQ ID NO: 129), GGS (SEQ ID NO: 137), GGGSGGGSGGGS (SEQ ID NO: 138), or variants or fragments thereof, or any number of repeats thereof, and combinations thereof. Additionally, KKYKPYVPVTTN (SEQ ID NO: 139) derived from DkTx and EPKSSKTHT (SEQ ID NO: 140) derived from human IgG3, or any number of repeats thereof and combinations thereof, can be used as peptide linkers. In some embodiments, the peptide linker comprises GGGSGGSGGGS (SEQ ID NO: 141), or a variant or fragment thereof, or any number of repeats thereof and combinations thereof. It is understood that any of the above linkers or variants or fragments thereof can be used with any number of repeats thereof or any combination thereof. It is also understood that other peptide linkers known in the art or variants or fragments thereof can be used with any number of repeats thereof or any combination thereof. The length of the linker can be adjusted to simultaneously maximize binding of the selective delivery complex to both the TfR and the target, including taking steric accessibility into consideration.In some embodiments, the linker between the TfR-binding peptide and the target-binding peptide in the selective depletion complex is at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 85, at , at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65 residues in a stepwise increase up to a maximum of 100 residues.
[0087] In some embodiments of the present disclosure, a peptide or peptide complex described herein comprises an amino acid sequence set forth in any one of SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, or SEQ ID NO:1-SEQ ID NO:64. The peptides disclosed herein may comprise at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least The peptide fragment may be a contiguous fragment of any one of SEQ ID NOs:96, 65-95, 97-128, 220-222, or 1-64 that is at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, or at least 65 residues in length, and the peptide fragment may be selected from any portion of the peptide. In some embodiments, the peptide sequence is flanked by additional amino acids. The one or more additional amino acids may, for example, confer a particular in vivo charge, isoelectric point, chemical conjugation site, stability, or physiological property to the peptide.
[0088] In some examples, peptides described herein capable of targeting and binding to TfR comprise a length of 80 or less amino acids, or a length of 70 or less, 60 or less, 40 or less, 35 or less, 30 or less, 25 or less, 20 or less, 15 or less, or 10 or less amino acids. In some examples, peptides described herein capable of targeting and binding to target molecules comprise a length of 80 or less amino acids, or a length of 70 or less, 60 or less, 50 or less, 40 or less, 35 or less, 30 or less, 25 or less, 24 or less, 23 or less, 22 or less, 21 or less, 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, or 10 or less amino acids.
[0089] In other embodiments, the peptides may be conjugated, linked, or fused to carriers or molecules that have targeting or homing functions to cells of interest or target cells, hi other embodiments, the peptides may be conjugated, linked, or fused to molecules that extend the half-life of the peptide, or alter its pharmacodynamic and / or pharmacokinetic properties, or any combination thereof.
[0090] In some examples, the peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues, such as Arg or Lys, or any combination thereof. In some examples, one or more lysine residues in the peptide are substituted with arginine residues. In some embodiments, the peptide comprises one or more Arg patches. In some embodiments, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more Arg or Lys residues in the peptide are solvent exposed. In some examples, the peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 histidine residues.
[0091] The peptides of the present disclosure may further comprise neutral amino acid residues. In some embodiments, the peptides have 35 or fewer neutral amino acid residues. In other embodiments, the peptides have 81 or fewer neutral amino acid residues, 70 or fewer neutral amino acid residues, 60 or fewer neutral amino acid residues, 50 or fewer neutral amino acid residues, 40 or fewer neutral amino acid residues, 36 or fewer neutral amino acid residues, 33 or fewer neutral amino acid residues, 30 or fewer neutral amino acid residues, 25 or fewer neutral amino acid residues, or 10 or fewer neutral amino acid residues.
[0092] The peptides of the present disclosure may further comprise negative amino acid residues. In some embodiments, the peptide has 6 or less negative amino acid residues, 5 or less negative amino acid residues, 4 or less negative amino acid residues, 3 or less negative amino acid residues, 2 or less negative amino acid residues, or 1 or less negative amino acid residue. The negative amino acid residues may be selected from any negatively charged amino acid residue, but in some embodiments, the negative amino acid residues are either E or D, or a combination of both E and D.
[0093] In some embodiments of the present disclosure, the three-dimensional or tertiary structure of the peptide is primarily composed of beta sheets and / or alpha helices. In some embodiments, the designed or engineered TfR-binding peptides or target-binding peptides of the present disclosure are small, compact peptides or polypeptides stabilized by cysteine and intrachain disulfide bonds (e.g., mediated by cysteines) that form a hydrophobic core. In some embodiments, the engineered TfR-binding peptide has a structure comprising a helical bundle with at least one disulfide bridge between each of the alpha helices, thereby stabilizing the peptide. In other embodiments, the engineered TfR-binding peptide or target-binding peptide comprises a structure with three alpha helices and three intrachain disulfide bonds, one between each of the three alpha helices in the alpha helical bundle.
[0094] Receptor-binding peptides Disclosed herein are peptide sequences, such as those listed in Tables 1 and 2, that can bind to receptors (e.g., transferrin receptor or programmed death ligand 1). Peptides capable of binding to receptors may be referred to as receptor-binding peptides. In some embodiments, the receptor-binding peptides can bind to recycled receptors that undergo recycling via the recycling pathway. The recycled receptors may be endocytosed into early endosomes and packaged into recycling endosomes before the early endosomes mature into late endosomes. The recycling endosomes containing the recycled receptors can fuse with the plasma membrane, returning the recycled receptors to the cell surface. In some embodiments, the receptor-binding peptides of the present disclosure may remain bound to the receptor during the recycling process, thereby also recycling the receptor-binding peptide. Examples of recycled receptors that can be targeted by receptor-binding peptides include transferrin receptor and programmed death ligand 1. In some embodiments, the receptor-binding peptides of the present disclosure may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, a scFv, a (scFv)2, a DARPin, or an affibody. In some embodiments, the receptor-binding peptide may comprise a cystine-dense peptide, an afftin, an adnectin, an avimer, a Kunitz domain, a nanophytin, a finomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
[0095] In some embodiments, receptor-binding peptides of the present disclosure can bind to receptors (e.g., recycled receptors) with pH-independent affinity. For example, receptor-binding peptides can bind to receptors at extracellular pH (about pH 7.4) with substantially the same affinity as the binding affinity at endocytic pH (e.g., about pH 5.5 or about pH 6.5). In some embodiments, receptor-binding peptides can bind to receptors at extracellular pH (about pH 7.4) with lower affinity than the binding affinity at endocytic pH (e.g., about pH 5.5 or about pH 6.5). In some embodiments, receptor-binding peptides can bind to receptors at extracellular pH (about pH 7.4) with higher affinity than the binding affinity at endocytic pH (e.g., about pH 5.5 or about pH 6.5). In some embodiments, the binding affinity of a receptor-binding peptide for its receptor at extracellular pH (about pH 7.4) may differ from the binding affinity of a receptor-binding peptide for its receptor at endocytic pH (about pH 5.5) by about 1% or less, about 2% or less, about 3% or less, about 4% or less, about 5% or less, about 6% or less, about 7% or less, about 8% or less, about 9% or less, about 10% or less, about 12% or less, about 15% or less, about 17% or less, about 20% or less, about 25%, about 30% or less, about 35% or less, about 40% or less, about 45% or less, or about 50% or less. In some embodiments, the affinity of a receptor-binding peptide for its receptor at pH 7.4 and pH 5.5 may differ by 2-fold or less, 5-fold or less, 10-fold or less, 15-fold or less, 20-fold or less, 25-fold or less, 30-fold or less, 40-fold or less, or 50-fold or less. In some embodiments, the receptor-binding peptide (e.g., any one of SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, SEQ ID NO:1-SEQ ID NO:64, SEQ ID NO:187, SEQ ID NO:233-SEQ ID NO:239, SEQ ID NO:400-SEQ ID NO:456, or SEQ ID NO:241) can be modified to remove one or more histidine amino acids in the TfR binding interface, thereby reducing the pH dependence of the binding affinity of the receptor-binding peptide for the receptor.In some embodiments, the receptor-binding peptide (e.g., any one of SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, SEQ ID NO:1-SEQ ID NO:64, SEQ ID NO:187, SEQ ID NO:233-SEQ ID NO:239, SEQ ID NO:400-SEQ ID NO:456, or SEQ ID NO:241) may lack a histidine amino acid in the receptor-binding interface.
[0096] In some embodiments, receptor-binding peptides with pH-independent binding have a dissociation constant (K) at extracellular pH (about pH 7.4) of less than 50 μM, less than 5 μM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM. D In some embodiments, receptor-binding peptides with pH-independent binding can bind to receptors at endosomal pH (about pH 5.5) with a dissociation constant (K) of less than 50 μM, less than 5 μM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM. D ) can bind to the receptor.
[0097] In some embodiments, the receptor-binding peptide can bind to the receptor with pH-dependent affinity, for example, the receptor-binding molecule can bind to the receptor with higher affinity at extracellular pH (about pH 7.4) and with lower affinity at endosomal pH (about pH 5.5), thereby releasing a selective depletion complex from the receptor upon internalization and acidification of the endosomal compartment.
[0098] In some embodiments, the recycling receptor may be TfR. Peptides capable of binding to transferrin receptor (TfR) can bind to TfR, or any of the known TfR homologs, including TfR1, TfR2, soluble TfR, or any combination or fragment thereof (e.g., extracellular domain). Peptides capable of binding to transferrin receptor or TfR homologs may be referred to herein as transferrin receptor-binding peptides or TfR-binding peptides. In some embodiments, the peptides disclosed herein can penetrate, pass through, or enter target cells in a TfR-mediated manner. These cell layers or cells may include TfR-expressing endothelial cells, epithelial cells, and TfR-expressing cells of various tissues or organs, such as tumor cells, brain cells, cancerous or tumor cells, liver cells (e.g., hepatocytes (HCs), hepatic stellate cells (HSCs), Kupffer cells (KCs), or hepatic sinusoidal endothelial cells (LSECs)), pancreatic cells, colon cells, ovarian cells, breast cells, spleen cells, bone marrow cells, and / or lung cells, or any combination thereof. In some embodiments, the TfR-binding peptides of the present disclosure may comprise a miniprotein, nanobody, antibody, IgG, antibody fragment, Fab, F(ab)2, scFv, (scFv)2, DARPin, or affibody. In some embodiments, the TfR-binding peptide may comprise a cystine-dense peptide, affitin, adnectin, avimer, Kunitz domain, nanophytin, phynomer, bicyclic peptide, beta-hairpin, or stapled peptide.
[0099] In some embodiments, the peptides disclosed herein can cross a cell layer or barrier (e.g., the BBB) or cell membrane, for example, via TfR-mediated vesicular transcytosis and TfR-mediated endocytosis, respectively. In addition to binding to TfR and promoting transcytosis and / or endocytosis, the peptides of the present disclosure can also bind to additional target proteins on cells, such as cancer cells. In some cases, the peptides are peptide or peptide complexes that include a TfR-binding peptide conjugated, linked, or fused to a targeting moiety or active agent (e.g., a therapeutic or diagnostic agent), such as a small molecule or peptide that has affinity for the additional target protein (e.g., a receptor or enzyme). In some cases, the TfR-binding peptide is linked to a target-binding peptide, enabling or promoting TfR-mediated transcytosis of the target-binding peptide across the BBB or TfR-mediated endocytosis into the cell. In some examples, after transcytosis, a peptide complex comprising a TfR-binding peptide and a target-binding peptide can target specific cells or tissues within the CNS and exert a biological effect (e.g., binding to a target protein) upon reaching the cells or tissue. In some cases, the peptide complex of the present disclosure exerts a biological effect mediated by the TfR-binding peptide, the target-binding peptide, an active agent, or a combination thereof. In some cases, a TfR-binding peptide complex of the present disclosure comprising one target-binding peptide can transport and / or deliver a target molecule to cells expressing TfR (e.g., deliver the target molecule to an endosome). In some cases, the TfR-binding peptide accumulates in tissues of the CNS. In some cases, CNS-specific accumulation reduces off-target effects. In some cases, the TfR-binding peptide accumulates in tissues other than the CNS (e.g., the liver, kidney, spleen, or skin). In some cases, the cells expressing TfR are tumor cells, and the TfR-binding peptide complex delivers an anti-tumor agent to these tumor cells.In some cases, anti-tumor agents alone have no or very limited therapeutic effect on tumor cells, but when the anti-tumor agents are combined with the TfR-binding peptides of the present disclosure, e.g., as a peptide conjugate, the therapeutic effect of these anti-tumor agents is greatly improved.
[0100] In some embodiments, the TfR-binding peptides of the present disclosure (e.g., SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, and SEQ ID NO:1-SEQ ID NO:64) can induce a biologically relevant response. For example, a TfR-binding peptide conjugated to a target-binding peptide can selectively deplete soluble or cell-surface target molecules. In some embodiments, a biologically relevant response can be elicited after intravenous, subcutaneous, intraperitoneal, intracranial, or intramuscular administration, and in some embodiments, after a single intravenous, subcutaneous, intraperitoneal, intracranial, or intramuscular administration. In some embodiments, the TfR-binding peptides can be used in combination with various other classes of therapeutic compounds used to treat and / or prevent pain, neuropathic pain, or other neurological disorders, such as neurodegenerative disorders, infectious diseases, immune disorders (e.g., autoimmune diseases), or lysosomal storage diseases. Binding of the peptides and peptide complexes (e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes) described herein to TfR and subsequent transport across a barrier, such as a cell layer or the BBB (e.g., via TfR-mediated vesicular transcytosis), or across a cell membrane (e.g., via TfR-mediated endocytosis) can affect a number of diseases, conditions, or conditions in a subject (e.g., a human) associated with overexpression or accumulation of a target molecule (e.g., cancer, neurodegeneration, or lysosomal storage disease), or diseases associated with mutations in soluble or surface proteins (e.g., mutations that cause constitutive activity, resistance to therapy, or dominant-negative activity).
[0101] Binding of the peptides and peptide complexes described herein (e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes) to TfR and subsequent transport across a barrier, such as a cell layer or the BBB (e.g., via vesicular transcytosis) or across a cell membrane (e.g., via endocytosis) can have an impact on numerous diseases, conditions, or disorders associated with neurodegeneration. Neurodegenerative diseases that can be treated, prevented, or diagnosed by selective depletion complexes comprising the TfR-binding peptides described herein include Alzheimer's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, disease with Lewy bodies, Parkinson's disease, spinal muscular atrophy, motor neuron disease, Lyme disease, ataxia-telangiectasia, autosomal dominant cerebellar ataxia, Batten disease, corticobasal syndrome, Creutzfeldt-Jakob disease, parafragile X tremor / ataxia syndrome, Kufour-Rakeb syndrome, Machado-Joseph disease, multiple sclerosis, chronic traumatic encephalopathy, or frontotemporal dementia.
[0102] In some embodiments, the TfR-binding peptides of the present disclosure can bind to any of the known TfR homologs, including TfR1, TfR2, soluble TfR, or any combination or fragment thereof (e.g., the extracellular domain). Thus, as used herein, "TfR" can refer to any known homolog, derivative, fragment, or member of the TfR family, including TfR1, TfR2, and soluble TfR. In other embodiments, the peptides are capable of binding to one, more than one, or all TfR homologs. In some embodiments, the peptides of the present disclosure can bind to TfR and promote a specific biological effect, such as vesicular transcytosis. In some embodiments, the TfR-binding peptides of the present disclosure, including peptides and peptide complexes comprising the amino acid sequences set forth in SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, and SEQ ID NO:220-SEQ ID NO:222, and SEQ ID NO:1-SEQ ID NO:64, and any derivatives or variants thereof, block or reduce binding of endogenous TfR-binding substances (e.g., transferrin or any derivatives such as apotransferrin or holotransferrin) to TfR. In some embodiments, peptides or peptide conjugates of the present disclosure include derivatives and variants having at least 40% homology, at least 50% homology, at least 60% homology, at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to the amino acid sequences set forth in SEQ ID NO:96, SEQ ID NO:65-95, SEQ ID NO:97-128, SEQ ID NO:220-222, and SEQ ID NO:1-64.
[0103] In various embodiments, the interface residues of the TfR-binding peptides of the present disclosure (e.g., amino acid residues that interact with TfR for receptor binding) can be separated into the two primary helical domains of the peptide. In some cases, the interface residues can include residues corresponding to residues 5-25 relative to SEQ ID NO: 32 (e.g., including residues corresponding to G5, A7, S8, M11, N14, L17, E18, and E21), or residues corresponding to residues 35-51 relative to SEQ ID NO: 32 (e.g., including residues corresponding to L38, L41, L42, L45, D46, H47, H49, S50, and Q51), or both. For example, the interface residues may include residues corresponding to residues 5-25 based on SEQ ID NO: 32 (e.g., including the corresponding residues of G5, A7, S8, M11, N14, L17, E18, and E21), or residues corresponding to residues 35-51 based on SEQ ID NO: 32 (e.g., including the corresponding residues of L38, L41, L42, L45, D46, H47, H49, S50, and Q51). In some embodiments, the TfR-binding peptide can include a fragment of a peptide provided herein, where the fragment includes the minimum interface residues for binding, e.g., residues corresponding to residues 5-25 relative to SEQ ID NO: 32 (e.g., including the corresponding residues of G5, A7, S8, M11, N14, L17, E18, and E21), or residues corresponding to residues 35-51 relative to SEQ ID NO: 32 (e.g., including the corresponding residues of L38, L41, L42, L45, D46, H47, H49, S50, and Q51). In some cases, the TfR-binding peptide is a peptide having the sequence set forth in SEQ ID NO: 32, which includes TfR-binding residues corresponding to residues G5, A7, S8, M11, N14, L17, E18, and E21 of the first domain, and TfR-binding residues corresponding to residues L38, L41, L42, L45, D46, H47, H49, S50, and Q51 of the second domain, based on SEQ ID NO: 32.
[0104] In some embodiments, the TfR-binding peptide has equal, similar, or higher affinity (e.g., a lower dissociation constant K) than an endogenous molecule (e.g., transferrin, holotransferrin (iron-bound transferrin), apotransferrin (iron-unbound transferrin), or any other endogenous TfR ligand) or other exogenous molecule. D In some embodiments, the peptide binds to TfR with a K of less than 50 μM, less than 5 μM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM. D In some embodiments, peptide transport by the TfR may have a lower affinity (e.g., a higher dissociation constant K) compared to endogenous molecules. D In some embodiments, peptide transport through the TfR is improved by having a faster off rate or higher k than the endogenous molecule. off In some embodiments, the off-rate or k off In some embodiments, peptide transport exhibits a faster on-rate or a higher, optionally higher than transferrin, k on In other embodiments, one or more conserved residues at the transferrin (Tf)-TfR binding interface are also present in the amino acid sequences of the peptides described herein. In some embodiments, the TfR-binding peptide has an off-rate that is slower than the recycling rate of TfR, such that the TfR-binding peptide is likely to remain bound to TfR during the recycling process. In some embodiments, the TfR-binding peptide may have an off-rate of 1 minute or less, 2 minutes or less, 3 minutes or less, 4 minutes or less, 5 minutes or less, 7 minutes or less, 10 minutes or less, 15 minutes or less, or 20 minutes or less. In some embodiments, the TfR-binding peptide may have an off-rate of about 1 minute to about 20 minutes, about 2 minutes to about 15 minutes, about 2 minutes to about 10 minutes, or about 5 minutes to about 10 minutes.
[0105] In some embodiments, TfR-binding peptides that exhibit improved TfR receptor binding exhibit improved transcytosis function, improved endocytosis function, improved recycling, or a combination thereof. In some embodiments, TfR-binding peptides that exhibit improved TfR receptor binding exhibit no or only a small change in transcytosis function, endocytosis function, recycling, or a combination thereof. In some embodiments, TfR-binding peptides that exhibit improved TfR receptor binding exhibit decreased transcytosis function, decreased endocytosis function, decreased recycling, or a combination thereof.In some embodiments, the TfR-binding peptide binds at a site of high affinity between human TfR and mouse TfR, including one or more or all of the amino acid domains corresponding to residues 506-510, 523-531, and 611-662 of human TfR1 (SEQ ID NO: 190). In some embodiments, the region of TfR to which the peptides disclosed herein or variants thereof bind is all or part of such a TfR domain.In some embodiments, the peptides disclosed herein bind to any one, any two, or all three highly homologous regions of the TfR, including the amino acid domains corresponding to residues 506-510, 523-531, and 611-662 of the human TfR (SEQ ID NO: 190). In some embodiments, the peptides disclosed herein bind to at least the domain corresponding to residues 611-662 of the human TfR.
[0106] In some embodiments, the K A value and K D Values can be adjusted and optimized (eg, via amino acid substitution) to provide the optimal ratio of TfR binding affinity and efficient transcytosis function.
[0107] In some embodiments, the peptides disclosed herein or variants thereof bind to TfR at residues found in the binding interface (e.g., binding domain or binding pocket) between TfR and other exogenous or endogenous ligands (e.g., transferrin (Tf), Tf derivatives, or Tf-like peptides or proteins). In some embodiments, the peptides disclosed herein that bind to TfR comprise at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to sequences that bind to residues of TfR that comprise the binding pocket. In some embodiments, the TfR-binding peptides or variants thereof disclosed herein comprise at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to an endogenous or exogenous polypeptide known to bind to TfR, e.g., endogenous transferrin, or any one of the peptides listed in Table 1. In other embodiments, the peptides described herein bind to a protein of interest that comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to TfR, a fragment, homolog, or variant thereof.
[0108] In some embodiments, a peptide disclosed herein or a variant thereof binds to a region of TfR that includes amino acid residues corresponding to residues 506-510, 523-531, and 611-662 (the numbering of these amino acid residues is based on the reference protein sequence of endogenous human TFRC UniProtKB-P02786 (SEQ ID NO: 190, TFR1_HUMAN)). In some embodiments, the region of TfR to which a peptide disclosed herein or a variant thereof binds overlaps with that of Tf, a fragment, homolog, or variant thereof.
[0109] In other embodiments, the nucleic acid, vector, plasmid, or donor DNA comprises a sequence encoding a peptide, peptide construct, peptide complex, or variant or functional fragment thereof described in the present disclosure. In further embodiments, a specific portion or fragment of a TfR-binding motif (e.g., a conserved binding motif) can be grafted onto a peptide or peptide complex comprising any one of the sequences set forth in SEQ ID NO:96, SEQ ID NO:65-SEQ ID NO:95, SEQ ID NO:97-SEQ ID NO:128, SEQ ID NO:220-SEQ ID NO:222, or SEQ ID NO:1-SEQ ID NO:64. In some embodiments, the peptide can cause degradation of TfR, prevent TfR from localizing to the nucleus of a cell, or prevent the interaction of TfR with transferrin or transferrin-like proteins.
[0110] In some embodiments, peptides can be selected for further testing or use based on their ability to bind to certain amino acid residues or amino acid residue motifs. Certain amino acid residues or amino acid residue motifs in the TfR can be identified in the amino acid residues or amino acid residue sequences involved in TfR binding to Tf. Certain amino acid residues or amino acid residue motifs can be identified from the crystal structure of the TfR:Tf complex. In some embodiments, peptides (e.g., CDPs) exhibit resistance to heat, proteases (pepsin), and reduction.
[0111] Peptides, peptide conjugates (e.g., peptide conjugates or fusion peptides), and selective delivery complexes comprising one or more of the amino acid sequences set forth in SEQ ID NO:96, SEQ ID NO:65-95, SEQ ID NO:97-128, SEQ ID NO:220-222, or SEQ ID NO:1-64 can bind to a protein of interest. In some embodiments, the protein of interest is TfR. In some embodiments, peptides and peptide conjugates (e.g., peptide conjugates or fusion peptides) that bind to TfR comprise at least one of the amino acid sequences set forth in SEQ ID NO:96, SEQ ID NO:65-95, SEQ ID NO:97-128, SEQ ID NO:220-222, or SEQ ID NO:1-64. In some embodiments, TfR-binding peptides, peptide complexes (e.g., peptide conjugates and fusion molecules) of the present disclosure include peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to the amino acid sequence set forth in SEQ ID NO:96, SEQ ID NO:65-95, SEQ ID NO:97-128, SEQ ID NO:220-222, or SEQ ID NO:1-64. For example, peptides or peptide complexes (e.g., peptide conjugates and fusion molecules) that bind to TfR of the present disclosure can include peptide derivatives or variants having at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology or at least 100% homology to the amino acid sequence set forth in SEQ ID NO:96.
[0112] Table 1 lists exemplary peptide sequences according to the methods and compositions of the present disclosure. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8]
[0113] In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCAX1RCX2KYX4DEX2X3KCX3ARMMSMSNTEEDCEQEX2EDX2X2YCX2X3X5CX5X1X4 (SEQ ID NO: 148) or REGCAX1RCX2KYX4DEX2X3KCX3ARMMSMSNTEEDCEQEX2EDX2X2YCX2X3X5CX5X1X4 (SEQ ID NO: 167), wherein X1 can be independently selected from S, T, D, or N; X2 can be independently selected from A, M, I, L, or V; X3 can be independently selected from D, E, N, Q, S, or T; X4 can be independently selected from D, E, H, K, R, N, Q, S, or T; and X5 can be independently selected from H, K, R, N, Q, S, or T.
[0114] In some embodiments, the TfR-binding peptide disclosed herein comprises GSREX1CX2X3RCX4KYX5DEX6X7KCX8ARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 149) or REX1CX2X3RCX4KYX5DEX6X7KCX8ARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 168), where X1, X2, X3, X4, X5, X6, X7, and X8 are TfR-binding interface residues and may independently be any amino acid. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQEX1EDX2X3YCX4X5X6CX7X8X9 (SEQ ID NO: 150) or REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQEX1EDX2X3YCX4X5X6CX7X8X9 (SEQ ID NO: 169), where X1, X2, X3, X4, X5, X6, X7, X8, and X9 are TfR-binding interface residues and may independently be any amino acid. 10 X 11 YCX 12 X 13 X 13 CX 15 X 16 X 17 (SEQ ID NO: 151) or REX1CX2X3RCX4KYX5DEX6X7KCX8ARMMSMSNTEEDCEQEX9EDX 10 X 11 YCX 12 X 13 X 13 CX 15 X 16 X 17 (SEQ ID NO: 170), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , and X17 are TfR binding interface residues and can independently be any amino acid. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 32).
[0115] In some embodiments, the TfR-binding peptide disclosed herein is 10 X 11 LEX 12 X 13 EX 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 X 40 X 41 X 42 X 43 (SEQ ID NO: 152), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 , X26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , X 40 , X 41 , X 42 , and X 43 can independently be any amino acid.
[0116] In some embodiments, the TfR-binding peptide disclosed herein is 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 LX 38 X 39 LLX 40 X 41 LDHX 42 HSQ (SEQ ID NO: 153), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X17 , X 18 , X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 , X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , X 40 , X 41 , and X 42 can independently be any amino acid.
[0117] In some embodiments, the TfR-binding peptide disclosed herein is 10 X 11 LEX 12 X 13 EX 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 LX 30 X 31 LLX 32 X 33 LDHX 34 HSQ (SEQ ID NO: 154), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 , X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , and X 34 can independently be any amino acid.
[0118] In some embodiments, a TfR-binding peptide or peptide complex disclosed herein has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to any one of SEQ ID NOs:96, 65-95, 97-128, 220-222, or 1-64, or any variant, homolog, or functional fragment thereof. In some embodiments, a TfR-binding peptide or peptide complex disclosed herein comprises any one of SEQ ID NOs:96, 65-95, 97-128, 220-222, or 1-64, or any variant, homolog, or functional fragment thereof. In some embodiments, the peptide that binds to TfR comprises the amino acid sequence set forth in SEQ ID NO:32.
[0119] In some embodiments, the TfR-binding peptide comprises standard amino acid residues as surface interface residues at any one of corresponding positions 5, 7, 8, 14, 17, 18, 21, 38, 42, 45, 46, 47, 50, 51, or a combination thereof, relative to SEQ ID NO: 32. In some embodiments, the TfR-binding peptide comprises standard amino acid residues as surface interface residues at any one of corresponding positions G5, A7, S8, N14, L17, E18, E21, L38, L42, L45, D46, H47, S50, Q51, or a combination thereof, relative to SEQ ID NO: 32. In some embodiments, a peptide or peptide complex of the present disclosure comprises at least one or more of these corresponding residues in SEQ ID NO: 96, SEQ ID NO: 65-95, SEQ ID NO: 97-128, SEQ ID NO: 220-222, or SEQ ID NO: 1-64. Thus, such peptides can be engineered to have increased binding to the TfR. In some embodiments, the TfR-binding peptide disclosed herein is 10 NX 11 X 12 LEX 13 X 14 EX 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 LX 31 X 32 X 33 LX 34 X 35 LDHX 36 X 37 SQ (SEQ ID NO: 155), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14, X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 , X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , and X 37 can independently be any amino acid.
[0120] In some embodiments, surface-distal hydrophilic amino acid residues (e.g., D, E, H, K, R, N, Q, S, or T) present in the amino acid sequence of the peptide contribute to the solubility of the peptide. In some embodiments, the peptides disclosed herein comprise a hydrophilic amino acid residue at any one of corresponding positions 3, 4, 9, 11, 15, 16, 19, 23, 26, 28, 29, 30, 31, 32, 33, 35, 36, 37, 39, 40, or any combination thereof, relative to SEQ ID NO: 32. In some examples, the peptides of the present disclosure comprise hydrophilic amino acid residues at the following corresponding positions relative to SEQ ID NO: 32: R3, E4, R9, K12, D15, E16, K19, R23, S26, S28, N29, T30, E31, E32, D33, E35, Q36, E37, E39, D40, or any combination thereof. In some embodiments, relative to SEQ ID NO: 32, any one or any combination of the corresponding positions R3, E4, R9, K12, D15, E16, K19, R23, S26, S28, N29, T30, E31, E32, D33, E35, Q36, E37, E39, D40 can be mutated to another hydrophilic residue without significantly affecting solubility or TfR binding. In some embodiments, the TfR-binding peptides disclosed herein are 10 DEX 11 X 12 KX 13 X 14 X 15 RX 16 X 17 SX 18 SNTEEDX 19 EQEX 20 EDX 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 SEQ ID NO: 156), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 , X 26 , X 27 , X 28 , X 29 , X 30 , and X 31 can be independently any amino acid. In some embodiments, the TfR-binding peptide disclosed herein is 10 X 11 X 12 X 13 X 14 X 15 CX 16 X 17 X 18 LX 19 X 20 LLYCLDHCHSQ (SEQ ID NO: 157) or X1X2GCASX3CMX4YNX5X6LEX7CEAX8MMX9MX 10 X 11 X 12 X 13 X 14 X 15 CX 16 X 17 X 18 LX 19 X 20 LLYCLDHCHSQ (SEQ ID NO: 171), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , and X 20can be independently selected from D, E, H, K, R, N, Q, S, or T.
[0121] In some embodiments, peptides of the present disclosure comprise cysteine amino acid residues at corresponding positions 4, 8, 18, 32, 42, and 46 relative to SEQ ID NO: 96. In some embodiments, peptides of the present disclosure comprise cysteine amino acid residues at corresponding positions 6, 10, 20, 34, 44, and 48 relative to SEQ ID NO: 32. In some embodiments, peptides of the present disclosure comprise hydrophilic residues (e.g., D, E, H, K, R, N, Q, S, or T) at corresponding positions 15, 35, 39, 49, or any combination thereof relative to SEQ ID NO: 32. In some examples, peptides of the present disclosure comprise hydrophilic amino acid residues at the following corresponding positions relative to SEQ ID NO: 32: D15, E35, E39, H49, or any combination thereof. In some embodiments, relative to SEQ ID NO: 32, any one or any combination of the corresponding positions D15, E35, E39, and H49 can be mutated to another hydrophilic residue without significantly affecting solubility or TfR binding. In some embodiments, the TfR-binding peptides disclosed herein comprise: X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 DX 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 EX 34 X 35 X 36 EX37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 HX 46 X 47 (Arrangement number: 158) 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46 , and びX 47can independently be any amino acid. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 159) or REGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 172), wherein X1, X2, X3, and X4 can be independently selected from D, E, H, K, R, N, Q, S, or T.
[0122] In some embodiments, a peptide of the present disclosure comprises a hydrophobic residue (e.g., A, M, I, L, V, F, W, or Y) at corresponding position 15, 35, 39, 49, or any combination thereof, relative to SEQ ID NO: 32. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 160) or REGCASRCMKYNX1ELEKCEARMMSMSNTEEDCX2QELX3DLLYCLDHCX4SQ (SEQ ID NO: 173), where Xi, X2, X3, and X4 can be independently selected from A, M, I, L, V, F, W, or Y. In some embodiments, a hydrophilic amino acid residue at any one of corresponding positions 15, 35, 39, and 49, relative to SEQ ID NO: 32, is associated with higher binding affinity (e.g., target binding) to TfR and higher solubility. In some embodiments, mutation of any one of the amino acid residues at corresponding positions 15, 35, 39, and 49 of SEQ ID NO: 32 from a hydrophobic residue to a hydrophilic residue can result in higher binding affinity (e.g., target binding) to TfR and higher solubility.
[0123] In some embodiments, a peptide of the present disclosure comprises a hydrophobic residue (e.g., A, M, I, L, V, F, W, or Y) at corresponding position 11, 25, 27, or any combination thereof, relative to SEQ ID NO: 32. In some embodiments, a peptide of the present disclosure comprises a hydrophilic residue (e.g., D, E, H, K, R, N, Q, S, or T) at corresponding position 11, 25, 27, or any combination thereof, relative to SEQ ID NO: 32. In some embodiments, a hydrophobic amino acid residue at any one of corresponding positions 11, 25, and 27, relative to SEQ ID NO: 32, is associated with higher binding affinity (e.g., target binding) to TfR and higher solubility. In some embodiments, mutation of an amino acid residue at any one of corresponding positions 11, 25, and 27, relative to SEQ ID NO: 32, from a hydrophilic residue to a hydrophobic residue can result in higher binding affinity (e.g., target binding) to TfR and higher solubility. In some embodiments, the peptides of the present disclosure comprise hydrophobic amino acid residues M11, M25, M27, or any combination thereof, at corresponding positions relative to SEQ ID NO: 32. In some examples, the peptides comprise hydrophobic amino acid residues M11, M25, and M27 at corresponding positions relative to SEQ ID NO: 32. In some embodiments, any combination of corresponding positions M11, M25, and M27 relative to SEQ ID NO: 32 can be mutated to another hydrophobic residue without significantly affecting solubility or TfR binding. In some embodiments, the TfR-binding peptides disclosed herein comprise a TfR-binding peptide of the formula X1X2X3X4X5X6X7X8X9X 10 MX 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 MX 24 MX 25 X 26 X 27 X 28 X29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46 X 47 X 48 (Arrangement No. 161) をincluding み, formula, X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46 X 47 , and びX 48can independently be any amino acid. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 162) or REGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 174), wherein X1, X2, and X3 can be independently selected from A, M, I, L, V, F, W, or Y. In some embodiments, the TfR-binding peptide disclosed herein comprises GSREGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 163) or REGCASRCX1KYNDELEKCEARMX2SX3SNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 175), wherein X1, X2, and X3 can be independently selected from D, E, H, K, R, N, Q, S, or T.
[0124] In some embodiments, a peptide of the present disclosure comprises an aliphatic amino acid residue (e.g., A, M, I, L, or V) at corresponding position 45 relative to SEQ ID NO: 32. In some embodiments, a peptide of the present disclosure comprises an aromatic amino acid residue (e.g., F, W, or Y) at corresponding position 45. In some embodiments, an aliphatic amino acid residue at corresponding position 45 is associated with higher binding affinity to TfR. In some examples, a peptide comprises an aliphatic amino acid residue corresponding to L45 relative to SEQ ID NO: 32. In some embodiments, mutation of the amino acid residue at corresponding position 45 from an aromatic residue to an aliphatic residue can result in higher binding affinity to TfR (e.g., target binding) and higher solubility. In some embodiments, mutation of corresponding position L45 to another aliphatic residue can have no significant effect on solubility or TfR binding. In some embodiments, a TfR-binding peptide disclosed herein comprises a TfR-binding peptide having a structure similar to that of X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 X 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 LX 45 X 46 X 47 X 48 X 49 X 50 (164) also includes X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 、X 11 、X 12 、X 13 、X 14 、X 15 、X 16 、X 17 、X 18 、X 19 、X 20 、X 21 、X 22 、X 23 、X 24 、X 25 、X 26 、X 27 、X 28 、X 29 、X 30 、X 31 、X 32 、X 33 、X 34 、X 35 、X 36 、X 37 、X 38 、X39 , X 40 , X 41 , X 42 , X 43 , X 44 , X 45 , X 46 , X 47 , X 48 , X 49 , and X 50 can be independently any amino acid. In some embodiments, a TfR-binding peptide disclosed herein comprises GSREGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCX1DHCHSQ (SEQ ID NO: 165) or REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCX1DHCHSQ (SEQ ID NO: 176), wherein X1 can be independently selected from A, M, I, L, or V.
[0125] In some embodiments, a peptide of the present disclosure comprises GSREGCASRCMX1YNDELEX2CEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 166) or REGCASRCMX1YNDELEX2CEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ (SEQ ID NO: 177), where X1 and X2 can be independently selected from K or R. In some embodiments, these residues at corresponding positions 12 and 19, relative to SEQ ID NO: 32, can be used for chemical conjugation to another molecule (e.g., an active agent or a detectable agent). In some embodiments, both X1 and X2 are R, and chemical conjugation is at the N-terminus of the peptide.
[0126] In some embodiments, the receptor-binding peptide may be derived from an antibody or antibody fragment, for example, the receptor-binding peptide may be derived from a single-chain antibody fragment (scFv). Examples of TfR-binding peptides that can be incorporated into the selective depletion complexes of the present disclosure include those of SEQ ID NO: 220 (QVQLQESGGGVVQPGRSLRLSCAASRFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSGYGDYPDYWGQGTLVTVSSGGGGSGGGGSGGGGSSSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVMYGRNERPSGVPDRFSGSSKSGTSASLAISGLQPEDEANYYCAGWDDSLTGPVFGGGTKLTVLG), SEQ ID NO: 221 (QVQLQESGGGVVQPGRSLRLSCAASRFTFNNYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSGY GDYPDYWGQGTLVTVSSGGGGSGGGGSGGGGSSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVMYGRNERPSGVPDRFSGSKSGTSASLAISGLQPEDEANYYCAGWDDSLTGPVFGGGTKLTVLG), and SEQ ID NO: 222 (QVQLQESGGGVVQPGRSLRLSCAASRYPFHHHDHHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSGYGDYPDYWGQGTLVTVSSGGGGSGGGGSGGGGSSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVMYGRNERPSGVPDRFSGSKSGTSASLAISGLQPEDEANYYCAGWDDSLTGPVFGGGTKLTVLG). In some embodiments, the TfR-binding peptide may have the sequence of any one of SEQ ID NOs: 220 to 222, or a fragment thereof.In some embodiments, the TfR-binding peptide may have a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 220-222, or a fragment thereof. In some embodiments, the peptide of SEQ ID NO: 220 or SEQ ID NO: 221 may function as a pH-independent TfR-binding peptide. In some embodiments, the peptide of SEQ ID NO: 222 may function as a pH-dependent TfR-binding peptide.
[0127] In some embodiments, mutation of any one or more of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 5 to 80% of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 1 to 100%, 5 to 100%, or 5 to 50% of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 15 to 50% of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 15 to 30% of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 25 to 30% of the amino acid residues of a peptide of the present disclosure can improve the binding affinity of the peptide to TfR. For example, mutation of 14 of the 51 amino acid residues (27.5%) of a peptide having the sequence of SEQ ID NO: 32 can improve the binding affinity of the peptide to TfR.
[0128] In some embodiments, mutations in any one or more amino acid residues of the peptides of the present disclosure may be in the binding interface of TfR. In some embodiments, mutations to the peptide can improve binding affinity, which may be beneficial for the binding and transcytosis of the peptides or peptide complexes disclosed herein. In some embodiments, the peptides provided herein may have many or few mutations to achieve optimal activity, where optimal activity is sufficient binding to TfR but not necessarily strong enough to prevent release of the peptide and / or peptide complex after transcytosis. Thus, the peptides of the present disclosure may include multiple mutations (also referred to as the percentage of mutated amino acid residues) that adjust binding affinity and off-rate to achieve optimal binding, function (e.g., transcytosis, BBB penetration, cell membrane penetration, transport across biological barriers, endocytosis, recycling, or a combination thereof) and release of the peptide or peptide complex. Therefore, mutations that result in maximum affinity may not necessarily correlate with a superior peptide with optimal binding and transcytosis.
[0129] In some embodiments, 1-100% or 5-100% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. In some embodiments, 10-90% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. In some embodiments, 20-80% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. In some embodiments, 30-70% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. In some embodiments, 40-60% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. In some embodiments, 30-35% of the amino acid residues of a peptide of the present disclosure are located in the binding interface of the TfR. For example, 17 of the 51 amino acid residues (33%) of a peptide having the sequence of SEQ ID NO: 32 may be located in the binding interface of the TfR.
[0130] In some embodiments, mutation of any one or more of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR can improve the binding affinity of the peptide to TfR. In some embodiments, mutation of 1-100% or 5-100% of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 5-80% of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 10-70% of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 15-60% of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 20-50% of the amino acid residues of a peptide of the present disclosure located in the binding interface of TfR improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 25-30% of the amino acid residues of a peptide of the present disclosure located at the binding interface of TfR improves the binding affinity of the peptide to TfR. For example, mutation of 5 of 17 amino acid residues (29%) of a peptide having the sequence of SEQ ID NO: 32 located at the binding interface of TfR can improve the binding affinity of the peptide to TfR.
[0131] In some embodiments, any one or more mutations in amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 1-100% or 5-100% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 10-90% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 20-80% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 30-70% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 40-60% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. In some embodiments, 65-70% of the amino acid residues of a peptide of the present disclosure are distal to the binding interface of the TfR. For example, 34 of the 51 amino acid residues (66%) of the peptide having the sequence of SEQ ID NO: 32 may be in the binding interface of the TfR.
[0132] In some embodiments, mutation of any one or more of the amino acid residues of the peptides of the present disclosure that are distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 1-100% or 5-100% of the amino acid residues of the peptides of the present disclosure that are distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 5-80% of the amino acid residues of the peptides of the present disclosure that are distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 10-70% of the amino acid residues of the peptides of the present disclosure that are distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 15-60% of the amino acid residues of the peptides of the present disclosure that are distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 20-50% of the amino acid residues of a peptide of the present disclosure distal to the TfR binding interface improves the binding affinity of the peptide to TfR. In some embodiments, mutation of 25-30% of the amino acid residues of a peptide of the present disclosure distal to the TfR binding interface improves the binding affinity of the peptide to TfR. For example, mutation of 5 of 17 amino acid residues distal to the TfR binding interface can improve the binding affinity of the peptide to TfR. For example, mutation of 9 of 34 amino acid residues (26.5%) of a peptide having the sequence of SEQ ID NO: 32 distal to the TfR binding interface can improve the binding affinity of the peptide to TfR. In some embodiments, without being bound by any theory, mutation of one or more amino acid residues of a peptide distal to the TfR binding interface can improve protein folding, increase protein solubility, and / or alter backbone geometry, which can improve binding through optimized interface shape complementarity.
[0133] In some embodiments, a receptor-binding peptide of the present disclosure may be a PD-L1-binding peptide. PD-L1-binding peptides can be incorporated into selective depletion complexes of the present disclosure to facilitate selective depletion of target molecules by PD-L1-mediated endocytosis. In some embodiments, a PD-L1-binding peptide that is a receptor-binding peptide may bind to PD-L1 with pH-independent affinity (e.g., similar affinity at extracellular pH and endosomal pH) or may bind to PD-L1 with pH-dependent affinity (e.g., high affinity at extracellular pH and low affinity at endosomal pH). Examples of PD-L1-binding peptides are provided in Table 2. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]
[0134] In some embodiments, the PD-L1-binding peptides disclosed herein comprise 1 X 2 X 3 CX 4 X 5 X 6 CX 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 CX 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X28 CX 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X 37 CX 38 X 39 X 40 CX 41 X 42 X 43 (SEQ ID NO: 392), wherein X 1 can be selected independently from E, M, V, or W; X 2 can be independently selected from G, E, L, or F; X 3 can be selected independently from D, E, or S; X 4 can be independently selected from K, R, or V; X 5 can be independently selected from E, Q, S, M, L, or V; X 6 can be independently selected from D, E, H, K, R, N, Q, S, or Y; X 7 can be selected independently from D, M, or V; X 8 can be independently selected from A, K, R, Q, S, or T; X 9 can be independently selected from A, D, E, H, Q, S, T, M, I, L, V, or W; X 10 can be independently selected from A, E, R, Q, S, T, W, or P; X 11 can be independently selected from A, E, K, R, N, Q, T, M, I, L, V, or W; X 12 can be independently selected from G, A, E, K, N, T, or Y; X 13 can be independently selected from G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 14 X can be independently selected from D, K, R, N, L, or V. 15 can be independently selected from G, A, D, T, L, W, or P; X 16can be independently selected from G, A, E, H, K, N, S, F, or P; X 17 can be independently selected from G, A, D, E, N, or P; X 18 can be independently selected from G, D, H, K, R, N, Q, S, T, V, or Y; X 19 can be independently selected from G, D, E, H, K, N, Q, S, T, M, I, F, W, Y, or P; X 20 can be independently selected from G, A, D, E, H, K, R, N, Q, S, Y, or P; X 21 can be independently selected from G, A, D, H, N, Q, S, V, F, or P; X 22 can be independently selected from A, D, H, N, Q, S, T, M, I, V, Y, or P; X 23 can be independently selected from G, A, D, K, R, T, W, or Y; X 24 can be independently selected from G, A, E, N, Q, T, I, V, or P; X 25 can be independently selected from G, D, N, Q, T, L, V, F, or P; X 26 can be independently selected from G, A, E, K, R, N, Q, S, T, I, Y, or P; X 27 can be independently selected from A, D, N, or I; X 28 can be independently selected from G, D, E, H, N, F, or W; X 29 can be independently selected from G, A, E, N, S, Y, or P; X 30 can be selected independently from G, M, or L; X 31 can be independently selected from G, A, D, K, N, Q, or W; X 32 can be independently selected from D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 33 can be independently selected from G, E, Q, or F; X 34 can be independently selected from D or K; X 35 can be selected independently from G, V, or P; X36 can be independently selected from G, H, R, V, F, W, or P; X 37 can be independently selected from A, D, or K; X 38 can be independently selected from E, H, Q, L, or F; X 39 can be independently selected from D, E, R, S, T, M, L, or F; X 40 can be independently selected from G, A, D, E, H, K, R, M, L, or P; X 41 can be independently selected from G, A, K, S, I, or L; X 42 can be independently selected from G, A, D, E, R, Q, T, or F; X 43 can be independently selected from A, H, N, Q, S, F, or P.
[0135] In some embodiments, the binding peptide disclosed herein is EEDCKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 CX 1 EX 1 X 4 X 1 X 1 X 1 X 1 X 1 X 1 X 1 AX 1 CX 1 GX 1 X 5 FX 6 VFX 6 CLX 1 X 1 CX 1 X 1 X 1 (SEQ ID NO: 393), wherein X 1 can be independently selected from any non-cysteine amino acid; X 2 can be independently selected from M, I, L, or V; X 3can be independently selected from Y, A, H, K, R, N, Q, S, or T; X 4 can be independently selected from D, E, N, Q, or P; X 5 can be independently selected from K or P; X 6 can be independently selected from D or K.
[0136] A PD-L1-binding peptide may contain a PD-L1-binding motif that forms part or all of the binding interface with PD-L1. One or more residues of the PD-L1-binding motif may interact with one or more residues of PD-L1 at the binding interface between the PD-L1-binding peptide and PD-L1. In some embodiments, multiple PD-L1-binding motifs may be present on the PD-L1-binding peptide. A PD-L1-binding motif may be CX 1 X 2 X 3 CX 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 394), wherein X 1 can be selected from K, R, or V; X 2 You can choose from E, Q, S, M, L, or V; X 3 can be selected from D, E, H, K, R, N, Q, S, or Y; X 4 You can choose from D, M, or V; X 5 can be selected from A, K, R, Q, S, or T; X 6 can be selected from A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 can be selected from A, E, R, Q, S, T, W, or P; X 8 can be selected from A, E, K, R, N, Q, T, M, I, L, V, or W; X 9 can be selected from G, A, E, K, N, T, or Y; X 10can be selected from G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 11 can be selected from D, K, R, N, L, or V; X 12 can be selected from G, A, D, T, L, W, or P. In some embodiments, the PD-L1 binding motif is CKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 C (SEQ ID NO: 396), wherein X 1 can be independently selected from any non-cysteine amino acid; X 2 can be independently selected from M, I, L, or V; X 3 may be independently selected from Y, A, H, K, R, N, Q, S, or T. In some embodiments, the PD-L1 binding motif may comprise the sequence of CKVHCVKEWMAGKAC (SEQ ID NO:398). In some embodiments, the PD-L1 binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO:398.
[0137] The PD-L1 binding motif is X 1 X 2 X 3 X 4 X 5 X 6 CX 7 X 8 X 9 C (SEQ ID NO: 395), and X 1 can be independently selected from D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 can be independently selected from G, E, Q, or F; X 3 can be independently selected from D or K; X 4can be selected independently from G, V, or P; X 5 can be independently selected from G, H, R, V, F, W, or P; X 6 can be independently selected from A, D, or K; X 7 can be independently selected from E, H, Q, L, or F; X 8 can be independently selected from D, E, R, S, T, M, L, or F; X 9 can be independently selected from G, A, D, E, H, K, R, M, L, or P. In some embodiments, the PD-L1 binding motif is X 1 FX 2 VFX 2 CLX 3 X 3 C (SEQ ID NO: 397), wherein X 1 can be independently selected from K or P; X 2 can be independently selected from D or K; X 3 can be independently selected from any non-cysteine amino acid. In some embodiments, the PD-L1 binding motif may comprise the sequence KFDVFKCLDHC (SEQ ID NO:399). In some embodiments, the PD-L1 binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO:399.
[0138] PD-L1-binding peptides that have high-affinity PD-L1 binding at endosomal pH (e.g., any one of SEQ ID NOs: 187, 233-239, 400-456, or 240, or pH-independent variants thereof) can be complexed with the target-binding peptides described herein to form selective depletion complexes for selective depletion of target molecules. The selective depletion complexes can be used to selectively deliver target molecules across a cell layer or plasma membrane. For example, the selective depletion complexes can be used to selectively deliver target molecules to endocytic compartments via PD-L1-mediated endocytosis. The target molecules can be selectively depleted by binding of the selective depletion complex to the target-binding peptide and endocytosis via PD-L1-mediated endocytosis, as described.
[0139] Selective depletion of target molecules using PD-L1-mediated endocytosis can be used to selectively deplete target molecules specifically in tissues that express PD-L1. In some embodiments, a selective depletion complex comprising a receptor-binding peptide that binds to PD-L1 can be used to selectively deplete target molecules in PD-L1-positive cancers, lung tissue, pancreatic islet tissue, lymphoid tissue, gastrointestinal tissue, bone marrow tissue, reproductive tissue, muscle tissue, adipose tissue, or other PD-L1-positive tissues. For example, a selective depletion complex comprising a PD-L1-binding peptide and an ACE2-binding peptide can be used to selectively deplete ACE2 in lung tissue to prevent viral infection (e.g., SARS-CoV-2 infection). In another example, a selective depletion complex comprising a PD-L1-binding peptide and an HLA-binding peptide can be used to selectively deplete HLA in pancreatic islet cells to prevent T cell attack on insulin-expressing cells in type 1 diabetes.
[0140] A PD-L1-binding peptide (e.g., any of SEQ ID NOs: 187, 233-239, 400-456, or 240) can function as a target-binding peptide or a receptor-binding peptide in a selective depletion complex. In some embodiments, a selective depletion complex for selectively depleting PD-L1 may comprise a receptor-binding peptide that does not bind to PD-L1 (e.g., a TfR-binding peptide) and a PD-L1-binding peptide (e.g., a pH-dependent PD-L1-binding peptide). In some embodiments, a selective depletion complex for selectively depleting a target that is not PD-L1 may comprise a target-binding peptide that binds to a target (e.g., an EGFR-binding peptide) and a PD-L1-binding peptide (e.g., a pH-independent PD-L1-binding peptide).
[0141] Target-binding peptides The peptides, peptide conjugates, or selective depletion complexes of the present disclosure may comprise a target-binding peptide. The target-binding peptide can bind to a target molecule (e.g., a target protein). In some embodiments, the target-binding peptide can bind to the target molecule with an affinity that is pH-dependent. For example, the target-binding peptide can bind to the target molecule with a higher affinity at extracellular pH (e.g., about pH 7.4) than at endosomal pH (e.g., about pH 5.5). The target-binding peptide can be conjugated to a receptor-binding peptide of the present disclosure (e.g., a TfR-binding peptide of any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64, or a PD-L1-binding peptide of any one of SEQ ID NOs: 187, 233, 239, 400-456, or 241) to form a selective depletion complex. The selective depletion complex can be used to selectively deliver a target molecule across a cell layer or cell membrane (e.g., the BBB or cell membrane). For example, a selective depletion complex can be used to selectively deliver a target molecule to an endocytic compartment via receptor-mediated endocytosis (e.g., PD-L1-mediated endocytosis or TfR-mediated endocytosis). The target molecule can be selectively depleted by binding of the selective depletion complex to a target-binding peptide and endocytosis via receptor-mediated endocytosis. The target molecule can be a soluble molecule. For example, the target molecule can be a secreted peptide or protein, a cell signaling molecule, an extracellular matrix macromolecule (e.g., collagen, elastin, microfibrillar protein, or proteoglycan), a neurotransmitter, a cytokine, a growth factor, a tumor-associated antigen, a tumor-specific antigen, or a hormone. The target molecule can be a cell surface molecule. For example, the target molecule can be a transmembrane protein, a receptor including a growth factor receptor, a checkpoint inhibitor, an immune checkpoint inhibitor, an inhibitory immunoreceptor, a ligand for an inhibitory immunoreceptor, a macrophage surface protein (e.g., CD14 or CD16), a lipopolysaccharide, or an antibody.Inhibitory immune receptors can be CD200R, CD300a, CD300f, CEACAM1, FcgRiib, ILT-2, ILT-3, ILT-4, ILT-5, LAIR-1, PECAM-1, PILR-α, SIRL-1, and SIRP-α, CLEC4A, Ly49Q, or MICL. Selective depletion of cell surface molecules using a selective depletion complex containing a target-binding peptide that binds to a cell surface molecule can result in a reduction of cell surface molecules (e.g., surface-exposed proteins). Surface-exposed proteins can be associated with a disease or condition. In some embodiments, the selective depletion complex of the present disclosure can contain two or more target-binding peptides to promote dimerization of the target molecule. Promoting dimerization increases internalization of the target molecule, resulting in selective depletion of the target molecule. For example, a selective depletion complex containing two copies of a target-binding peptide can promote homodimerization of the target molecule. In some embodiments, the target-binding peptides of the present disclosure may comprise a miniprotein, a nanobody, an antibody, an IgG, an antibody fragment, a Fab, a F(ab)2, a scFv, a (scFv)2, a DARPin, or an affibody. In some embodiments, the target-binding peptides may comprise a cystine-dense peptide, an affitin, an adnectin, an avimer, a Kunitz domain, a nanophytin, a phynomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
[0142] In some embodiments, the target-binding peptides of the present disclosure can bind to target molecules with an affinity that is pH-dependent. For example, the target-binding peptides can bind to target molecules at extracellular pH (such as about pH 7.4) with higher affinity than the binding affinity at endocytic pH (such as about pH 7.0, pH 6.5, pH 6.0, or pH 5.5). In some embodiments, the binding affinity of the target-binding peptide to the target molecule at extracellular pH (such as about pH 7.4) is at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, or at least about 3.5-fold higher than the binding affinity of the target-binding peptide to the target molecule at endosomal pH (such as about pH 7.0, pH 6.5, pH 6.0, pH 5.5, or pH 5.0). , at least about 4 times, at least about 4.5 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 45 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, at least about 200 times, at least about 500 times, at least about 1000 times, or at least about 10,000 times. In some embodiments, the affinity of the target-binding peptide for the target at pH 6.5 or pH 5.5 is about 0.1% or less, about 0.5% or less, about 1% or less, about 5% or less, about 10% or less, about 20% or less, about 30% or less, about 40% or less, or about 50% or less of the affinity of the target-binding peptide for the target at pH 7.4. In some embodiments, the affinity of the target-binding peptide for the target at pH 7.4 is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, or at least 20-fold greater than the affinity of the target-binding peptide for the target at pH 6.5 or pH 5.5.
[0143] In some embodiments, a target-binding peptide with pH-dependent binding has a dissociation constant (K) of less than 50 μM, less than 5 μM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM at extracellular pH (such as about pH 7.4). D In some embodiments, the target-binding peptide with pH-dependent binding can bind to the target molecule at an endosomal pH (about pH 5.5 or about pH 6.5) with a dissociation constant (K) of at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 20 nM, at least 50 nM, at least 100 nM, at least 200 nM, at least 500 nM, at least 1 μM, at least 2 μM, at least 5 μM, at least 10 μM, at least 20 μM, at least 50 μM, at least 100 μM, at least 500 μM, at least 1 mM, at least 2 mM, at least 5 mM, at least 10 mM, at least 20 mM, at least 50 mM, at least 100 mM, at least 200 mM, at least 500 mM, or at least 1 M. D ) and can bind to a target molecule.
[0144] In some embodiments, the target-binding molecule is capable of internalization into an endosomal compartment and release of the target molecule upon endosomal acidification, which release of the target molecule upon endosomal acidification can occur at about pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower. In some embodiments, release of the target molecule can occur at a pH of about pH 7.0 to about pH 4.5, about pH 6.5 to about pH 5.0, or about pH 6.0 to about pH 5.5, or lower.
[0145] Target-binding peptides with pH-dependent binding affinity can be engineered by selectively incorporating histidine (His) amino acid residues into their target-binding interface. In some examples, target-binding peptides with pH-dependent binding affinity contain at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 histidine residues in their target-binding interface. Because histidine side chains are primarily uncharged at pHs between about 6.0 and about 9.2 and primarily positively charged at pHs below about 6.0, selective insertion or removal of His residues into target-binding peptides can confer pH-dependent binding properties. Target-binding peptides (e.g., target-binding peptides with pH-dependent binding affinity) can include cystine-dense peptides (CDPs), affibodies, DARPins, centrins, nanophytins, or adnectins. The target-binding CDP, target-binding affibody, target-binding adnectin may be stable at low pH (e.g., endosomal pH). In some embodiments, the target-binding peptide may comprise an antibody (e.g., an IgG or other antibody), an antibody fragment (e.g., an scFv, scFv2, Fab, F(ab)2, or other antibody fragment), or a nanobody (e.g., a VHH domain nanobody or a VNAR domain nanobody derived from camel or shark) that may be stable at low pH.
[0146] In some embodiments, the release of a target molecule by a target-binding peptide upon internalization into an endosomal compartment may be affected by the difference in ionic strength between the extracellular physiological environment and the endosomal compartment. In some embodiments, the ionic strength of the endosomal compartment is higher than the ionic strength of the extracellular physiological environment. Ionic strength, which varies with salt concentration, can be affected by the difference in ionic strength between various electrolytes in the solution, such as hydrogen (H + ), hydroxide (OH - ), hydronium (HO + ), sodium (Na+ ), potassium (K + ), calcium (Ca 2+ ), magnesium (Mg 2+ ), manganese (Mn 2+ ), chloride (Cl - ), carbonate (CO3 2- ), cobalt (Co 2+ ), phosphate (PO4 3- ), or nitrate (NO3 - ) concentration. In some embodiments, target-binding peptides with salt- or ionic strength-dependent binding affinities can be engineered by selective incorporation of salt-labile moieties (e.g., polar or charged amino acid side chains) at the target-binding interface, which allow dissociation of the target-binding molecule in the endosome. For example, the target-binding interface of the target-binding peptide can form one or more polar or charge-charge interactions with the target-binding peptide that can be disrupted as the ionic strength of the environment increases.
[0147] In some cases, target-binding peptides with ionic strength-dependent binding affinities (e.g., hydrogen, hydroxide, hydronium, sodium, potassium, calcium, magnesium, manganese, chloride, carbonate, cobalt, phosphate, and / or nitrate-dependent) may dissociate over a range of ionic strengths, for example, from about 30 mM to about 1 M. In some embodiments, ionic strength-dependent target-binding peptides with ionic strength-dependent binding affinities may dissociate over a range of ionic strengths, such as greater than about 50 mM, from about 50 mM to about 1 M, from about 60 mM to about 950 mM, from about 70 mM to about 900 mM, from about 80 mM to about 850 mM, from about 90 mM to about 800 mM, from about 100 mM to about 750 mM, from about 110 mM to about 700 mM, or the like. In some embodiments, the ionic strength-dependent target-binding peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 polar or charge-charge interactions at the target-binding interface.
[0148] The target-binding peptides of the present disclosure can bind to target molecules, such as clinically relevant target molecules. In some embodiments, the target molecule can be a soluble molecule, an extracellular molecule, or a cell surface molecule. In some embodiments, the target molecule can be a protein, a peptide, a lipid, a carbohydrate, a nucleic acid, or a glycan. In some embodiments, the target molecule can be a protein that is overexpressed or overactivated in a disease or condition. For example, the target molecule can be a transmembrane protein involved in oncogenic signaling, immunosuppression, or pro-inflammatory signaling. Examples of target molecules that can be targeted by the target-binding peptides of the present disclosure include CD3, CD47, CD28, CD137, CD89, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD25, CD74, CD40L, MUC1, MUC16, MUC2, MUC5AC, MUC4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TNF-α, EGFR, EGFRvIII, TKI-resistant EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, IGFR1, CTLA 4, STRO1, complement factor C4, complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, amyloid beta, huntingtin, α-synuclein, glucocerebrosidase, α-glucosidase, IL-1, IL-1R, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, members of the B7 family, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, PD-1, and PD-L1. Additional examples of target molecules include mannose-6-phosphate glycans, glucose-6-phosphate, and sugar-specific receptors (eg, lectins).Additional examples of target molecules include autoantibodies such as rheumatoid factor, antinuclear antibodies, antineutrophil cytoplasmic antibodies, anti-dsDNA, anticentromere antibodies, antihistone antibodies, cyclic citriurinated peptide antibodies, extractable nuclear antigen antibodies, cardiolipin antibodies, beta-2 glycoprotein 1 antibodies, antiphospholipid antibodies, lupus anticoagulant, diabetes-associated autoantibodies, anti-tissue translugtaminase, anti-gliadin antibodies, intrinsic factor antibodies, parietal cell antibodies, thyroid autoantibodies, smooth muscle antibodies, anti-mitochloria antibodies, liver-renal microsomal type 1 antibodies, anti-glomerular basement membrane, and acetylcholine receptor antibodies. target molecules (e.g., CD3, CD47, CD28, CD137, CD89, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD25, CD74, CD40L, MUC1, MUC16, MUC2, MUC5AC, MU C4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TNF-α, EGFR, EGFRvIII, TKI-resistant EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, IGFR1, CTLA4, STRO1, complement factor C4, Upon binding to the target-binding peptide of the selective elimination complex, the following proteins may be endocytosed and degraded: complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, amyloid beta, huntingtin, α-synuclein, glucocerebrosidase, α-glucosidase, IL-1, IL-1R, IL-1α, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, B7 family members, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, PD-1, or PD-L1.
[0149] In some embodiments, the target molecule can be a transmembrane protein such as a receptor tyrosine kinase. Examples of receptor tyrosine kinases that can be targeted using the selective depletion complex include EGF receptor, ErbB, insulin receptor, PDGF receptor, VEGF receptor, FGF receptor, CCK receptor, NGF receptor, HGF receptor, Eph receptor, AXL receptor, TIE receptor, RYK receptor, DDR receptor, RET receptor, ROS receptor, LTK receptor, ROR receptor, MuSK receptor, and LMR receptor. Targeting a transmembrane protein using the selective depletion complex can result in the internalization and degradation of the transmembrane protein. In some embodiments, the target molecule can be a pathogen (e.g., a virus or bacterium) or a pathogen surface molecule (e.g., a protein or glycoprotein). For example, the target molecule can be the spike protein of coronavirus, the hemagglutinin of influenza virus, or the glycoprotein M of herpes simplex virus. Targeting a pathogen or a surface protein of a pathogen using a selective depletion complex can result in the internalization and degradation of the pathogen, thereby treating or preventing infection caused by the pathogen.
[0150] Endocytosis of the target molecule and subsequent degradation can treat (e.g., eliminate, alleviate, delay progression, or treat symptoms of) a disease or condition associated with the target molecule. In some embodiments, targeting and degradation of receptor tyrosine kinases by selective depletion complexes can be beneficial for treating variants of cancer. For example, targeting and degradation of EGFR by selective depletion complexes comprising EGFR-binding peptides can be beneficial for treating cancers such as non-small cell lung cancer, primary non-small cell lung cancer, metastatic non-small cell carcinoma, lung cancer, head and neck cancer, head and neck squamous cell carcinoma, glioblastoma, brain cancer, metastatic brain cancer, colorectal cancer, colon cancer, tyrosine kinase inhibitor (TKI)-resistant cancer, cetuximab-resistant cancer, necitumumab-resistant cancer, panitumumab-resistant cancer, localized cancer, locally advanced cancer, recurrent cancer, metastatic cancer, refractory cancer, KRAS wild-type cancer, KRAS mutant cancer, or exon 20 mutant non-small cell lung cancer. In another example, targeting and degradation of TNF-α by selective depletion complexes comprising TNF-α binding peptides may be beneficial in treating inflammatory or neurological conditions, including those in the CNS, such as neuroinflammation, neuroinflammatory diseases, stroke, traumatic brain injury, Alzheimer's disease, or other tauopathies, including neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), age-related tau astrogliopathy, frontotemporal dementia, Parkinsonism, progressive supranuclear palsy, corticobasal degeneration, Lyticko-Boedig's disease, ganglioglioma, meningioangiomatosis, or subacute sclerosis panencephalitis. For example, targeting and degradation of TNF-α by selective depletion complexes containing TNF-α binding peptides may also be beneficial in treating inflammatory conditions that may not be confined to the CNS (e.g., ankylosing spondylitis, antiphospholipid syndrome, gout, inflammatory arthritis center, myositis, rheumatoid arthritis, scleroderma, Sjögren's disease, systemic lupus erythematosus (lupus), vasculitis, psoriasis, inflammatory bowel disease, Crohn's disease, or ulcerative colitis). The selective depletion complexes of the present disclosure can be used to target pathogenic immune complexes, such as those in the circulation. Circulating antigen-antibody complexes can be involved in autoimmune diseases, inflammatory diseases, and malignancies, including glomerulonephritis, systemic lupus erythematosus (lupus), rheumatoid arthritis, and cutaneous vasculitis.
[0151] The selective depletion complexes of the present disclosure can be used to target the complement pathway in complement-mediated diseases such as facioscapulohumeral muscular dystrophy (FSHD) or schizophrenia. Because TfR is highly expressed in muscle cells, such selective depletion complexes may be suitable for treating FSHD and are expected to efficiently degrade complement pathway components. In some embodiments, targeting and degrading complement factor C4 in the CNS, or factors upstream of C4 in the complement pathway (e.g., complement factor C1q, complement factor C1s, or complement factor C1r), or downstream factors (e.g., complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, or complement factor C5a), may treat schizophrenia. C4 is then used as a paradigm for this pathway, with the understanding that other complement components that regulate C4 activation or carry out the continuation of this pathway have equal standing in regulating the biological consequences of increased activity of this pathway. Because schizophrenia most commonly develops during adolescence, affecting approximately 1% of people, compositions containing selective depletion complexes for treating schizophrenia would be beneficial. The complement pathway can serve as a common pathway in schizophrenia, and therapies containing selective depletion complexes of the present disclosure that promote degradation of C4 or downstream complement pathways would be beneficial to patients. In some embodiments, selective depletion complexes of the present disclosure can be used to target complement-mediated diseases in the central nervous system. For example, selective depletion complexes containing peptides that bind to one or more C4A forms can be used to target long forms (e.g., including HERV uptake) or short forms of C4A for degradation as described herein. Additional target molecules that can be targeted and depleted using selective depletion complexes for the treatment of schizophrenia include molecules encoded by the extended MHC complex on chromosome 6, molecules encoded by the complement C4 locus (e.g., molecules encoded by the C4Along locus or the c4Ashort locus), the CUB and Sushi multiple domain 1 (CSMD1) genes on chromosome 8, complement factor C4, complement factor C3, or molecules encoded by sequences containing single nucleotide polymorphisms in the C3 receptor.Targeted degradation of complement factor C4, complement factor C3, or molecules that prevent the degradation of complement factor C4 or complement factor C3 may be beneficial in the treatment of schizophrenia. For example, the selective depletion complexes of the present disclosure can treat schizophrenia by reducing excessive synaptic pruning, preventing gray matter loss, and preventing psychotic symptoms in patients predisposed to schizophrenia due to polymorphisms in C4, CSMD1, or other genes. Selective depletion complexes for the treatment of schizophrenia (e.g., containing complement factor C4-binding peptides) can provide a narrow, precise form of immunosuppression that can prevent the toxicity that occurs when broad-spectrum immunosuppression is used for long periods of time, which is common in chronic diseases such as schizophrenia. In some embodiments, selective depletion complexes for the treatment of schizophrenia can be administered in combination with additional drugs (e.g., minocycline, doxycycline, steroids, inhibitors of C4 degradation, or antipsychotics). Furthermore, the selective depletion complexes of the present disclosure may be suitable for treating CNS-related disorders, such as schizophrenia, due to their ability to penetrate the blood-brain barrier (BBB) and access the CNS via TfR binding. The selective depletion complexes (e.g., comprising TfR-binding peptides) may promote higher BBB penetration.
[0152] In some embodiments, binding and subsequent depletion of target molecules using selective depletion complexes of the present disclosure comprising target-binding peptides can be used to treat diseases or conditions, where the target molecule is a cell-based or soluble moiety associated with the disease or condition and is expressed or present in diseased tissues or cells. In some embodiments, depletion of target molecules can be cell type or tissue dependent. For example, depletion of target molecules can be specific to cells or tissues that express both the target molecule targeted by the target-binding peptide of the selective depletion complex and the cell surface receptor targeted by the receptor-binding peptide of the selective depletion complex. Degradation and depletion of target molecules using selective depletion complexes can prevent, treat, or ameliorate a disease or condition.
[0153] In some embodiments, the target-binding peptide may comprise the sequence of any one of SEQ ID NO:187, SEQ ID NO:219, SEQ ID NOs:233-244, or SEQ ID NOs:400-456. In some embodiments, the target-binding peptide may comprise a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:233, SEQ ID NO:187, or any one of SEQ ID NOs:234-244, or a fragment thereof. For example, the target-binding peptide may comprise a sequence having at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:233, or the target-binding peptide may comprise the sequence of SEQ ID NO:233. Examples of target-binding peptides and their corresponding target molecules are provided in Table 3. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5]
[0154] Cystine-Dense Peptides In some embodiments, the TfR-binding or target-binding peptides of the present disclosure comprise one or more Cys or one or more disulfide bonds. In some embodiments, the TfR-binding or target-binding peptides are derived from cysteine-dense peptides (CDPs), knot peptides, or hitchins. As used herein, the term "peptide" is considered interchangeable with the terms "knot peptide," "cysteine-dense peptide," "CDP," and "hitchin." (See, e.g., Correnti et al. Screening, large-scale production, and structure-based classification for cystine-dense peptides. Nat Struct Mol Biol. 2018 Mar;25(3):270-278.)
[0155] The TfR-binding peptides of the present disclosure, or derivatives, fragments, or variants thereof, may have affinity and selectivity for TfR or derivatives or analogs thereof. The target-binding peptides of the present disclosure, or derivatives, fragments, or variants thereof, may have affinity and selectivity for target molecules. In some cases, the TfR-binding peptides of the present disclosure can be engineered using site-saturation mutagenesis (SSM) to exhibit improved TfR-binding properties or to more effectively promote transcytosis or endocytosis. In some cases, the target-binding peptides of the present disclosure can be engineered using site-saturation mutagenesis (SSM) to exhibit improved TfR-binding properties. In some cases, the peptides of the present disclosure are knot peptides or cysteine-dense peptides (CDPs) related to knottin-derived peptides or knottin-derived peptides. The TfR-binding peptide can be a cysteine-dense peptide (CDP). Knottins may be a subclass of CDPs, in which six cysteine residues form disulfide bonds according to the connectivity [1-4], 2-5, 3-6, indicating that the first cysteine residue forms a disulfide bond with the fourth residue, the second cysteine residue forms a disulfide bond with the fifth residue, and the third cysteine residue forms a disulfide bond with the sixth residue. The parentheses in this nomenclature indicate that the cysteine residues form a notching disulfide bond. (See, e.g., Correnti et al. Screening, large-scale production, and structure-based classification for cystine-dense peptides. Nat Struct Mol Biol. 2018 Mar;25(3):270-278.) Knottins may be a subclass of CDPs, in which six cysteine residues form disulfide bonds according to the connectivity [1-4], 2-5, [3-6]. Knottins are a class of peptides that typically range in length from about 20 to about 80 amino acids and often fold into compact structures characterized by numerous intramolecular disulfide bridges and assemble into complex tertiary structures that may contain beta-strands and other secondary structures.The presence of disulfide bonds confers remarkable environmental stability to knottins and hittins, allowing them to withstand extreme temperatures and pH and resist proteolytic enzymes in the bloodstream. In some cases, the peptides described herein may be derived from knot peptides. The amino acid sequences of the peptides disclosed herein may contain multiple cysteine residues. In some cases, at least one cysteine residue of multiple cysteine residues present in the amino acid sequence of the peptide participates in disulfide bond formation. In some cases, all cysteine residues of multiple cysteine residues present in the amino acid sequence of the peptide participate in disulfide bond formation. As described herein, the term "knot peptide" may be used interchangeably with the terms "cysteine-dense peptide," "CDP," or "peptide."
[0156] Provided herein are methods for identifying, maturing, characterizing, and utilizing CDPs that enable the selection, optimization, and characterization of CDP-TfR binding peptides that bind to the transferrin receptor and can be used in selective depletion complexes, including as bioactive molecules at therapeutically relevant concentrations in subjects (e.g., humans or non-human animals). This disclosure demonstrates the utility of CDPs as a diverse family of scaffolds that can be screened for potential applications in modern drug discovery strategies. CDPs offer an alternative to existing biologics, primarily antibodies, and avoid some of the disadvantages of immunoglobulin scaffolds, including poor tissue penetration, immunogenicity, and long serum half-lives, which can be problematic if toxicity occurs. The peptides of the present disclosure, ranging from 20 to 80 amino acids, are medium-sized and medically relevant therapeutic agents that possess many of the favorable binding specificity and affinity characteristics of antibodies, but with improved stability, reduced immunogenicity, and simpler manufacturing methods. The intramolecular disulfide structure of CDPs confers a particularly high stability index, thereby reducing fragmentation and immunogenicity, and their small size improves tissue or cell penetration and facilitates tailoring of serum half-life. Disclosed herein are peptides that represent candidate peptides that can function as vehicles for delivering target molecules to endocytic compartments.
[0157] In some embodiments, the TfR-binding peptide can be an engineered peptide. An engineered peptide can be a non-naturally occurring, artificial, isolated, synthetic, designed, or recombinantly expressed peptide. In some embodiments, the TfR-binding peptide of the present disclosure comprises one or more properties of a CDP, knot peptide, or hitchin, such as stability, resistance to proteolysis, resistance to reducing conditions, and / or the ability to cross the blood-brain barrier. In some embodiments, the target-binding peptide of the present disclosure comprises one or more properties of a CDP, knot peptide, or hitchin, such as stability, resistance to proteolysis, or resistance to reducing conditions.
[0158] CDPs may be advantageous for delivery to the CNS due to their small size, enhanced tissue or cellular penetration, lack of Fc function, and rapid clearance from serum compared to other molecules such as antibodies, and their resistance to proteases compared to small peptides (both stability and reduced immunogenicity). In some embodiments, the TfR-binding or target-binding peptides (e.g., CDPs, knot peptides, or hitchins), selective depletion complexes (e.g., comprising one or more TfR-binding peptides and one or more target-binding peptides), or engineered TfR-binding fusion peptides (e.g., comprising one or more TfR-binding peptides and one or more peptides) of the present disclosure may have superior properties to TfR-binding antibodies or target-binding peptides. For example, the peptides and complexes described herein may provide better, deeper, and / or faster tissue or cellular penetration into cells and target tissues (e.g., penetration into brain parenchyma, penetration into solid tumors), as well as faster clearance from non-target tissues and serum. The TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of the present disclosure may have a lower molecular weight than TfR-binding antibodies or target-binding antibodies. This lower molecular weight may confer advantageous properties to the TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of the present disclosure compared to TfR-binding antibodies or target-binding antibodies. For example, the TfR-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of the present disclosure may penetrate cells or tissues more easily than anti-TfR antibodies or have lower molar dose toxicity than anti-TfR antibodies. The TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of the present disclosure may be advantageous because they lack the Fc function of antibodies. The TfR-binding peptides, target-binding peptides, selective depletion complexes, or TfR-binding fusion peptides of the present disclosure may be advantageous because they allow for higher concentrations of formulations on a molar basis.
[0159] In some embodiments, CDPs or knot peptides (e.g., target-binding peptides), including engineered, non-naturally occurring CDPs and those found in nature, can be conjugated, linked, or fused to TfR-binding peptides of the present disclosure, such as those listed in Table 1, to selectively deliver target molecules to the endocytic compartment of a cell. The cells can be cancer cells, pancreatic cells, liver cells, colon cells, ovarian cells, breast cells, lung cells, spleen cells, bone marrow cells, or any combination thereof. The cells can be any cell that expresses TfR. The engineered peptide can be a non-naturally occurring, artificial, synthetic, designed, or recombinantly expressed peptide. In some embodiments, the TfR-binding peptides or complexes comprising the TfR-binding peptides of the present disclosure (e.g., selective depletion complexes) enable TfR-mediated transcytosis and / or cellular endocytosis, and additional CDPs or knot peptides conjugated, linked, or fused to the TfR-binding peptide can selectively target molecules (e.g., enzymes or other proteins of interest) within cells associated with a disease or condition. In some cases, the cell is a cancer cell. The cancer may include breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, myeloma, blood-derived cancer, spleen cancer, salivary gland cancer, kidney cancer, muscle cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, sarcoma, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, diffuse intrinsic pontine glioma, lung cancer, myeloid cell carcinoma, or skin cancer, genitourinary cancer, osteosarcoma, muscle-derived sarcoma, melanoma, head and neck cancer, neuroblastoma, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, and diffuse intrinsic pontine glioma (DIPG), or CMYC-overexpressing cancer. In some cases, other CDPs or knot peptides (e.g., those found in nature) can be conjugated, linked, or fused to the TfR-binding peptide to localize the TfR-binding peptide across the blood-brain barrier and deliver the TfR-binding peptide to target cells in the central nervous system.
[0160] CDPs (e.g., knot peptides or hitchins) are a class of peptides typically ranging from about 11 to about 81 amino acids in length that often fold into compact structures. Knot peptides are characterized by numerous intramolecular disulfide bridges and assemble into complex tertiary structures that may include beta-strands, alpha-helices, and other secondary structures. The presence of disulfide bonds confers remarkable environmental stability to knot peptides, allowing them to withstand extreme temperatures and pH and resist proteolytic enzymes in the bloodstream. The presence of disulfide knots can also provide resistance to reduction by reducing agents. The rigidity of knot peptides also allows them to bind to targets without incurring the "entropy penalty" that occurs when flexible peptides bind to targets. For example, binding can be adversely affected by the entropy loss that occurs when a peptide binds to a target and forms a complex. Thus, the "entropy penalty" is a detrimental effect on binding, and the greater the entropy loss that occurs during binding, the greater the "entropy penalty." Furthermore, flexible unbound molecules lose more entropy when forming complexes than rigidly structured molecules because they lose flexibility when bound into complexes. However, the rigidity of unbound molecules also generally limits the number of complexes a molecule can form, thereby increasing specificity. Peptides can bind to targets with affinity similar to that of antibodies, or with nanomolar or picomolar affinities. Close examination of the sequence structure and sequence identity or homology of knot peptides reveals that knot peptides have arisen through convergent evolution in all kinds of animals and plants. In animals, knot peptides are often found in venoms, such as those of spiders and scorpions, and are involved in regulating ion channels. Plant knot proteins can inhibit animal proteolytic enzymes or have antibacterial activity, suggesting that knot peptides may function in molecular defense systems found in plants.
[0161] Peptides of the present disclosure (e.g., target-binding peptides, TfR-binding peptides, or selective depletion complexes) may contain cysteine amino acid residues. In some embodiments, the peptides have at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 cysteine amino acid residues. In some embodiments, the peptides have at least 6 cysteine amino acid residues. In some embodiments, the peptides have at least 8 cysteine amino acid residues. In other embodiments, the peptides have at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues, or at least 16 cysteine amino acid residues.
[0162] The knot peptide may contain a disulfide bridge. The knot peptide may be a peptide in which 5% or more of the residues are cysteines that form intramolecular disulfide bonds. The disulfide-linked peptide may be a drug scaffold. In some embodiments, the disulfide bridge forms a knot. The disulfide bridge may be formed between cysteine residues, for example, between cysteines 1 and 4, 2 and 5, or 3 and 6. In some embodiments, one disulfide bridge passes through a loop formed by two other disulfide bridges, for example, to form a knot. In other embodiments, the disulfide bridge may be formed between any two cysteine residues.
[0163] The present disclosure further includes peptide scaffolds, which can be used, for example, as a starting point for generating additional peptides. In some embodiments, these scaffolds can be derived from various knot peptides (such as CDPs, knot peptides, or hitchins). In certain embodiments, CDPs (e.g., knot peptides or hitchins) feature multiple intramolecular disulfide bridges and assemble into complex tertiary structures, optionally including beta strands and other secondary structures such as alpha helices. For example, CDPs (e.g., knot peptides) in some embodiments include small disulfide-rich proteins characterized by disulfides mediated by a disulfide knot. This knot can be obtained, for example, when one disulfide bridge passes through a macrocyclic macromolecule formed by two other disulfides and their interconnected backbones. In some embodiments, the knot peptide can include a growth factor cysteine knot or an inhibitory factor cysteine knot. Other possible peptide structures include peptides with two parallel helices linked by two disulfide bridges without a beta sheet (eg, hefutoxin).
[0164] Some peptides of the present disclosure may contain at least one amino acid residue that is in the L-configuration. Peptides may contain at least one amino acid residue that is in the D-configuration. In some embodiments, peptides are 15-75 amino acid residues in length. In other embodiments, peptides are 11-55 amino acid residues in length. In still other embodiments, peptides are 11-65 amino acid residues in length. In further embodiments, peptides are at least 20 amino acid residues in length.
[0165] Some CDPs (e.g., knot peptides) can be derived or isolated from classes of proteins known to be present in or associated with toxins or venoms. In some cases, the peptides can be derived from toxins or venoms associated with scorpions or spiders. The peptides can be derived from the venoms and toxins of various genera and species of spiders and scorpions. For example, peptides can be found in Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heterometrus laoticus, Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Haplopelma huwenum, Haplopelma hainanum, Haplopelma schmidti, Agelenopsis aperta, Hadronyche versuta, Selenocosmia huwena, Heteropoda venatoria, Grammostola rosea, Ornithoctonus huwena, Hadronyche versuta, Atrax robustus, Angelenopsis aperta, Psalmopoeus cambridgei, Hadronyche infensa, Paracoelotes luctosus, and Chilobrachys jingzhaoor, or another suitable genus or species of scorpion or spider venom or toxin. In some cases, the peptide may be derived from Buthus martensii Karsh (scorpion) venom.
[0166] In some embodiments, a peptide of the present disclosure (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) may comprise a sequence having a cysteine residue at one or more of the following positions: 11, 12, 13, 14, 19, 20, 21, 22, 36, 38, 39, 41, e.g., with reference to SEQ ID NO: 96. In some embodiments, a peptide comprises a Cys at position 11, 12, 19, 20, 36, 39, or any combination thereof. For example, in certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 11. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 12. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 13. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 14. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 19. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 20. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 21. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 22. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 36. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 38. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 39. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 41. In some embodiments, the first cysteine residue in the sequence can form a disulfide bond with the fourth cysteine residue in the sequence, the second cysteine residue in the sequence can form a disulfide bond with the fifth cysteine residue in the sequence, and the third cysteine residue in the sequence can form a disulfide bond with the sixth cysteine residue in the sequence. Optionally, the peptide may contain one disulfide bridge passing through a ring formed by two other disulfide bridges, also known as a "two-and-through" structural system.In some embodiments, the peptides disclosed herein can have one or more cysteines mutated to serines.
[0167] In some embodiments, a peptide of the present disclosure (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) comprises at least one cysteine residue. In some embodiments, a peptide of the present disclosure comprises at least two cysteine residues. In some embodiments, a peptide of the present disclosure comprises at least three cysteine residues. In some embodiments, a peptide of the present disclosure comprises at least four cysteine residues. In some embodiments, a peptide of the present disclosure comprises at least five cysteine residues. In some embodiments, a peptide of the present disclosure comprises at least six cysteine residues. In some embodiments, a peptide of the present disclosure comprises at least ten cysteine residues. In some embodiments, a peptide of the present disclosure comprises six cysteine residues. In some embodiments, a peptide of the present disclosure comprises seven cysteine residues. In some embodiments, a peptide of the present disclosure comprises eight cysteine residues.
[0168] In some embodiments, a peptide (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) of the present disclosure comprises an amino acid sequence having a cysteine residue at one or more positions, e.g., with reference to SEQ ID NO: 96. In some embodiments, the one or more cysteine residues are located at any one of amino acid positions 6, 10, 20, 34, 44, 48, or any combination thereof. In some aspects of the present disclosure, the one or more cysteine (C) residues are paired in various patterns (e.g., C 10 -C 20 In some embodiments, the corresponding pairing pattern involves a disulfide bond having a C6-C 48 , C 10 -C 44 , and C 20 -C 34In some embodiments, the peptides described herein comprise at least one, at least two, or at least three disulfide bonds. In some embodiments, at least one, at least two, or at least three disulfide bonds are C6-C 48 , C 10 -C 44 , and C 20 -C 34 or a combination thereof. In some embodiments, the peptides described herein are arranged according to the corresponding pairing pattern C6-C 48 , C 10 -C 44 , and C 20 -C 34 It contains three disulfide bonds having the formula:
[0169] In certain embodiments, a peptide (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) comprises a sequence having a cysteine residue at corresponding position 6. In certain embodiments, a peptide comprises a sequence having a cysteine residue at corresponding position 10. In certain embodiments, a peptide comprises a sequence having a cysteine residue at corresponding position 20. In certain embodiments, a peptide comprises a sequence having a cysteine residue at corresponding position 34. In certain embodiments, a peptide comprises a sequence having a cysteine residue at corresponding position 44. In certain embodiments, a peptide comprises a sequence having a cysteine residue at corresponding position 50. In some embodiments, the first cysteine residue in the sequence forms a disulfide bond with the last cysteine residue in the sequence. In some embodiments, the second cysteine residue in the sequence forms a disulfide bond with the penultimate cysteine residue in the sequence. In some embodiments, the third cysteine residue in the sequence forms a disulfide bond with the third penultimate cysteine residue in the sequence, etc.
[0170] In some embodiments, the first cysteine residue in the sequence is disulfide bonded to the sixth cysteine residue in the sequence, the second cysteine residue in the sequence is disulfide bonded to the fifth cysteine residue in the sequence, and the third cysteine residue in the sequence is disulfide bonded to the fourth cysteine residue in the sequence. Optionally, the peptide may contain one disulfide bridge that passes through the ring formed by two other disulfide bridges, also known as a "two-and-through" structural system. In some embodiments, the peptides disclosed herein have one or more cysteines mutated to serine.
[0171] In some embodiments, the peptide (e.g., TfR-binding peptide, target-binding peptide, or selective depletion complex) does not contain cysteines or disulfides. In some embodiments, the peptide contains 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more cysteines or disulfides. In other embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more cysteine residues are substituted with serine residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more cysteine residues are substituted with threonine residues.
[0172] In some embodiments, the peptide (e.g., TfR-binding peptide, target-binding peptide, or selective depletion complex) does not contain a Cys or disulfide. In some embodiments, the peptide contains 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more Cys or disulfides. In other embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues are substituted with Ser residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues are substituted with Thr residues.
[0173] In some examples, one or more or all methionine residues in the peptide are substituted with leucine or isoleucine. In some examples, one or more or all tryptophan residues in the peptide are substituted with phenylalanine or tyrosine. In some examples, one or more or all asparagine residues in the peptide are substituted with glutamine. In some embodiments, the N-terminus of the peptide is blocked with an acetyl group or the like. Alternatively, or in combination, in some examples, the C-terminus of the peptide is blocked with an amide group or the like. In some embodiments, the peptide is modified by methylation on the free amine.
[0174] For example, complete methylation can be achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0175] In some embodiments, a peptide or peptide conjugate described herein targets and / or penetrates a TfR-expressing cell layer or barrier and / or the membrane of a TfR-expressing cell. In some embodiments, the peptide targets and / or penetrates the plasma membrane of a cell located in the CNS, such as the brain. For example, a peptide conjugate comprising a TfR-binding peptide and one or more active agents (e.g., therapeutic or diagnostic compounds) crosses a cell barrier (e.g., the BBB) via vesicular transcytosis and then targets and / or penetrates the plasma membrane of a cell located in the CNS, delivering the one or more active agents to the cell.
[0176] In various embodiments, a selective depletion complex comprising a TfR-binding peptide and a target-binding peptide binds to TfR-expressing cells located in the gastrointestinal tract, spleen, liver, kidney, muscle, bone marrow, brain, or skin. In some cases, the TfR-expressing cells are tumor cells, immune cells, erythrocytes, erythroid progenitor cells, stem cells, bone marrow cells, or stem cells. In some cases, the TfR-binding peptide is involved in targeting of the cells, for example, when the cells overexpress TfR. In various embodiments, the peptide complexes described herein comprise a TfR-binding peptide conjugated, linked, or fused to a target-binding peptide that binds to cells located in various organs, such as the spleen, brain, liver, kidney, muscle, bone marrow, gastrointestinal tract, or skin.
[0177] In some cases, the target-binding peptide promotes endocytosis of the target molecule. In some embodiments, a peptide or peptide complex (e.g., a peptide conjugate or fusion peptide) of the present disclosure is used to target a target molecule to exert a particular biological (e.g., therapeutic) effect. In some embodiments, a selective depletion complex (e.g., a complex comprising a TfR-binding peptide and a target-binding peptide) of the present disclosure can be used to promote endocytosis of the target molecule into the cell to exert a particular biological effect (e.g., selective depletion of the target molecule).
[0178] Peptide Linker The peptides of the present disclosure (e.g., TfR-binding peptides, target-binding peptides, selective depletion complexes, or combinations thereof) can be dimerized in a number of ways. For example, a TfR-binding peptide can dimerize with a target-binding peptide via a peptide linker to form a selective depletion complex. In some embodiments, the peptide linker does not interfere with the independent folding of the peptide domains (e.g., TfR-binding peptides or target-binding peptides). In some embodiments, the peptide linker may comprise a sufficient length relative to the peptide complex to facilitate contact between the target molecule and TfR via the peptide complex (e.g., selective depletion complex). In some embodiments, the peptide linker does not adversely affect the manufacturability (synthetic or recombinant) of the peptide complex (e.g., selective depletion complex). In some embodiments, the peptide linker does not impair post-synthetic chemical modification (e.g., conjugation of a fluorophore or albumin-binding chemical group) of the peptide complex (e.g., selective depletion complex).
[0179] In some embodiments, a peptide linker can connect the C-terminus of a first peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a half-life-modifying peptide) to the N-terminus of a second peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a half-life-modifying peptide). In some embodiments, a peptide linker can connect the C-terminus of a second peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a half-life-modifying peptide) to the N-terminus of a third peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a half-life-modifying peptide). For example, a linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can join the C-terminus of a target-binding peptide to the N-terminus of a TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64) to form a selective depletion complex. In another example, a linker (e.g., any one of SEQ ID NOs:129-141 or 195-218) can connect the C-terminus of a TfR-binding peptide (e.g., any one of SEQ ID NOs:96, 65-95, 97-128, 220-222, or 1-64) to the N-terminus of a target-binding peptide to form a selective depletion complex. In another example, a linker (e.g., any one of SEQ ID NOs: 129 to 141 or 195 to 218) can connect the C-terminus of a TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65 to 95, 97 to 128, 220 to 222, or 1 to 64) to the N-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, 179, or 192), and the C-terminus of the half-life extending peptide can be connected to the N-terminus of a target-binding peptide to form a selective depletion complex.In another example, a linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of the target-binding peptide to the N-terminus of the half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 192), and a second linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of the half-life extending peptide to the N-terminus of the TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64) to form a selective depletion complex. In another example, a first linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of the target-binding peptide to the N-terminus of the half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 192), and a second linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of the half-life extending peptide to the N-terminus of the TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64) to form a selective depletion complex. In another example, a linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of a half-life extending peptide (e.g., SEQ ID NO: 178, SEQ ID NO: 179, or SEQ ID NO: 192) to the N-terminus of a target-binding peptide, and a second linker (e.g., any one of SEQ ID NOs: 129-141 or 195-218) can connect the C-terminus of the target-binding peptide to the N-terminus of a TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64) to form a selective depletion complex.
[0180] In some embodiments, the linker can comprise Tau-therafotoxin-Hs1a, also known as DkTx (double knot toxin), extracted from a natural knottin-knottin dimer from Haplopelma schmidti (e.g., SEQ ID NO: 139). The linker can lack structural features that prevent dimerization of independently functioning CDPs (e.g., TfR-binding CDP and target-binding CDP). In some embodiments, the linker can comprise a glycine-serine (Gly-Ser or GS) linker (e.g., SEQ ID NOs: 129-138, 141, or 195-218). The Gly-Ser linker can have minimal chemical reactivity and can provide flexibility to the linker. Serine can increase the solubility of the linker or peptide conjugate due to the hydrophilic nature of the hydroxyl side chain. In some embodiments, the linker can be derived from the peptide that separates the Fc from the Fv domain in the heavy chain of human immunoglobulin G (e.g., SEQ ID NO: 140). In some embodiments, the linker derived from a peptide from the heavy chain of human IgG may contain a cysteine to serine mutation compared to the native IgG peptide.
[0181] In some embodiments, the peptides of the present disclosure can be dimerized using an immunoglobulin heavy chain Fc domain. These Fc domains can be used to dimerize functional domains (e.g., TfR-binding peptides and target-binding peptides) based on either antibodies or other soluble functional domains. In some embodiments, the dimerization can be homodimerization when the Fc sequence is natural. In some embodiments, the dimerization can be heterodimerization by mutating the Fc domain to create a "hole-in-knob" format, in which one Fc CH3 domain contains a novel residue (knob) designed to fit into a cavity (hole) on the other Fc CH3 domain. A first peptide domain (e.g., a TfR-binding peptide or a target-binding peptide) can be bound to the knob, and a second peptide domain (e.g., a TfR-binding peptide or a target-binding peptide) can be bound to the hole. Knob+knob dimers can be energetically highly unfavorable. A purification tag can be added to the "knob" side to remove hole+hole dimers and select for knob+hole dimers.
[0182] A peptide of the present disclosure (e.g., a target-binding peptide, a TfR-binding peptide, or a selective depletion complex) can be linked to another peptide (e.g., a target-binding peptide, a TfR-binding peptide, a selective depletion complex, or a half-life-altering peptide) at its N-terminus or C-terminus. In some embodiments, one or more peptides can be linked or fused via a peptide linker (e.g., a peptide linker comprising any one of SEQ ID NOs: 129-141 or 195-218). For example, a TfR-binding peptide can be fused to a target-binding peptide via a peptide linker comprising any one of SEQ ID NOs: 129-141 or 195-218. Peptide linkers (e.g., linkers connecting TfR-binding peptides, target-binding peptides, half-life-modifying peptides, or combinations thereof) can have a length of about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 30, about 35, about 40, about 45, or about 50 amino acid residues. The peptide linker (e.g., a linker connecting a TfR-binding peptide, a target-binding peptide, a half-life-modifying peptide, or a combination thereof) may be about 2 to about 5, about 2 to about 10, about 2 to about 20, about 3 to about 5, about 3 to about 10, about 3 to about 15, about 3 to about 20, about 3 to about 25, about 5 to about 10, about 5 to about 15, about 5 to about 20, about 5 to about 25, about 10 to about 15, about 10 to about 20, about 10 to about 25, about 15 to about 2 The amino acid sequence may be 0, about 15 to about 25, about 20 to about 25, about 20 to about 30, about 20 to about 35, about 20 to about 40, about 20 to about 45, about 20 to about 50, about 3 to about 50, about 3 to about 40, about 3 to about 30, about 10 to about 40, about 10 to about 30, about 50 to about 100, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 500 to about 600 amino acid residues in length.
[0183] In some embodiments, a first peptide (e.g., a TfR-binding peptide) and a second peptide (e.g., a target-binding peptide) can be linked by a flexible peptide linker. The flexible linker can provide rotational freedom between the first and second peptides, allowing the first and second peptides to bind to their respective targets (e.g., transferrin receptor and target molecule) with minimal strain. In some embodiments, the peptide linker can have a persistence length of 6 Å or less, 7 Å or less, 8 Å or less, 9 Å or less, 10 Å or less, 12 Å or less, 15 Å or less, 20 Å or less, 25 Å or less, 30 Å or less, 40 Å or less, or 50 Å or less. In some embodiments, the peptide linker can have a persistence length of about 4 Å to about 100 Å, about 4 Å to about 50 Å, about 4 Å to about 20 Å, about 4 Å to about 10 Å, about 10 Å to about 20 Å, about 20 Å to about 30 Å, about 30 Å to about 50 Å, or about 50 Å to about 100 Å. The linker persistence length can be a measure of the flexibility of the peptide linker and can be quantified as the peptide length at which tangential correlation is lost.
[0184] In some embodiments, peptide linkers can be selected based on desired linker length, hydrodynamic radius, chromatographic mobility, propensity for post-translational modification, or a combination thereof. In some embodiments, linkers separating two or more functional domains of a peptide complex (e.g., separating a TfR-binding peptide and a target-binding peptide) can comprise a large, stable globular domain, e.g., to reduce the propensity for glomerular filtration. In some embodiments, linkers separating two or more functional domains of a peptide complex (e.g., separating a TfR-binding peptide and a target-binding peptide) can comprise a small, flexible linker, e.g., to reduce the hydrodynamic radius of the complex for use in narrow spaces such as dense-core tumor stroma. Examples of selective depletion complexes formed from a single polypeptide chain containing a target-binding peptide and a receptor-binding peptide connected via a peptide linker are shown in Figures 25A and 25B. In some embodiments, the peptide linker can support independent folding of two or more functional domains and cannot inhibit interactions between the two or more functional domains and their binding targets (e.g., between the TfR-binding peptide and TfR, or between the target-binding peptide and a target molecule).
[0185] In some embodiments, a peptide can be added to the N-terminus of any peptide of the present disclosure after the N-terminal GS dipeptide and before, for example, a GGGS (SEQ ID NO: 129) spacer. In some embodiments, the peptide (e.g., target-binding peptide) can be G x S yA peptide linker such as (GS) (SEQ ID NO: 130), where x and y can be any integer such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, can be used to append to either the N-terminus or C-terminus of any peptide disclosed herein (e.g., a TfR-binding peptide). In some embodiments, the peptide linker comprises (GS) (SEQ ID NO: 131), where x can be any integer such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGSSG (SEQ ID NO: 132), GGGGG (SEQ ID NO: 133), GSGSGSGS (SEQ ID NO: 134), GSGG (SEQ ID NO: 135), GGGGS (SEQ ID NO: 136), GGGS (SEQ ID NO: 129), GGS (SEQ ID NO: 137), GGGSGGGSGGGS (SEQ ID NO: 138), or a variant or fragment thereof. Additionally, KKYKPYVPVTTN (SEQ ID NO: 139) derived from DkTx and EPKSSDDKTHT (SEQ ID NO: 140) derived from human IgG3 can be used as peptide linkers. In some embodiments, the peptide linker comprises GGGSGGSGGGS (SEQ ID NO: 141). In some embodiments, the peptide linker comprises any one of SEQ ID NOs: 195-218. Examples of peptide linkers compatible with the target depletion complexes of the present disclosure are provided in Table 4. It is understood that any of the foregoing linkers or variants or fragments thereof can be used with any number of repeats or any combination thereof. It is also understood that other peptide linkers or variants or fragments thereof known in the art can be used with any number of repeats or any combination thereof.
[0186] In some embodiments, a tag peptide (e.g., a peptide of any one of SEQ ID NOs: 142-147) can be added to a peptide (e.g., a target-binding peptide, a TfR-binding peptide, or a selective depletion complex) at any amino acid residue. In further embodiments, a tag peptide (e.g., a peptide of any one of SEQ ID NOs: 142-147) can be added to a peptide at any amino acid residue without interfering with TfR-binding activity, target-binding activity, selective depletion activity, or a combination thereof. In some embodiments, the tag peptide is added via conjugation, linkage, or fusion techniques. In other embodiments, a peptide (e.g., a target-binding peptide) can be added to a second peptide (e.g., a TfR-binding peptide) at any amino acid residue. In further embodiments, a peptide (e.g., a target-binding peptide) can be added to a second peptide (e.g., a TfR-binding peptide) at any amino acid residue without interfering with TfR-binding activity, target-binding activity, selective depletion activity, or a combination thereof. In some embodiments, the peptide is added via conjugation, linkage, or fusion techniques. In other embodiments, the peptide (eg, the target-binding peptide) can be appended to the second peptide (eg, the TfR-binding peptide) at any amino acid residue. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]
[0187] In some embodiments, a selective depletion complex can comprise two or more polypeptide chains. For example, a target-binding peptide and a receptor-binding peptide can complex via a dimerization domain to form a selective depletion complex. The dimerization domain can be a heterodimerization domain or a homodimerization domain. Examples of selective depletion complexes comprising a target-binding peptide and a receptor-binding peptide connected via a dimerization domain (e.g., an Fc homodimerization domain or a knobs-in-holes heterodimerization domain) are shown in Figures 25A, 25B, and 25C.
[0188] The target-binding peptide and the receptor-binding peptide can form a complex by forming a heterodimer through the heterodimerization domain. The target-binding peptide can be linked or fused to a first heterodimerization domain, and the receptor-binding peptide can be linked or fused to a second heterodimerization domain. The first heterodimerization domain can bind to the second heterodimerization domain to form a heterodimeric complex comprising the target-binding peptide and the receptor-binding peptide. For example, the receptor-binding peptide can be linked or fused to an Fc "knob" peptide (e.g., SEQ ID NO: 260), and the immune cell targeting agent can be linked or fused to an Fc "hole" peptide (e.g., SEQ ID NO: 261). In another example, the receptor-binding peptide can be linked or fused to an Fc "hole" peptide (e.g., SEQ ID NO: 261), and the target binding agent can be linked or fused to an Fc "knob" peptide (e.g., SEQ ID NO: 260). In some embodiments, a receptor-binding peptide (e.g., any one of SEQ ID NOs: 1-222) can form a heterodimer with a target-binding peptide via a heterodimerization domain provided in Table 5. For example, the receptor-binding peptide can be fused to chain 1 of an Fc pair (e.g., SEQ ID NO: 260), and the target-binding peptide can be fused to chain 2 of the Fc pair (e.g., SEQ ID NO: 261). In another example, the receptor-binding peptide can be fused to chain 2 of the Fc pair (e.g., SEQ ID NO: 263), and the target-binding peptide can be fused to chain 1 of the Fc pair (e.g., SEQ ID NO: 262). A selective depletion complex comprising a heterodimerization domain can form a monovalent selective depletion complex, as shown in Figure 25B. Alternatively, a selective depletion complex comprising a heterodimerization domain can form a multivalent selective depletion complex, as shown in Figure 25C. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8] [Table 5-9]
[0189] In some embodiments, the target-binding peptide and the receptor-binding peptide can form a selective depletion complex comprising homodimers complexed via the homodimerization domain. The target-binding peptide can be linked or fused to the N-terminus of the homodimerization domain, and the receptor-binding peptide can be linked or fused to the C-terminus of the homodimerization domain. In some embodiments, the target-binding peptide can be linked or fused to the C-terminus of the homodimerization domain, and the receptor-binding peptide can be linked or fused to the N-terminus of the homodimerization domain. In some embodiments, the target-binding peptide and the receptor-binding peptide can both be fused to the N-terminus of the homodimerization domain, or both can be fused to the C-terminus of the homodimerization domain. Selective depletion complexes comprising the homodimerization domain can form multivalent selective depletion complexes, as shown in Figure 25C. Examples of homodimerization domains that can be used to link or fuse the target-binding peptide to the receptor-binding peptide are provided in Table 6. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4]
[0190] Peptide Modification Peptides can be modified (e.g., chemically modified) in one or more different ways. In some embodiments, peptides can be mutated to add function, remove function, or alter in vivo behavior. One or more loops between disulfide bonds in a peptide (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) can be modified or replaced to include active components derived from other peptides (e.g., as described in Moore and Cochran, Methods in Enzymology, 503, pp. 223-251, 2012). In some embodiments, peptides (e.g., a TfR-binding peptide, a target-binding peptide, or a selective depletion complex) of the present disclosure can be further functionalized and multimerized by adding additional functional domains. For example, an albumin-binding domain (ABD) can be added to the albumin-binding domain (ABD) of Finegoldia magna. Albumin-binding protein of peptostreptococcal (SEQ ID NO: 192, MKLNKKLLMAALAGAIVVGGGVNTFAADEPGAIKVDKAPEAPSQELKLTKEEAEKALKKEKPIAKERLRRLGITSEFILNQIDKATSREGLESLVQTIKQSYLKDHPIKEEKTEETPKYNNLFDKHELGGLGKDKGPGRFDENGWENNEHGYETRENAEKAAVKALGDKEINKSYTI SQGVDGRYYYVLSREEAETPKKPEEKKPEDKRPKMTIDQWLLKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKAHAGKEVNPSTPEVTPSVPQNHYHENDYANIGAGEGTKEDGKKENSKEGIKRKTAREEKPGKEEKPAKEDKKENKKKENTDSPNKKKKEKAALPEAGRRKAEILTLAAASLSSVAGAFISLKKRK). For example, the albumin binding domain of SEQ ID NO: 193 (LKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKA) can be added to a peptide of the disclosure.In some embodiments, peptides of the present disclosure can be functionalized with an albumin-binding domain that has been modified for improved albumin affinity, improved stability, reduced immunogenicity, improved manufacturability, or a combination thereof. For example, a peptide can be functionalized with a modified albumin-binding domain of SEQ ID NO: 194 (LKEAKEKAIEELKKAGITSDYYFDLINKAKTVEGVNALKDEILKA) or SEQ ID NO: 227 (LKEAKEKAIEELKKAGITSDYYFDLINKAKAVEGVNALKDEILKA), which has increased thermal stability and improved serum half-life compared to the albumin-binding domain of SEQ ID NO: 193. In some embodiments, the albumin-binding peptide can be selected based on the desired off-rate of albumin. For example, the albumin-binding peptide of SEQ ID NO: 227 can be selected for its faster off-rate compared to SEQ ID NO: 194. The albumin-binding domain contains a simple three-helix structure that is unlikely to disrupt the independent folding of other peptide domains (e.g., CDP domains). In some embodiments, a functional domain (e.g., an albumin-binding domain) can increase the serum half-life of a peptide or peptide conjugate of the present disclosure. A functional domain (e.g., an albumin-binding domain) can be included in any orientation relative to the TfR-binding peptide or target-binding peptide. For example, the functional domain can be linked to the TfR-binding peptide, the target-binding peptide, or between the TfR-binding peptide and the target-binding peptide, as shown in Figures 16A-16C. In some embodiments, an albumin-binding peptide (e.g., SEQ ID NO: 194 or SEQ ID NO: 227) can be used to link the target-binding peptide to the receptor-binding peptide. Additional functional domains can be linked to one or more peptides (e.g., TfR-binding peptides or target-binding peptides) via linkers (e.g., SEQ ID NOs: 129-141 or SEQ ID NOs: 195-218).
[0191] The peptides of the present disclosure (e.g., TfR-binding peptides, receptor-binding peptides, target-binding peptides, or selective depletion complexes) can be modified with a signal peptide to tag the peptide for secretion. For example, peptides can be modified with a signal peptide corresponding to SEQ ID NO: 230 (METDTLLLWVLLLWVPGSTG). In some embodiments, the signal peptide can be added to either the N- or C-terminus of the peptide. Peptides can be modified for additional stability during translation or secretion. For example, peptides can be modified with sidrocalin, which has a furin cleavage site corresponding to SEQ ID NO: 229 (GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDGGGSRRRRKRSGS). In some embodiments, sidrocalin with a furin cleavage site can be added to the N- or C-terminus of the peptide. The peptide can be modified with a signal peptide to tag the peptide for secretion or to provide additional stability during translation or secretion. For example, a peptide can be modified with sidrocalin with a signal peptide and furin cleavage site corresponding to SEQ ID NO: 231 (METDTLLLWVLLLWVPGSTGGSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDGGGSRRRRKRSGS). In some embodiments, sidrocalin with a signal peptide and furin cleavage site can be added to the N- or C-terminus of the peptide.
[0192] Amino acids of a peptide or peptide complex (e.g., a TfR-binding peptide, receptor-binding peptide, target-binding peptide, or selective depletion complex) can also be mutated to extend half-life, alter, add, or eliminate in vivo binding behavior, add new targeting functions, alter surface charge and hydrophobicity, or enable conjugation sites. N-methylation is one example of methylation that can be performed on the peptides of the present disclosure. In some embodiments, peptides are modified by methylation on free amines. For example, complete methylation can be achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0193] Peptides can be modified to add function, such as by grafting loops or sequences from other proteins or peptides onto the peptides of the present disclosure. Similarly, domains, loops, or sequences from the present disclosure can be grafted onto other peptides or proteins, such as antibodies, with additional function.
[0194] In some embodiments, the selective depletion complex can include a tissue-targeting domain and accumulate in a target tissue upon administration to a subject. For example, the selective depletion complex can be conjugated, linked, or fused to a molecule (e.g., a small molecule, peptide, or protein) that has targeting or homing function for a cell of interest or a target protein located on the surface or within the cell. In some embodiments, the selective depletion complex can be conjugated, linked, or fused to a molecule that extends the plasma half-life and / or biological half-life of the peptide, or alters the pharmacodynamics (e.g., improved binding to the target protein) and / or pharmacokinetic properties (e.g., rate and mode of clearance), or any combination thereof.
[0195] Chemical modifications can result in, for example, an increase in the half-life of the peptide or an alteration in the biodistribution or pharmacokinetic profile. Chemical modifications can include polymers, polyethers, polyethylene glycol, biopolymers, polyamino acids, fatty acids, dendrimers, Fc regions, simple saturated carbon chains such as palmitic acid or myristic acid, or albumin. Polyamino acids can include, for example, polyamino acid sequences in which a single amino acid is repeated (e.g., polyglycine), and mixed polyamino acid sequences that may or may not follow a pattern (e.g., gly-ala-gly-ala; SEQ ID NO: 457), or any combination of the foregoing.
[0196] The peptides of the present disclosure can be modified such that the modification increases the stability and / or half-life of the peptide. The half-life of the peptides of the present disclosure can be extended using attachment of hydrophobic moieties, such as to the N-terminus, C-terminus, or internal amino acids. The peptides can also be modified to increase or decrease their intestinal or cellular permeability. In some cases, peptides of the present disclosure exhibit high accumulation in intestinal glandular cells, demonstrating applicability in the treatment and / or prevention of intestinal diseases or conditions, such as Crohn's disease or, more generally, inflammatory bowel disease. The peptides of the present disclosure can include post-translational modifications (e.g., methylation and / or amidation and / or glycosylation) that can affect, for example, serum half-life. In some embodiments, simple carbon chains (e.g., by myristoylation and / or palmitylation) can be conjugated and linked to fusion proteins or peptides. The simple carbon chains can allow the fusion proteins or peptides to be easily separated from unconjugated materials. For example, methods that can be used to separate fusion proteins or peptides from non-conjugated materials include, but are not limited to, solvent extraction and reverse-phase chromatography. The lipophilic moiety can extend half-life by reversible binding to serum albumin. The conjugate moiety can be, for example, a lipophilic moiety that extends the half-life of the peptide by reversible binding to serum albumin. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative, including cholestene, cholestane, cholestadiene, and oxysterols. In some embodiments, the peptide can be conjugated or linked to myristic acid (tetradecanoic acid) or a derivative thereof. In other embodiments, the peptides of the present disclosure can be linked (e.g., conjugated, linked, or fused) to a half-life modifying agent.Examples of half-life modifying agents may include, but are not limited to, polymers, polyethylene glycol (PEG), hydroxyethyl starch, polyvinyl alcohol, water-soluble polymers, zwitterionic water-soluble polymers, water-soluble poly(amino acids), water-soluble polymers of proline, alanine, and serine, water-soluble polymers comprising glycine, glutamic acid, and serine, Fc regions, fatty acids, palmitic acid, or molecules that bind to albumin. In some embodiments, the half-life modifying agent may be a serum albumin-binding peptide, such as SA21 (SEQ ID NO: 178, RLIEDIC LPRWGCLWEDD). In some embodiments, the SA21 peptide may be conjugated or fused to a CDP of the present disclosure (e.g., any of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64). The SA21 fusion peptide may comprise the SA21 TfR-binding peptide complex disclosed herein (e.g., SEQ ID NO: 181 or SEQ ID NO: 184). The SA21 peptide may include a linker sequence for conjugation to, or fusion between, one or more peptides (e.g., SEQ ID NO: 179, GGGGSGGGGSRLIEDICLPRWGCLWEDDGGGGSGGGGS). Exemplary SA21 peptides, fusion peptides, and linkers are provided in Table 5. The control SA21 fusion peptide can include a control peptide fused to SA21 (e.g., SEQ ID NO: 180 (GSRLIEDICLPRWGCLWEDDGGGGSGGGGSKCLPPGKPCYGATQKIPCCGVCSHNNCT), SEQ ID NO: 183 (RLIEDICLPRWGCLWEDDGGGGSGGGGSKCLPPGKPCYGATQKIPCCGVCSHNNCT), SEQ ID NO: 182 (GSRLIEDICLPRWGCLWEDDGGGGSGGGGSVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK), or SEQ ID NO: 185 (RLIEDICLPRWGCLWEDDGGGGSGGGGSVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK)).Furthermore, conjugation of the peptide to a near-infrared dye such as Cy5.5 or an albumin-binding agent such as an Albu tag can extend the serum half-life of any of the peptides described herein. In some embodiments, immunogenicity is reduced by using minimal non-human protein sequences, and the serum half-life of the peptide is extended. [Table 7]
[0197] In some embodiments, the first two N-terminal amino acids (GS) of SEQ ID NOs: 1-64 serve as a spacer or linker to facilitate conjugation or fusion to another molecule and to facilitate cleavage from such a conjugated, linked, or fused molecule. In some embodiments, the fusion proteins or peptides of the present disclosure may be conjugated, linked, or fused to other moieties that may, for example, modify or change the properties of the peptide.
[0198] In some embodiments, peptides or peptide complexes of the present disclosure may also be conjugated, linked, or fused to other affinity handles. Other affinity handles may include gene fusion affinity handles. Gene fusion affinity handles may include 6xHis (HHHHHH (SEQ ID NO: 142) or GGGGSHHHHHH (SEQ ID NO: 228); capable of immobilized metal affinity column purification), FLAG (DYKDDDDK (SEQ ID NO: 143); anti-FLAG immunoprecipitation), "short" FLAG (DYKDE (SEQ ID NO: 144); anti-FLAG immunoprecipitation), hemagglutinin (YPYDVPDYA (SEQ ID NO: 145); anti-HA immunoprecipitation), and streptavidin-binding peptide (DVEAWLGAR (SEQ ID NO: 146); streptavidin-mediated precipitation). In some embodiments, peptides or peptide complexes of the present disclosure may also be conjugated, linked, or fused to expression tags or sequences that improve protein expression and / or purification. Such expression tags may include gene fusion expression tags. The gene fusion expression tag can include siderocalin (SEQ ID NO: 147, METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQ).
[0199] Additionally, more than one peptide sequence (e.g., peptides derived from toxins or knot venom proteins) may be present, conjugated, linked, or fused to a particular peptide. Peptides can be incorporated into biomolecules by a variety of techniques. Peptides can be incorporated by chemical transformations, such as the formation of covalent bonds, such as amide bonds. Peptides can be incorporated, for example, by solid-phase or solution-phase peptide synthesis. Peptides can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, where the nucleic acid sequence includes a subsequence encoding the peptide. The subsequence may be added to the sequence encoding the biomolecule or may replace a subsequence of the sequence encoding the biomolecule.
[0200] Selective depletion complex In some embodiments, one or more peptides of the present disclosure can form a selective depletion complex (SDC). The selective depletion complex can include a target-binding peptide that binds to a target molecule and a receptor-binding peptide that binds to a cell receptor (e.g., a cell surface receptor). In some embodiments, the cell surface receptor is a receptor that is endocytosed (e.g., transferrin receptor or programmed death ligand 1). In some embodiments, the cell surface receptor is a receptor that is recycled to the cell surface after endocytosis. The receptor-binding peptide of the present disclosure can be a transferrin receptor (TfR)-binding peptide or a programmed death ligand 1 (PD-L1)-binding peptide. For example, the selective depletion complex can include a TfR-binding peptide and a target-binding peptide. In some embodiments, the receptor-binding peptide (e.g., a TfR-binding peptide or a PD-L1-binding peptide) and the target-binding peptide can be connected via a linker (e.g., a peptide linker). In some embodiments, the receptor-binding peptide and the target-binding peptide can be directly connected without a linker. In some embodiments, the receptor-binding peptide and the target-binding peptide can be connected via a heterodimerization domain. The receptor-binding peptide can bind to a receptor (e.g., TfR or PD-L1) with high affinity at both extracellular pH (e.g., about pH 7.4) and endosomal pH (e.g., about pH 5.5). In some embodiments, the receptor-binding peptide of the selective depletion complex can be a TfR-binding peptide (e.g., any one of SEQ ID NOs: 96, 65-95, 97-128, 220-222, or 1-64). In some embodiments, the receptor-binding peptide of the selective depletion complex can be a PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 187, 233-239, 400-456, or 141).
[0201] The target-binding peptide can bind to the target molecule with pH-dependent affinity. For example, the target-binding molecule can bind to the target molecule with higher affinity at extracellular pH (about pH 7.4) and with lower affinity at lower endosomal pH (such as about pH 5.5 or about pH 6.5). In some embodiments, the target-binding molecule can release the target molecule upon internalization into the endosomal compartment and acidification of the endosome. Release of such target molecules upon endosomal acidification can occur at about pH 7.3, pH 7.2, pH 7.1, pH 7.0, pH 6.9, pH 6.8, pH 6.7, pH 6.6, pH 6.5, pH 6.4, pH 6.3, pH 6.2, pH 6.1, pH 6.0, pH 5.9, pH 5.8, pH 5.7, pH 5.6, pH 5.5, pH 5.4, pH 5.3, pH 5.2, pH 5.1, pH 5.0, pH 4.9, pH 4.8, pH 4.7, pH 4.6, pH 4.5, or lower. In some embodiments, release of target molecules can occur at a pH of about pH 7.0 to about pH 4.5, about pH 6.5 to about pH 5.0, or about pH 6.0 to about pH 5.5. In some embodiments, the receptor-binding peptide binds to a receptor (e.g., a receptor that undergoes recycling) with pH-independent binding (e.g., high affinity at extracellular pH and high affinity at endosomal pH), and the target-binding peptide binds to a target with pH-dependent binding (e.g., high affinity at extracellular pH and low affinity at endosomal pH). A selective depletion complex (SDC) comprising a pH-independent receptor-binding peptide and a pH-dependent target-binding peptide can be catalytic (e.g., reused). SDC can remain bound to the receptor through multiple rounds of endocytosis, carrying a different target molecule with each round and leaving the target molecule in the endosome / lysosome for degradation. Thus, one catalytic SDC molecule can cause the degradation of multiple target molecules.
[0202] In some embodiments, the receptor-binding peptide can bind to the receptor with pH-dependent affinity. For example, the receptor-binding molecule can bind to the receptor with higher affinity at extracellular pH (e.g., about pH 7.4) and with lower affinity at lower endosomal pH (e.g., about pH 5.5 or pH 6.5), thereby releasing the selective depletion complex from the receptor upon internalization and acidification of the endosomal compartment. In some embodiments, the receptor-binding peptide can bind to the receptor with pH-dependent affinity, and the target-binding peptide can bind to the target with pH-dependent or pH-independent affinity. The selective depletion molecule can be used to selectively deplete a target molecule (e.g., a soluble protein or a cell-surface protein). For example, a selective depletion complex comprising a receptor-binding peptide and a target-binding peptide can bind to the receptor via the receptor-binding peptide and to the target molecule (e.g., a soluble protein or a cell-surface protein). The target molecule can be delivered to an endocytic compartment via receptor-mediated endocytosis of the receptor and the selective depletion molecule. In the endocytic compartment, the selective depletion complex remains bound to the receptor, and the target molecule is released from the selective depletion complex as the endocytic compartment acidifies. The selective depletion molecule can be recycled to the cell surface along with the receptor, and the target molecule can proceed to lysosomes for degradation. In some embodiments, the target molecule can remain in the lysosome without being degraded, resulting in enrichment of the target molecule in the lysosome. The selective depletion complexes of the present disclosure can have a low molecular weight compared to target-binding antibodies and can be used to bind and deplete targets without the need for a supply and distribution cold chain.
[0203] In some embodiments, the receptor-binding peptide (TfR-binding peptide or PD-L1-binding peptide) has a dissociation constant (K) of less than 50 μM, less than 5 μM, less than 500 nM, less than 100 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM. D ) can bind to a cellular receptor (e.g., TfR or PD-L1). In some embodiments, the receptor-binding peptide has an off-rate that is slower than the recycling rate of the cellular receptor, such that the receptor-binding peptide is likely to remain bound to the receptor during the recycling process. In some embodiments, the receptor-binding peptide may have an off-rate of 1 minute or less, 2 minutes or less, 3 minutes or less, 4 minutes or less, 5 minutes or less, 7 minutes or less, 10 minutes or less, 15 minutes or less, or 20 minutes or less. In some embodiments, the receptor-binding peptide may have an off-rate of about 1 minute to about 20 minutes, about 2 minutes to about 15 minutes, about 2 minutes to about 10 minutes, or about 5 minutes to about 10 minutes.
[0204] The selective depletion complexes of the present disclosure can be used to treat diseases or conditions by selectively depleting target molecules associated with the disease or condition. For example, the selective depletion complexes can be used to selectively deplete soluble or cell surface proteins that accumulate, contain disease-associated mutations (e.g., mutations that cause constitutive activity, resistance to treatment, or dominant-negative activity), or are overexpressed in disease states. In some embodiments, the selective depletion complexes of the present disclosure can be used to treat and prevent various neurological disorders, including, but not limited to, epilepsy, schizophrenia, depression, anxiety, bipolar disorder, brain development disorders (e.g., autism spectrum disorder), or mood disorders.
[0205] Binding of the selective depletion complexes described herein (e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes) to TfR and subsequent transport across a barrier such as a cell layer or the BBB (e.g., via vesicular transcytosis) or across a cell membrane (e.g., via endocytosis) can impact numerous diseases, conditions, or disorders associated with neurodegeneration. Neurodegenerative diseases that can be prevented by the selective depletion complexes described herein can include Alzheimer's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, disease with Lewy bodies, Parkinson's disease, multiple system atrophy (MSA), spinal muscular atrophy, motor neuron disease, Lyme disease, ataxia-telangiectasia, autosomal dominant cerebellar ataxia, Batten disease, corticobasal syndrome, Creutzfeldt-Jakob disease, para-fragile X tremor / ataxia syndrome, Kufour-Rakeb syndrome, Machado-Joseph disease, multiple sclerosis, chronic traumatic encephalopathy, or frontotemporal dementia. In some embodiments, the TfR-binding peptides can be used in combination with BACE inhibitors such as galantamine, amantadine, benzatropine, biperiden, bromocriptine, carbidopa, donepezil, entacapone, levodopa, pergol, pramipexole, procyclidine, rivastigmine, ropinirole, selegiline, tacrine, tolcapone, or trihexyphenidyl to treat and / or prevent neurodegenerative diseases. For example, selective depletion complexes comprising target-binding peptides that bind to proteins associated with neurodegeneration (e.g., tau, amyloid beta (Aβ), huntingtin, or α-synuclein) can be used to treat neurodegenerative diseases.
[0206] Binding of the selective depletion complexes described herein (e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes) to TfR followed by transport across a barrier, such as a cell layer or the BBB (e.g., via vesicular transcytosis) or across a cell membrane (e.g., via endocytosis) can affect a variety of cancers. Cancers that can be treated or prevented by the selective depletion complexes described herein include breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, myeloma, blood-derived cancers, spleen cancer, lung cancer, pancreatic cancer, prostate cancer, sarcoma, stomach cancer, esophageal cancer, gastrointestinal (GI) cancer, thyroid cancer, endometrial cancer, bladder cancer, salivary gland cancer, kidney cancer, muscle cancer, ovarian cancer, glioblastoma, astrocytoma, neuroblastoma, and the like. These cancers may include glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, diffuse intrinsic pontine glioma, lung cancer, myeloid cell carcinoma, or skin cancer, melanoma, genitourinary cancer, osteosarcoma, muscle-derived sarcoma, melanoma, head and neck cancer, neuroblastoma, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, and diffuse intrinsic pontine glioma (DIPG), or CMYC-overexpressing cancer. For example, a selective depletion complex containing a target-binding peptide that binds to a cancer-related protein (e.g., HER2, EGFR, FGFR-1, PD-L1, VEGF, PD-1, CD38, GD2, SLAMF7, CTLA-4, CCR4, CD20, PDGFRα, VEGFR2, CD33, CD30, CD22, CD79B, nectin-4, or TROP2) can be used to treat cancer. In some embodiments, selective depletion complexes for the treatment of cancer can comprise target-binding peptides that bind to extracellular, soluble, or cell surface proteins associated with cell proliferation, cell division, evasion of cell death, immune evasion, suppression of inflammatory responses, promotion of vascular growth, or protection from hypoxia. In some embodiments, selective depletion complexes of the present disclosure can be used to deplete anti-inflammatory stimuli (e.g., molecules associated with N2-polarized macrophages or molecules associated with microglia or regulatory T cells) to enhance the tumor-targeting capabilities of the innate and adaptive immune systems.Selective depletion complexes containing target-binding peptides that bind to molecules associated with anti-inflammatory stimuli can enhance treatments that are otherwise prone to immune exhaustion (such as ionizing radiation or CAR-T cell therapy).
[0207] In some embodiments, the selective depletion complex may be used to reduce immunosuppression or suppress pro-inflammatory signaling, such as in immune-mediated diseases. For example, the selective depletion complex may comprise a target-binding peptide that binds to a protein associated with immunosuppression or pro-inflammatory signaling (e.g., CD47, CD39, CD24, CD25, CD74, TNF-α, IL-1, IL-1R, IL-2, IL-2R, IL-6, IL-6R, IL-10, IL-10R, IL-23, IL-12, PD-1, PD-L1). In some embodiments, the selective depletion complexes can be used to treat inflammatory or neurological conditions (e.g., neuroinflammation, neuroinflammatory diseases, stroke, traumatic brain injury, Alzheimer's disease, or other tauopathies, including neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), age-related tau astrogliopathy, frontotemporal dementia, Parkinsonism, progressive supranuclear palsy, corticobasal degeneration, Lyticko-Boedig's disease, ganglioglioma, meningioangiomatosis, or subacute sclerosis panencephalitis). For example, selective depletion complexes comprising TNF-α binding peptides can be used to treat neuroinflammation, neuroinflammatory diseases, stroke, traumatic brain injury, or Alzheimer's disease.
[0208] Binding of the selective depletion complexes (e.g., peptide conjugates, fusion peptides, or recombinantly produced peptide complexes) described herein to TfR and subsequent transport across a barrier, such as a cell layer or the BBB (e.g., via vesicular transcytosis) or across a cell membrane (e.g., via endocytosis) can affect numerous diseases, conditions, or disorders associated with harmful inflammation. Harmful inflammation that can be treated or prevented with the selective depletion complexes described herein can include rheumatoid arthritis, psoriasis, multiple sclerosis, lupus, ankylosing spondylitis, antiphospholipid syndrome, gout, inflammatory arthritis center, myositis, scleroderma, Sjogren's disease, vasculitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft-versus-host disease, cytokine storm, cystic fibrosis, inflammation-associated neurodegeneration (e.g., age-related tauopathy or Alzheimer's disease), or autoimmune diseases. For example, a selective depletion complex comprising a target-binding peptide that binds to a target associated with acute or chronic inflammation (e.g., apolipoprotein E4, TNF-α, IL-1, IL-6, IL-7, IL-12, and IL-23) can selectively deplete inflammatory cytokines or chemokines. In some embodimen...
Claims
1. 1. A peptide conjugate comprising: Transferrin receptor binding peptide and a target binding peptide complexed to the transferrin receptor binding peptide, the target-binding peptide has a lower target-binding affinity for the target in an endosome than in the extracellular environment; The peptide conjugate.
2. The peptide complex of claim 1, wherein the affinity of the transferrin receptor binding peptide for the target is pH independent.
3. The peptide complex of claim 1 , wherein the affinity of the target-binding peptide for the target is pH dependent.
4. The peptide complex of claim 1, wherein the affinity of the target-binding peptide at pH 5.5 is lower than the transferrin receptor binding affinity of the transferrin receptor-binding peptide for the transferrin receptor at pH 5.
5.
5. The peptide complex of claim 1, wherein the target binding affinity of the target-binding peptide is at least two times greater at pH 7.4 than at pH 5.
5.
6. The peptide complex of claim 1 , wherein the target-binding peptide comprises one or more histidine amino acid residues at the target-binding interface.
7. 2. The peptide conjugate of claim 1, wherein the transferrin receptor binding peptide and the target binding peptide form a single polypeptide chain.
8. The peptide complex of claim 1 , wherein the peptide complex comprises a dimer dimerized via a dimerization domain.
9. 9. The peptide complex of claim 8, wherein the dimerization domain comprises an Fc domain, a homodimerization domain, a first heterodimerization domain, a second heterodimerization domain, or a combination thereof.
10. 10. The peptide complex of claim 9, wherein the homodimerization domain comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs:245 to 259.
11. 10. The peptide complex of claim 9, wherein the first heterodimerization domain comprises a sequence having at least 90% sequence identity to any one of SEQ ID NO:260, SEQ ID NO:262, SEQ ID NO:264, SEQ ID NO:266, SEQ ID NO:268, SEQ ID NO:270, SEQ ID NO:272, SEQ ID NO:274, SEQ ID NO:276, SEQ ID NO:278, SEQ ID NO:280, SEQ ID NO:282, SEQ ID NO:284, or SEQ ID NO:
286.
12. 10. The peptide complex of claim 9, wherein the second heterodimerization domain comprises a sequence having at least 90% sequence identity to any one of SEQ ID NO:261, SEQ ID NO:263, SEQ ID NO:265, SEQ ID NO:267, SEQ ID NO:269, SEQ ID NO:271, SEQ ID NO:273, SEQ ID NO:275, SEQ ID NO:277, SEQ ID NO:279, SEQ ID NO:281, SEQ ID NO:283, SEQ ID NO:285, or SEQ ID NO:
287.
13. 2. The peptide conjugate of claim 1, wherein the transferrin receptor binding peptide, the target binding peptide, or both, comprise a miniprotein, a nanobody, an antibody, an antibody fragment, a scFv, a DARPin, or an affibody.
14. 14. The peptide complex of claim 13, wherein the miniprotein comprises a cystine-dense peptide, an afftin, an adnectin, an avimer, a Kunitz domain, a nanophytin, a finomer, a bicyclic peptide, a beta-hairpin, or a stapled peptide.
15. 2. The peptide conjugate of claim 1, wherein the transferrin receptor binding peptide comprises a cystine-dense peptide containing at least three disulfide bonds.
16. 2. The peptide conjugate of claim 1, wherein the transferrin receptor binding peptide comprises the sequence of SEQ ID NO:
170.
17. The transferrin receptor binding peptide is (a) a sequence having at least 90% sequence identity to SEQ ID NO: 96, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 65 to 95, 97 to 128, 220 to 222, or 1 to 64, or a fragment thereof comprising at least 24 amino acid residues. The peptide conjugate of claim 1 , comprising:
18. The transferrin receptor binding peptide is (a) the sequence of SEQ ID NO: 96, or (b) the sequence of SEQ ID NO: 66, SEQ ID NO: 220, SEQ ID NO: 221, or SEQ ID NO:
222. The peptide conjugate of claim 1 , comprising:
19. 2. The peptide conjugate of claim 1, wherein the target-binding peptide comprises any one of the sequences set forth in SEQ ID NOs: 392 to 399.
20. the target binding peptide (a) a sequence having at least 90% sequence identity to SEQ ID NO: 187, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity to SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:233, SEQ ID NO:402, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:219, SEQ ID NO:244, SEQ ID NO:234, SEQ ID NO:235 to SEQ ID NO:403 to SEQ ID NO:456, or SEQ ID NO:240, or a fragment thereof comprising at least 24 amino acid residues. The peptide conjugate of claim 1 , comprising:
21. The peptide complex of claim 1 , wherein the target-binding peptide comprises one or more histidine residues in the target-binding interface.
22. 2. The peptide conjugate of claim 1, wherein the target is a growth factor receptor, a receptor tyrosine kinase, a cell signaling molecule, an extracellular matrix macromolecule, a neurotransmitter, a cytokine, a growth factor, a tumor-associated antigen, a tumor-specific antigen, a hormone, a checkpoint inhibitor, an immune checkpoint inhibitor, an inhibitory immunoreceptor, a ligand for an inhibitory immunoreceptor, a macrophage surface protein, lipopolysaccharide, an antibody, an inhibitory immunoreceptor, a tumor-associated antigen, a tumor-specific antigen, or an autoantibody.
23. The target is selected from the group consisting of EGFR, EGFRvIII, collagen, elastin, microfibrillar proteins, proteoglycans, CD200R, CD300a, CD300f, CEACAM1, FcgRiib, ILT-2, ILT-3, ILT-4, ILT-5, LAIR-1, PECAM-1, PILR-α, SIRL-1, SIRP-α, CLEC4A, Ly49Q, MIC, CD3 , CD47, CD28, CD137, CD89, CD14, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD 25, CD74, CD40L, MUC1, MUC16, MUC2, MUC5AC, MUC4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TN F-α, TKI-resistant EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, VEGFR2, IGFR1, CTLA4, STRO1, complement factor C4, complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, ami 5. The peptide conjugate of claim 1, which is loid beta, huntingtin, alpha-synuclein, glucocerebrosidase, alpha-glucosidase, IL-1, IL-1R, IL-1alpha, IL-1beta, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, a member of the B7 family, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, AXL receptor, PD-1, or PD-L1.
24. 2. The peptide conjugate of claim 1, wherein the target is EGFR, EGFRvIII, PD-L1, IL-1R, IL-1β, c-Met, FGFR-1, ERBB3, HER2, AXL receptor, CD44, IGF1R, MUC1, PDGFR, CD47, CD73, CD30, VEGFR, VEGFR2, complement factor C4, tau, amyloid beta, α-synuclein, PCSK9, or TNFα.
25. (a) a sequence having at least 90% sequence identity to SEQ ID NO: 313, or to a fragment thereof comprising at least 94 amino acid residues; or (b) a sequence having at least 90% sequence identity with SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:308, SEQ ID NO:292, SEQ ID NO:304, SEQ ID NO:306, SEQ ID NO:294, SEQ ID NO:303, SEQ ID NO:288 to SEQ ID NO:313, or SEQ ID NO:315 to SEQ ID NO:346, or a fragment thereof comprising at least 94 amino acid residues. The peptide conjugate of claim 1 , comprising:
26. 2. The peptide complex of claim 1, wherein the target is an extracellular protein, a secreted peptide, a secreted protein, a circulating protein, a soluble protein, a cell surface protein, or a transmembrane protein.
27. 1. A composition for use in a method for delivering a targeted molecule to an endosome, the composition comprising a peptide complex, the method comprising: contacting the peptide complex with a cell expressing a transferrin receptor, the peptide complex comprising a transferrin receptor-binding peptide and a target-binding peptide complexed to the transferrin receptor-binding peptide; allowing the target-binding peptide to bind to the target molecule under extracellular conditions; binding the transferrin receptor binding peptide to the transferrin receptor under extracellular conditions; endocytosing the peptide complex, the target molecule, and the transferrin receptor; dissociating the target-binding peptide from the target molecule under endosomal conditions, thereby delivering the target molecule to the endosome; The composition comprising:
28. The composition described in claim 27, wherein the method further comprises depleting the target molecule.
29. The composition of claim 27, wherein the method further comprises recycling the peptide complex and the transferrin receptor.
30. The composition described in claim 27, wherein the method further comprises degrading the target molecule in an endocytic or lysosomal compartment.
31. The composition of claim 27, wherein the method further comprises recycling the peptide complex and the transferrin receptor.
32. 28. The composition of claim 27, wherein the target molecule is an extracellular protein, a secreted peptide, a secreted protein, a circulating protein, a soluble protein, a cell surface protein, or a transmembrane protein.
33. The composition of claim 27, wherein the method comprises permeating the peptide complex through a cell layer comprising the blood-brain barrier (BBB).
34. The transferrin receptor binding peptide is (a) a sequence having at least 90% sequence identity to SEQ ID NO: 96, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 65 to 95, 97 to 128, 220 to 222, or 1 to 64, or a fragment thereof comprising at least 24 amino acid residues.
28. The composition of claim 27 comprising:
35. 1. A composition for use in a method of treating a disease or condition in a subject, the composition comprising a peptide complex comprising a transferrin receptor binding peptide and a target binding peptide complexed to the transferrin receptor binding peptide, the method comprising: administering the peptide conjugate to the subject; Binding the target-binding peptide under extracellular conditions to a target molecule associated with a disease or condition on cells of the subject that express the target molecule and a transferrin receptor; allowing the transferrin receptor binding peptide to bind to the transferrin receptor on the cells of the subject under extracellular conditions; endocytosing the peptide complex, the target molecule, and the transferrin receptor; and under endosomal conditions dissociating the target binding peptide from the target molecule, the transferrin receptor binding peptide from the transferrin receptor, or both, thereby treating a disease or condition.
36. The composition described in claim 35, wherein the method further comprises degrading the target molecule in an endocytic or lysosomal compartment.
37. The composition described in claim 35, wherein the method further comprises depleting the target molecule.
38. The composition of claim 35, wherein the target molecule is an extracellular protein, a secreted peptide, a secreted protein, a circulating protein, a soluble protein, a cell surface protein, or a transmembrane protein.
39. 36. The composition of claim 35, wherein the disease or condition is cancer, a neurodegenerative disease, a lysosomal storage disease, an inflammatory disease, an autoimmune disease, a neuroinflammatory disease, an immune disease, or pain.
40. 40. The composition of claim 39, wherein the cancer is lung cancer, breast cancer, liver cancer, colon cancer, brain cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, myeloma, cancer derived from blood cells, sarcoma, gastric cancer, gastrointestinal cancer, glioblastoma, head and neck cancer, non-small cell lung cancer, squamous non-small cell lung cancer, pancreatic cancer, ovarian cancer, blood cancer, skin cancer, liver cancer, kidney cancer, uterine endothelial cancer, melanoma, bladder cancer, osteosarcoma, prostate cancer, myeloma, splenic cancer, bone marrow cell carcinoma, or colorectal cancer.
41. 41. The composition of claim 40, wherein the cancer is kras mutant cancer, exon 20 mutant non-small cell lung cancer, TKI resistant, cetuximab resistant, necitumumab resistant, or panitumumab resistant, advanced cancer, metastatic cancer, metastatic cancer of the central nervous system, metastatic breast cancer, metastatic skin cancer, refractory cancer, or KRAS wild-type cancer.
42. 40. The composition of claim 39, wherein the neurodegenerative disease is Alzheimer's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, schizophrenia, Parkinson's disease, or spinal muscular atrophy.
43. 40. The composition of claim 39, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, multiple sclerosis, glomerulonephritis, lupus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, cutaneous vasculitis, neuroinflammatory disease, inflammation-associated neurodegeneration, Alzheimer's disease, stroke, traumatic brain injury, Sjogren's disease, or cystic fibrosis.
44. The composition of claim 35, wherein the transferrin receptor binding peptide comprises any one of the sequences of SEQ ID NO:
170.
45. The transferrin receptor binding peptide, (a) a sequence having at least 90% sequence identity to SEQ ID NO: 96, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 65 to 95, 97 to 128, 220 to 222, or 1 to 64, or a fragment thereof comprising at least 24 amino acid residues.
36. The composition of claim 35, comprising:
46. The target-binding peptide of claim 1, (a) a sequence having at least 90% sequence identity to SEQ ID NO: 187, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity to SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:233, SEQ ID NO:402, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:219, SEQ ID NO:244, SEQ ID NO:234, SEQ ID NO:235 to SEQ ID NO:403 to SEQ ID NO:456, or SEQ ID NO:240, or a fragment thereof comprising at least 24 amino acid residues.
36. The composition of claim 35, comprising:
47. A peptide conjugate comprising: Transferrin receptor binding peptide and a target binding peptide complexed to the transferrin receptor binding peptide, the target-binding peptide has a binding affinity for a target; The peptide conjugate.
48. The peptide complex of claim 47, wherein the binding affinity of the target-binding peptide for the target is pH independent.
49. The peptide complex of claim 48, wherein the binding affinity of the target-binding peptide for the target is substantially the same binding affinity at pH 7.4 and pH 5.
5.
50. The peptide complex of claim 47, wherein the target is an extracellular protein, a secreted peptide, a secreted protein, a circulating protein, a soluble protein, a cell surface protein, or a transmembrane protein.
51. The peptide complex of claim 47, wherein the target is a growth factor receptor, a receptor tyrosine kinase, a cell signaling molecule, an extracellular matrix macromolecule, a neurotransmitter, a cytokine, a growth factor, a tumor-associated antigen, a tumor-specific antigen, a hormone, a checkpoint inhibitor, an immune checkpoint inhibitor, an inhibitory immunoreceptor, a ligand for an inhibitory immunoreceptor, a macrophage surface protein, lipopolysaccharide, an antibody, an inhibitory immunoreceptor, a tumor-associated antigen, a tumor-specific antigen, or an autoantibody.
52. The method according to claim 52, wherein the target is collagen, elastin, microfibrillar protein, proteoglycan, CD200R, CD300a, CD300f, CEACAM1, FcgRiib, ILT-2, ILT-3, ILT-4, ILT-5, LAIR-1, PECAM-1, PILR-α, SIRL-1, SIRP-α, CLEC4A, Ly49Q, MIC, CD3, CD47, CD28, CD13 7, CD89, CD14, CD16, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, CD39, CD24, CD25, CD74, CD40L, M UC1, MUC16, MUC2, MUC5AC, MUC4, OX40, 4-1BB, HLA-G, LAG3, Tim3, TIGIT, GITR, TCR, TNF-α, EGFR, EGFRvII I, TKI resistance EGFR, HER2, ERBB3, PDGFR, FGF, VEGF, VEGFR, IGFR1, CTLA4, STRO1, complement factor C4, complement factor C1q, complement factor C1s, complement factor C1r, complement factor C3, complement factor C3a, complement factor C3b, complement factor C5, complement factor C5a, TGFβ, PCSK9, P2Y6, HER3, RANK, tau, amyloid β, huntingtin 48. The peptide conjugate of claim 47, wherein the peptide conjugate is selected from the group consisting of IL-1, IL-1R, IL-1α, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-10, IL-10R, IL-17, IL-23, IL-12, p40, a member of the B7 family, c-Met, SIGLEC, MCP-1, MHC, MHC I, MHC II, PD-1, and PD-L1.
53. The peptide conjugate of claim 47, wherein the target is EGFR, EGFRvIII, PD-L1, IL-1R, IL-1β, c-Met, FGFR-1, ERBB3, HER2, AXL receptor, CD44, IGF1R, MUC1, PDGFR, CD47, CD73, CD30, VEGFR, VEGFR2, complement factor C4, tau, amyloid beta, alpha-synuclein, PCSK9, or TNFα.
54. The peptide complex of claim 47, wherein the transferrin receptor-binding peptide, the target-binding peptide, or both, comprise a miniprotein, a nanobody, an antibody, an antibody fragment, a scFv, a DARPin, or an affibody.
55. The peptide complex of claim 47, wherein the transferrin receptor-binding peptide comprises a cystine-high density peptide containing at least three disulfide bonds.
56. The peptide complex of claim 47, wherein the transferrin receptor binding peptide comprises the sequence of SEQ ID NO:
170.
57. The transferrin receptor binding peptide, (a) a sequence having at least 90% sequence identity to SEQ ID NO: 96, or to a fragment thereof comprising at least 24 amino acid residues; or (b) a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 65 to 95, 97 to 128, 220 to 222, or 1 to 64, or a fragment thereof comprising at least 24 amino acid residues.
48. The peptide conjugate of claim 47, comprising:
58. The transferrin receptor binding peptide, (a) the sequence of SEQ ID NO: 96, or (b) the sequence of SEQ ID NO: 66, SEQ ID NO: 220, SEQ ID NO: 221, or SEQ ID NO:
222.
48. The peptide conjugate of claim 47, comprising:
59. The peptide complex of claim 47, wherein the target-binding peptide comprises a sequence having at least 90% sequence identity to SEQ ID NO:219 or SEQ ID NO:
242.
60. The peptide complex of claim 47, wherein the target-binding peptide comprises an array having at least 90% sequence identity to SEQ ID NO:
242.
61. The peptide complex of claim 47, wherein the target-binding peptide comprises an array having at least 90% sequence identity to SEQ ID NO:
219.
62. The peptide complex of claim 47, wherein the target-binding peptide comprises one or more histidine residues at the target-binding interface.
63. The peptide complex of claim 47, wherein the peptide complex comprises a dimer dimerized via a dimerization domain, the dimerization domain comprising an Fc domain, a homodimerization domain, a first heterodimerization domain, a second heterodimerization domain, or a combination thereof.
64. The peptide complex of claim 63, wherein the first heterodimerization domain comprises a sequence having at least 90% sequence identity to any one of SEQ ID NO:260, SEQ ID NO:262, SEQ ID NO:264, SEQ ID NO:266, SEQ ID NO:268, SEQ ID NO:270, SEQ ID NO:272, SEQ ID NO:274, SEQ ID NO:276, SEQ ID NO:278, SEQ ID NO:280, SEQ ID NO:282, SEQ ID NO:284, or SEQ ID NO:
286.
65. The peptide complex of claim 47, comprising a sequence having at least 90% sequence identity with any one of SEQ ID NO:292, SEQ ID NO:295, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:301, SEQ ID NO:311, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:347, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:353, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:371 to SEQ ID NO:380, SEQ ID NO:382 to SEQ ID NO:389, or a fragment thereof comprising at least 94 amino acid residues.
66. A composition for use in a method for depleting a target molecule from a cell surface or extracellular space, said composition comprising a peptide complex, said method comprising: contacting the peptide complex with a cell expressing a transferrin receptor, the peptide complex comprising a transferrin receptor-binding peptide and a target-binding peptide complexed to the transferrin receptor-binding peptide; allowing the target-binding peptide to bind to the target molecule under extracellular conditions; binding the transferrin receptor binding peptide to the transferrin receptor under extracellular conditions; endocytosing the peptide complex, the target molecule, and the transferrin receptor, thereby depleting the target molecule from the cell surface or the extracellular space; The composition comprising:
67. The composition of claim 66, wherein the target molecule is an extracellular protein, a secreted peptide, a secreted protein, a circulating protein, a soluble protein, a cell surface protein, or a transmembrane protein.
